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ABSTRACT 
The oxidative modification of LDL by ROS/RNS is recognised as playing an 
important role in the development and progression of atherosclerosis. Adequate 
intake of dietary antioxidants such as the antioxidant vitamins, carotenoids, and 
plant antioxidants such as the polyphenols are important in reducing the risk of 
development of diseases where the pathogenesis involves free radical-mediated 
damage to proteins, lipids, and micleic acids. Antioxidants act to prevent 
oxidative damage by multiple mechanisms. The non-antioxidant beneficial 
properties of garlic in preventing cardiovascular disease are well documented and 
include lowering of blood lipids, reducing platelet aggregation and subsequent 
thrombus formation, and reducing blood pressure. In this study the antioxidant 
properties of a commercial aged garlic extract (AGE, Kyolice) were investigated. 
AGE displayed the ability to scavenge superoxide in cell ftee assays, and reduced 
both 15-lipoxygenase-mediated lipid peroxidation and Cu2ý-mediated lipid 
peroxidation and protein oxidation of isolated human LDL. Two different 
mechanisms were identified that may be responsible for the observed reduction in 
Cuý'-mediated oxidation of LDL in the presence of AGE. The first mechanism is 
the chelation of Cu2+ and the second mechanism is the partial preservation of the 
endogenous LDL antioxidant P-carotene. Chromatographic and colourimetric 
analyses suggested that AGE is a rich source of phenolic compounds and that they 
may bind or become incorporated within the LDL particle and this may help to 
explain the efficacy of AGE in preventing LDL oxidation by preserving 0- 
carotene rather than a-tocopherol levels. Smoking is a human syndrome of 
increased oxidative stress and an important risk factor for the development of 
atherosclerotic heart disease. Thus the antioxidant properties of AGE were also 
identified in vivo using non-smoking and smoking human volunteers. A reliable 
and sensitive novel marker of increased oxidative stress and lipid peroxidation in 
vivo (8-iso-PGF2(,, ) and the antioxidant capacity of plasma to scavenge superoxide 
were used to assess the antioxidant effects of AGE. Smokers had elevated plasma 
and urinary levels of 8-iso-PGF2(,, and a decreased antioxidant capacity of plasma 
to scavenge superoxide when compared to non-smokers. Dietary supplementation 
with AGE significantly decreased plasma and urinary 8-iso-PGF2,, levels in 
smokers and non-smokers and increased the antioxidant capacity of plasma to 
scavenge superoxide in smokers. These studies demonstrated that AGE is an 
efficient antioxidant plant extract in vitro and in vivo and may be beneficial in 
reducing oxidative damage to lipid and proteins and thus prevent or reduce the 
development and progression of free-radical-mediated diseases such as 
atherosclerosis. 
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CHAPTER 1 
INTRODUCTION 
1. INTRODUCTION 
1.1. CARDIOVASCULAR DISEASE AND ATHEROSCLEROSIS 
Cardiovascular disease is the chief cause of death in the USA and Europe with 
most cases of heart attacks (myocardial infarctions) and many cases of ischaemia 
(stroke) being secondary to the condition of atherosclerosis (Genest & Cohn, 
1995). Epidemiological studies have identified a number of risk factors for the 
development of atherosclerosis which include elevated serum lipids (cholesterol 
and triglycerides), increased plasma fibrinogen and coagulation factors, increased 
platelet activation, alterations in glucose metabolism, and smoking (Frishman, 
1998, Wood, 2001). The oxidative modification of low-density lipoprotein (LDL) 
is now considered an important mechanism in the development of atherosclerosis 
(Keaney, 2000). Atherosclerosis is a disease of arteries that is characterised by a 
local thickening of the vessel wall. The effects of atherosclerosis are mainly 
evident in the muscular arteries e. g. coronary, carotid, femoral and iliac arteries as 
well as in the aorta. 
in general, three types of thickening (atherosclerotic lesion) are recognized 
(Schwartz et. al., 1991): (1) Fatty streaks are characterized by the presence of 
foam cells. These are lipid-laden cells that arise from both macrophages and 
smooth muscle cells. Fatty streaks are the precursors for fibrous plaques. (2) 
Fibrous plaques often slightly obstruct the vascular lumen and consist of a fibrous 
cap composed mainly of smooth muscle cells, collagen, elastin and proteoglycans 
covering an area rich in macrophages, smooth muscle cells, and T-lymphocytes. 
Often there is a deep necrotic core, which contains debris from dead cells, 
extracellular lipid deposits and cholesterol crystals. (3) Complicated plaques are 
fibrous plaques that have been altered by necrosis, calcium deposition, bleeding, 
and thrombosis. Plaques cause disease by limiting blood flow to an organ such as 
the heart or brain. A stroke or myocardial infarction occurs when the lumen of an 
essential artery becomes completely occluded, usually by a thrombus forming at 
the site of a plaque. Thrombus formation is often triggered by plaque rupture. 
Plaque disruption occurs most frequently where the fibrous cap is thinnest and 
most heavily infiltrated by foam cells. 
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1.1.1. The Oxidative Modification Hypothesis of Atherosclerosis 
Evidence implicating oxidative stress in the pathogenesis of atherosclerosis was 
first reported in 1979 when Brown and Goldstein observed that unlike native LDL 
chemical modification of LDL in the form of acetylation leads to foam cell 
formation when incubated with macrophages. The uptake of this chemically 
modified LDL was shown to take place via saturable, specific receptors termed 
6scavenger receptors' (Goldstein et al., 1979). While they could not identify any 
known endogenous means of LDL acetylation in vivo, they did speculate that 
other modifications of LDL might facilitate recognition of LDL by the scavenger 
receptor (SR). This prediction was proven as Henriksen and colleagues 
(Henriksen et al., 1981) found that incubation of LDL with endothelial cells 
modified LDL in such a way that it served as a ligand for uptake by macrophages 
and eventual foam cell formation. To date numerous scavenger receptors that 
share an affinity for oxidised LDL have been identified and characterised which 
include scavenger receptor class A type I/type 11 (SR-AMI), a plasma membrane 
glycoprotein termed CD36, and scavenger receptor class B type I (SR-BI) 
(Dhaliwal & Steinbrecher, 1999). 
The oxidative hypothesis of atherosclerosis begins initially with an accumulation 
of LDL in the extracellular sub-endothelial space of arteries. This LDL 
subsequently becomes progressively oxidised by a number of cell-mediated 
mechanisms involving reactive species such as superoxide (02*), hydrogen 
peroxide (H202), nitric oxide (NO), and catalytic metal ions (Fe 2+ and Cu2) (Klatt 
& Esterbauer, 1996). This modified LDL is not subject to normal regulatory 
mechanisms and is taken up via scavenger receptors expressed on monocyte- 
derived macrophages present in the sub-endothelial space (Fuhrman et al., 1997a, 
Henriksen et al., 1981, Steinberg et al, 1990). This unregulated uptake may also 
occur in smooth muscle cells (Tertov & Orekhov, 1997) and leads to increased 
cholesterol deposition within these cells, which transform into the foam cells 
characteristic of the early atherosclerotic lesion (Henriksen et al., 1983, 
Kritharides et al., 1998). 
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1.1.2. Structure of LDL 
Human LDL is a particle containing both lipid and protein that is isolated by 
gradient ultracentrifugation between the densities of 1.019-1.063g/ml dependent 
on the gradient medium utilised (Lowe et al., 1999, Tribble et al., 1992). LDL is 
spherical with a diameter that ranges between 19 and 25nm, and a molecular 
weight between 1.8 and 2.8 million. A LDL particle consists of a lipophilic core 
containing approximately 1600 molecules of cholesteryl ester, and 170 molecules 
of triglyceride (Esterbauer et al., 1990). The particle surface contains 
phospholipid, free cholesterol and is embedded with a single apolipoprotein B- 
100 (apo B). A typical LDL particle contains 2700 fatty acid molecules, about 
half of these fatty acids are polyunsaturated fatty acids (PUFAs) with the 
predominant PUFAs being linoleic acid and arachidonic acid, and a small amount 
of docosahexaenoic acid (Table 1.1). 
These PUFAs are highly susceptible to oxidation and are protected by the 
presence of a variety of lipophilic antioxidants contained in the shell and inner 
core of LDL (Table 1.1). The major antioxidant is (x-tocopherol with 
approximately 6-8 molecules per LDL particle. All of the other lipid soluble 
antioxidants are present at amounts <1 molecule per LDL particle. These include 
y-tocopherol, ubiquinol-10, P-carotene, lycopene, 0-cryptoxanthin, and (X- 
carotene. Since most of these compounds are contained in the diet the content of 
lipid soluble antioxidants will vary considerably among individuals. More 
notably, the antioxidative capacity of LDL subfractions markedly differs from 
each other with the more atherogenic, dense subfractions being more susceptible 
to oxidation than the less dense ones (Lowe et al., 1999, Tribble et al., 1995). 
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Table 1.1: Lipid and Antioxidant Composition of Human LDL 
Lipid/Antioxidant mnol/mg LDL protein mol/mol LDL 
Mean ± S. D. Mean 
Total phospholipids 1300 ± 227 700 
Phosphatidylcholine 818 ± 143 450 
Lysophosphatidylcholine 145 ± 25 80 
Sphingomyelin 336 ± 59 185 
Fatty acids -2700 
Linoleic acid 2000 ± 541 1100 
Palmitic acid 1260 ± 375 693 
Palmitoleic acid 80 ± 44 44 
Steric acid 260 ± 118 143 
Oleic acid 825 ± 298 454 
Arachidonic acid 278 ± 100 153 
Docosahexaenoic acid 53 ± 31 29 
Free fatty acids 48 26 
Triglycerides 304 ± 140 170 
Free cholesterol 1130 ± 82 600 
Total cholesterol 4090 2200 
Antioxidants 
Vitamin E (a-Fy-tocopherol) 15.5 ± 2.9 7.95 
Ubiquinol-10 0.65 ± 0.28 0.33 
P-Carotene 0.53 ± 0.47 0.27 
Lycopene 0.41 ± 0.2 0.21 
P-Cryptoxanthin 0.25 ± 0.23 0.13 
a-Carotene 0.22 ± 0.25 0.11 
Adapted from Keaney, 2000 
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1.13. Chemistry of LDL Oxidation 
LDL oxidation is principally a free-radical-driven lipid peroxidation chain 
reaction (Esterbauer et al, 1993, Klatt & Esterbauer, 1996) for which the 
simplified elementary reactions are shown in Figure 1.1. The oxidation process is 
started by the attack of an initiating free radical (X*) and the abstraction of a 
hydrogen atom from one of the PUFAs bound to the LDL lipids (LH). This 
reaction yields a carbon-centred PUFA radical (Lý which reacts very quickly with 
molecular oxygen to yield a lipid peroxyl radical (LOO*) which in turn abstracts a 
hydrogen atom from an adjacent PUFA (LH), yielding a lipid hydroperoxide 
(1,00H) and a new PUFA radical (L*). It is the latter reaction that carries the 
lipid peroxidation chain. If no chain termination takes place, a single initiating 
event could convert all LDL PUFAs into lipid hydroperoxides. The actual 
number of PUFAs oxidised per initiation event depends primarily on the amount 
of chain-breaking antioxidants contained in the LDL particle. The antioxidants; of 
LDL compete with chain propagation by very efficiently scavenging LOO*. This 
has been demonstrated in vitro when isolated LDL is exposed to pro-oxidative 
conditions (e. g. Cu2). Before substantial amounts of LOOH are formed LDL 
becomes depleted of its antioxidants, with a-tocopherol being consumed first and 
P-carotene last (Esterbauer & Ramos, 1995); this is the lag phase of the process. 
It is not until the LDL has lost most of its antioxidant compounds that the 
propagation phase commences and the PUFAs in LDL are rapidly oxidised to 
LOOM This is followed by the decomposition phase, when the LOOH breaks 
down and/or rearranges to form a wide range of products, including aldehydes, 
ketones, alcohols, epoxides, and 172-isoprostanes (Bhadra et al., 1991, Brown et 
al., 1997, Esterbauer et al, 1991a, Moore et al., 1995). As lipid peroxidation 
proceeds, the lipid radicals and decomposition products attack apo, B, which leads 
to numerous protein modifications such as cross-linking, fragmentation and 
covalent binding of aldehydes. 
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Figure I. I. Elementary Reactions of Lipid Peroxidation, 
Initiation: 
Oxygen Addition 
Chain Propagation 
Inhibition by antioxidants 
LH + X* -> C+ XH 
02 LOO 
LOW + LH -,, LOOH + L* 
LOO* + AH --),. LOOH + A* 
LH: lipid containing a PUFA; V: Carbon centred PUFA radical; X*: initiating 
free radical; LOO*: lipid peroxyl radical; LOOM lipid hydroperoxide; AH: 
antioxidant 
Taken from Klatt & Esterbauer, 1996 
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1.1.4. The F24soprostanes 
The 172-isoprostanes are isomers of the enzymatically formed prostaglandins. 
Prostaglandins are formed from arachidonic acid through a cyclooxygenase 
(COX-)-dependent pathway after its release from membrane phospholipids via the 
action of phospholipases. In contrast, the 172-isoprostanes are formed in situ in 
membranes following free radical attack on the arachidonic acid and are 
subsequently released from membrane or LDL phospholipids presumably by the 
action of phospholipases. They then circulate in the plasma and are subsequently 
excreted in urine (Morrow et al., 1990a, 1990b, 1992, Pratico et al., 1998). 
Depending on which of the labile hydrogen atoms is first abstracted by free 
radical attack up to 64 different F2-isoprostane isomers, sub-divided into 4 
structural classes can be generated (Pratico, 1999). To date the most extensively 
studied is 8-iso-Prostaglandin F2a (8-iso-PGF2,, ), also known as 8-epi-PGF2,, or 
iPF2,, -Ill, a class IV member. 
8-iso-PGF2a is a biologically active F2-isoprostane that shares certain properties 
with conventional prostaglandins. 8-iso-PGF2,, causes renal vasoconstriction. in 
rats, potent pulmonary vasoconstriction in rabbits and rats, and constricts coronary 
arteries with a potency twice that of prostaglandin F2a (PGF2a) (Baneýee et al., 
1992, Kang et al., 1993, Kromer & Tippins, 1996, Takahashi et al., 1992). 8-iso- 
PGF2,, also causes a dose-dependent irreversible platelet aggregation in the 
presence of sub-threshold doses of common platelet agonists and increases 
platelet adhesion by reducing the anti-adhesive and anti-aggregatory effects of NO 
(Minuz et al., 1998, Pratico et al., 1996). As well as demonstrating potent 
bioactive properties a large body of evidence has been accumulated indicating that 
F2-isoprostanes and more specifically 8-iso-PGF2,, can be reliably monitored 
through non-invasive techniques and yield sensitive and specific markers of lipid 
peroxidation in vitro and in vivo (Pratico, 1999). 
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1.1.5. Proatherogenic Properties of Oxidised LDL 
Oxidised LDL elicits numerous pro-atherogenic properties (Figure 1.2) and these 
include increased smooth muscle proliferation (Auge et al., 1996, Koba et al., 
1999, Natarajan, 1995), together with cytotoxicity to vascular endothelial cells, 
smooth muscle cells, macrophages, and fibroblasts (Cathcart et al., 1985, Clare et 
al., 1995, Guyton et al., 1995, Sevanian et al., 1995). Oxidised LDL also induces 
apoptotic cell death in vascular endothelial cells (Claise et al., 1999, Heenneier et 
al., 2001, Li et al., 1998, Napoli et al., 2000). 
The adhesion of monocytes to endothelial cells is mediated by cell adhesion 
molecules, which include intercellular cell adhesion molecule-I (ICAM-1) and 
vascular cell adhesion molecule-I (VCAM-1). Oxidised LDL induces expression 
of these cell adhesion molecules (Erl et al., 1998, Frostegard et al., 1993). 
Oxidised LDL is also chemotactic for monocytes, via induced expression of 
monocyte chemoattractant protein-I (MCP-1) in endothelial cells and prevents 
monocyte egress from the arterial wall (Cushing et al., 1990, Quinn et al., 1987). 
Oxidised LDL can stimulate the release of macrophage-colony stimulating factor 
(M-CSF) from endothelial cells, which then induces monocyte differentiation into 
macrophages (Liao et al., 1991). 
Imppirment of endothelium-dependent arterial relaxation is also elicited by 
oxidised LDL (Deckert et al., 1997, Froese et al., 1999, Murohara et al, 1994). 
Platelet activating activity has also been demonstrated by oxidised LDL (Heery et 
al., 1995, Marathe et al., 1999, Takahashi et al., 1996, Vlasova, 2000). These pro- 
atherogenic properties of LDL are involved in the development and progression of 
atherosclerotic lesions. 
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1.1.6. Evidence Supporting the 'Oxidative Hypothesis of Atherosclerosis' 
There is much evidence consistent with the 'oxidative hypothesis of 
atherosclerosis'. It includes: 
(1) The presence of oxidation products in human and animal atherosclerotic 
lesions (Breuer et al., 1996, Leeuwenburgh et al., 1997, Oguogho et al., 1999, 
Suama et al., 1995). 
(2) LDL extracted from atherosclerotic lesions but not plasma-derived LDL 
resembles LDL oxidised in vitro (Yla-Herttuala et al., 1989). 
(3) Antibodies raised against oxidised LDL react with atherosclerotic lesions but 
not with nonnal arterial tissue (Palinski et al., 1989). 
(4) Patients with carotid atherosclerosis have higher levels of autoantibodies to 
oxidised LDL than normal subjects and the degree of atherosclerosis 
correlates with the concentration of autoantibodies present (Cheisa et al., 
1998, Inoue et al., 2001, Lehtimaki et al., 1999, Salonen et al., 1992). 
(5) Dietary antioxidant treatment is consistent with preventing the progression of 
atherosclerosis (Parker et al., 1995, Sasahara et al., 1994, Sun et al., 1997, 
Williams et al., 1992). 
1.2. DIETARY ANTIOXIDANTS 
If oxidation of LDL plays a significant role in the pathogenesis of atherosclerosis, 
its inhibition by antioxidant intervention should reduce the development and 
progression of the disease. Moreover it has been reported that nutritional 
antioxidants such as vitamin E, carotenoids, and flavonoids inhibit LDL oxidation 
in vitro and ex vivo (Avirain & Fuhrman, 1998, Bowen et al., 1998, Jialal & 
Fuller, 1995). 
1.2.1. Vitamin E 
Considerable evidence supports the hypothesis that vitamin E reduces the risk for 
atherosclerosis. Vitamin E inhibits the proliferation of smooth muscle cells in 
vitro (Boscoboinik et al., 1991) and increases the resistance of low-density 
lipoprotein to oxidation when it is added to plasma or administered to humans 
(Dieber-Rotheneder et al., 1991, Esterbauer et al., 1991b, Fuller et al., 1996,2000, 
Mabile et al., 1999). Furthermore, platelets isolated from subjects taking vitamin 
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E supplements had reduced adhesiveness to collagen and decreased platelet 
aggregation in response to ADP and arachidonic acid (Calzada et al., 1997, 
Mabile et al., 1999). Vitamin E supplementation also reduces atherosclerosis in 
hypercholesterolaernic rabbits (Fruebis et al., 1999). 
Plasma levels of vitamin E are significantly lower in patients with coronary artery 
disease (Delport et al., 1998, Kim et al., 1996) Intake of vitamin E from food or 
vitamin E supplementation are both inversely related to the risk of and mortality 
from coronary artery disease (Knekt et al., 1994, Kushi et al., 1996, Rimin et al., 
1993, Stampfer et al., 1993) although not all studies have observed a beneficial 
effect (Ascherio et al., 1999, Klipstein-Grobusch et al., 1999). 
1.2.2. Carotenoids 
The most abundant carotenoids in human plasma are P-carotene and lycopene. In 
contrast with other antioxidants, P-carotene and lycopene can inhibit LDL 
oxidation to a limited degree (Fuhrman et al., 1997b). The protection observed by 
lycopene was greater than the protection exhibited by p-carotene and both exerted 
a greater protection when LDL had a high vitamin E content. Dietary 
supplementation with P-carotene but not lycopene inhibited in vitro cndothelial 
cell-mediated oxidation of isolated LDL (Dugas et al., 1999) and 0-carotene 
supplementation normalises the increased susceptibility to oxidation of LDL 
derived from patients with diabetes mellitus (Levy et al., 2000). It is also 
important to note that both of these carotenoids exert a hypocholesterolaernic 
effect by reducing cholesterol synthesis via inhibition of P-hydroxy-p- 
methylglutaryl. coenzyme A (HMG CoA) reductase (Fuhrman et al., 1997c). 
Plasma levels of O-carotene are significantly lower in patients with coronary 
artery disease (Kim et al., 1996). Intake of P-carotene/lycopene from food or P- 
carotene/lycopene supplementation are both inversely related to the risk of 
coronary artery disease (Klipstcin-Grobusch ct al., 1999, Knekt et al., 1994) 
although, as observed with vitamin E not all studies have observed a beneficial 
effect (Ascherio et al., 1999, Hennekens ct al., 1996, Klipstein-Grobusch et al., 
1999). 
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1.2.3. Plant Polyphenols: Flavonoids 
Dietary flavonoids are potent antioxidants, and their consumption in the form of 
red wine or licorice or pomegranate juice by human volunteers for 2 weeks 
resulted in a significant reduced susceptibility of isolated LDL to lipid 
peroxidation (Avirarn et al., 2000, Fuhrman et al., 1997d, Hayek et al., 1997). 
These studies also demonstrated that consumption of pomegranate juice, or the 
red wine polyphenols catechin. or quercetin, or the licorice polyphenol glabridin 
by atherosclerotic apolipoprotein,, E-deficient mice for 6 weeks resulted in a 
substantial reduction in the atherosclerotic lesion area, along with a similar 
reduced susceptibility of their LDL to oxidation. Consumption of flavonoids in 
tea also reduces the susceptibility of LDL to oxidation (Hodgson et al., 1999b, 
2000, Ishikawa et al., 1997). 
Intake of flavonoids has been inversely correlated with risk of and mortality from 
coronary artery disease in the Zutphen Elderly Study and other studies (Geleijnse 
et al., 1999, Hertog et al., 1993, Knekt et al., 1996). The French Paradox also 
supports these studies in that despite the pro-atherogenic lifestyle of the Southern 
French people (high fat diet and smoking tendencies) the incidence of coronary 
heart disease is relatively low (Renaud & De Lorgeril, 1992). This reduced risk of 
coronary disease has been attributed to a high consumption of red wine along with 
a high intake of olive oil and a fresh fruit- and vegetable-rich mediterranean diet. 
This hypothesis is now controversial as recent evidence suggests that the lower 
incidence of cardiovascular disease in France is due to a historically lower 
consumption of animal fat which only recently increased in France but did so 
decades ago in Britain (Law & Wald, 1999). 
It has recently been identified that garlic is also a rich source of antioxidant 
flavonoids and these include apigenin, myricetin, and quercetin (Miean & 
Mohamed, 2001). The potent antioxidant activity of a garlic preparation such as 
aged garlic extract (AGE) may in part be attributed to the presence of a plethora 
of different antioxidants with differing sites and mechanisms of action (Borek, 
2001), which may act alone or in concert with each other. This has been 
exemplified by lycopene, which synergistically inhibits LDL oxidation in 
combination with vitamin E, garlic or plant polyphenols (Fuhrman et al., 2000). 
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This suggests that dietary supplementation with antioxidant plant extracts such as 
AGE may be more beneficial than supplementation with singular pure 
antioxidants in reducing the development and progression of multi-risk factor 
diseases such as atherosclerosis. 
Treatment of cardiovascular disease in the western world has involved 
management of risk factors such as hyperlipidaemia using dietary 
modification/life-style change and/or drug therapy, and while drug therapy is 
expensive, compliance with dietary modifications/life-style changes often fails. 
This has encouraged the current environment, which now promotes self- 
medication with plant extracts such as garlic, which have numerous beneficial 
effects on the cardiovascular system (Agarwal, 1996, Rahman, 2001). 
13. GARLIC: AN HISTORICAL PERSPECTIVE 
Garlic (Allium sativum) is believed to have originated from Central Asia and to 
date the genus Allium comprises over 600 known species, which include Allium 
cepa (onion), Allium porrum (leek), and Allium schoenoprasum (chives). The 
genus Allium belongs to the Alliacae family. Garlic is widely cultivated in many 
countries with the most notable producers being the U. S., Argentina, Mexico, and 
China and is used universally as a flavouring agent, traditional medicine, and a 
functional food to enhance physical and mental health. The beneficial effects of 
garlic consumption in treating a wide variety of human diseases and disorders 
have been recorded and passed down by many ancient civilisations (Hahn, 1996). 
One of the earliest recorded uses of garlic as a spice, condiment, and medicine 
was provided by the Sumarians and dates back to 2600-2100 BC. Sanskrit texts 
dated around 500 AD records the use of garlic to treat a wide variety of ailments 
such as skin diseases, eating disorders, rheumatic conditions, spleen enlargement 
and haernorrhoids. The Egyptians also new the value of garlic and ancient papyri 
uncovered during excavations also detailed the seasoning and medicinal 
properties of garlic. Interestingly, the remains of garlic bulbs were found in the 
burial chambers of Tutankhamun who was buried in 1352 BC. Records similar to 
these detailing the uses of garlic are available for many other ancient civilisations 
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such as the Greeks and Babylonians who acquired their knowledge of garlic from 
the Egyptians and the Sumarians, respectively. The Romans who gained their 
knowledge of garlic from the Greeks introduced garlic to Europe where it was 
accepted and appreciated to a greater or lesser extent. This still remains true 
today especially in Great Britain were garlic and its somewhat odorous properties 
are still little appreciated. 
Throughout the history of civilisation the medicinal properties of garlic have been 
greatly valued and have been used to treat a wide variety of human ailments. Yet 
it is only over the past 10 years that interest has arisen in trying to identify the 
specific medicinal properties of garlic and, its active principles responsible for 
these therapeutic effects. Garlic is most commonly used to promote a healthy 
cardiovascular system due its cholesterol lowering, antithrombotic, antiplatelet, 
and antihypertensive actions (Agarwal, 1996, Rahman, 2001). These therapeutic 
actions of garlic may extend beyond the cardiovascular system to reducing the 
risk of development of certain cancers (Fleischauer et. al., 2000). 
1.4. THE COMPOSITION OF GARLIC 
The general composition of garlic is shown in Table 1.2.65% of garlic is water, 
which is low compared to most fruits and vegetable (80-90%). The bulk of the dry 
weight is composed of fructose-containing carbohydrates, followed by sulphur 
compounds, protein, fibre, and free amino acids (Lawson, 1996). 
Garlic also contains high levels of saponins, phosphorus, potassium, sulphur, zinc, 
moderate levels of selenium, and vitamins A and C, and low levels of calcium, 
magnesium, sodium, iron, manganese and B-complex vitamins. Garlic also 
appears to have a high phenolic content (12.9pmol/g wet weight) (Vinson et al., 
1998). Nearly all of these compounds present in garlic are water-soluble (97%) 
with a small amount of oil-soluble compounds (0.15-0.7%). 
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Table 1.2. The General Composition of Garlic 
Component Amount (% fresh weight) 
Water 62-68 
Carbohydrates (mainly fructans) 26-30 
Protein 1.5-2.1 
Amino acids: common 1-1.5 
Amino acids: cysteine sulphoxides 0.6-1.9 
y-Glutamylcysteines 0.5-1.6 
Lipids 0.1-0.2 
Fibre 1.5 
Total sulphur compounds 1.1-3.5 
Sulphur 0.23-0.37 
Nitrogen 0.6-1.3 
Minerals 0.7 
Vitamins 0.015 
Saponins 0.04-0.11 
Total oil-soluble compounds 0.15(whole)-0.7(cut) 
Total water-soluble compounds 97 
'Excluding protein and inorganic sulphate (0.5%) 
Taken from Lawson, 1996. 
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1.4.1. The Sulphur Compounds of Garlic 
Garlic contains unique organosulphur compounds, which provide its characteristic 
flavour and odour and most of its potent biological activity (Block, 1985). In fact, 
over 90% of investigations on garlic's active principles have focused on the 
sulphur compounds. About 85% of the sulphur compounds in whole garlic 
comprise of allfin and two main y-glutamylcysteines (Table 1.3). Allfin is 
considered the parent substance of the therapeutically active sulphur components 
of garlic. When garlic is crushed, cut, or chewed alliin is exposed to the enzyme 
alliinase, and the thiosulphinate allicin is formed. Allicin is a reactive 
intermediate species that can be transformed into a variety of compounds 
depending on environmental conditions and extraction methods. Of the entire 
sulphur compounds present in garlic only three minor compounds do not contain 
the arnino acid cysteine (methionine, y-glutamylmethionine, and thiamine). 
1.4.1.1. *Glutamylcysteines: Important Storage Compounds 
Although the cysteine sulphoxide allfin is considered to be the parent substance of 
many of garlic sulphur compounds it has been demonstrated that the y- 
glutarnylcysteines may be the precursors for the cysteine sulphoxides (Lawson et 
al., 1991a, 1991b). These studies showed that cool storage of garlic bulbs for a 
few months resulted in steady decreases of the y-glutamylcysteines with almost 
equimolar increases in the cysteine sulphoxides. This transformation process is 
due to increased activity of the enzyme y-glutarnyltranspeptidase which slowly 
hydrolyses the y-glutamylcysteines to S-alkylcysteines followed by rapid 
oxidation to form cysteine sulphoxides (Figure 1.3) and may function to increase 
the antibiotic capacity of young garlic plants during wintering and sprouting 
(Lawson, 1996). 
The abundance of the y-glutamylcysteines is indicated in Table 1.3. The main y- 
glutamylcysteines found in garlic cloves are y-glutamyl-S-trans-I - 
propenylcysteine and y-glutainyl-S-allylcysteine (Lawson, 1996). Small amounts 
of y-glutamyl-S-methylcysteine are also usually found and y-glutamyl-S-cis-1- 
propenylcysteine is barely detectable in fresh garlic cloves, but increases slowly 
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upon clove storage or boiling of cloves indicating it is formed from the trans- 
isomer. 
1.4.1.2. Cysteine Sulphoxides: Precursors of the Thiosulphinates 
Garlic contains three cysteine sulphoxides capable of producing thiosulphinates, 
S-allylcysteine sulphoxide (alliin), S-trans-l-propenylcysteine sulphoxide 
(isoalliin) and S-methylcysteine (methiin). Allfin constitutes the major sulphoxide 
(85%) while isoalliin (5%) and methiin (10%) are considerably less abundant. 
Garlic also contains a cyclic cysteine sulphoxide cycloallfin, which cannot be 
cleaved by alliinase and hence produces no thiosulphinates. The function of 
cycloalliin is unknown. The cysteine sulphoxide content in garlic is indicated in 
Table 1.3. 
The cysteine sulphoxides are rare in nature and are found almost exclusively in 
the Alliacae family especially among the genus Allium. Allfin however has only 
been found abundantly in a few Allium species one of these being garlic (Lawson 
et al., 1991b). The cysteine sulphoxides have no known physiological function 
other than to be enzymatically transformed by alliinase into biologically active 
thiosulphinates (Figure 1.3) (Lawson, 1996). 
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Table 13. Total Known Sulphur Compounds in Whole and Crushed Garlic 
Compound Whole Garlic Crushed Garlic 
(mglg fresh weight) (mglg fresh weight) 
Cvsteine Sulohoxides 
S-Allylcysteine sulphoxide (alliin) 5-14 nd 
S-Methylcysteine sulphoxide (methiin) 0.5-2 nd 
S-trans-l-Propenyl cysteine sulphoxide 0.2-1.2 nd 
(isoalliin) 
Cycloallfin 0.5-1.5 0.5-1.5 
y-Glutamylcysteines 
y-Glutamyl-S-trans-l-propenylcysteine 3-9 3-9 
y-Glutamyl-S-cis-l-propenylcysteine 0.06-0.15 0.06-0.15 
y-Glutamyl-S-allylcysteine 2-6 2-6 
y-Glutamyl-S-methylcysteine 0.1-0.4 0.1-0.4 
Thiosulohinates 
Allyl 2-propenethiosulphinate (aflicin) nd 2-6 
Allyl methyl thiosulphinates ' nd 0.3-1.5 
Allyl trans- I -propenyl thiosulphinates nd 0.05-1.0 
Methyl trans- I -propenyl thiosulphinates' nd 0.02-0.2 
Methyl methanethiosulphinate nd 0.05-0.1 
Others 
y-Glutamyl-methionine 0.02-0.12 0.02-0.12 
y-Glutamyl-cysteine, oxidized tr tr 
S-2-carboxypropylglutathione 0.09 0.09 
y-Glutamyl-S-allylmercaptocysteine 0.01-0.03 0.01-0.03 
S-Methylcysteine tr tr 
S- I -Propenyl cysteine nd nd-0.006 
S-Allylcysteine nd-0.026 nd-0.026 
Methionine 0.02 0.02 
Thiamine 0.002 nd-0.001 
Allithiamine nd nd-0.001 
Scordinins 0.03 <0.03 
Sulpholipids nd-0.0 I nd-0.0 I 
Protein, soluble 0.3 0.3 
Protein, insoluble 0.6 0.6 
inorganic sulphate 0.5 0.5 
Not detectable (nd), Trace (tr) 
'Indicates two isomers 
Adapted from Lawson, 1996. 
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Figure 13. Transformation of the y-Glutamylcysteines and Cysteine Sulphoxides 
to Thiosulphinates (THS). The y-glutamylcysteines are slowly hydrolysed to the 
S-alkylcysteines (cysteines) followed by transformation to the cysteine 
sulphoxides if oxidase activity is present. Sulphenic acids are formed from the 
cysteine sulphoxides in the presence of alliinase and these spontaneously 
condense to form the thiosulphinates. Typical weight percentages for compounds 
found in whole or crushed cloves are shown. Taken from Lawson, 1996. 
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1.4.1.3. Alficin and Other Thiosulphinates 
The rapid transformation of the cysteine sulphoxides (alliin, isoalliin, methiin) by 
allinase in crushed garlic bulbs results in the formation of sulphenic acids, which 
rapidly condense to form the thiosulphinates (Figure 1.3) (Block, 1985). The 
abundance of these thiosulphinates in crushed garlic is shown in Table 1.3. 
Because alliin is much more abundant than the other cysteine sulphoxides, allicin 
is the main thiosulphinate produced (-70%) while allyl methanethiosulphinate 
(-12%) is the second most abundant. 
Allicin is also thought to be responsible for the usual odour of fresh cut or crushed 
garlic. The stability of allicin can vary from hours to weeks depending on the 
storage conditions (Lawson, 1993). Allicin appears to be most stable in water, 
with a half-life of about 30 days at room temperature and least stable in hexane, 
with a half-life of 2 hours. Because of this it is assumed that allicin will only be 
consumed in notable amounts by people who eat raw garlic. Although the 
pathways of its metabolism in humans are not known in detail and its 
bioavailability is yet to be proven it is converted to allyl mercaptan and diallyl 
disulphide (DADS) in the perfased rat liver (Egen-Schwind et al., 1992a) and to 
allyl mercaptan when incubated with human blood (Lawson & Wang, 1993). The 
same substances are formed in vivo since both are present in human breath after 
ingestion of raw garlic (Minami et al., 1989, Tamaki & Sonoki, 1999). Allicin 
decomposes under a variety of conditions and depending on the medium polarity 
and temperature various transformation products are formed such as the 
disulphides, vinyldithiins, and mercaptocysteines (Figure 1.4). 
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1.4.1.4. The S-Alkylcysteines 
Trace amounts of the S-alkylcysteines (S-allylcysteine, S-1-propenylcysteine, and 
S-methylcysteine) have been reported in garlic cloves (Lawson, 1993, Table 1.3). 
These compounds are thought to be the biosynthetic precursors of the cysteine 
sulphoxides (Figure 1.3). The content of S-alkylcysteines greatly increases when 
garlic cloves are dried during the manufacture of garlic powders or aged for 3 
months or longer in dilute ethanol or water (Lawson, 1993, Lawson & Wang, 
1995). These increases are due to the hydrolysis of the y-glutamylcysteines, 
which is more efficient and complete when garlic is aged in dilute ethanol or 
water. This transformation of the y-glutamylcysteines to S-alkylcysteines without 
further transformation to cysteine sulphoxides is due to the absence of oxidase 
activity during the ageing process (Lawson & Wang, 1995). 
1.4.2. Non-Sulphur Compounds of Garlic 
1.4.2.1. Carbohydrates 
Carbohydrates are the most abundant class of compounds in garlic and account for 
26-30% of the wet weight (Lawson, 1996, Table 1.2). The majority of the 
carbohydrate material in garlic consists of water-soluble fructose polymers called 
fructans, which constitute approximately 84% of the total carbohydrate material. 
Besides a carbohydrate storage function, the fructans may play an important role 
in osmotic regulation and in cold resistance. The known mono- and disaccharides 
of garlic comprise sucrose (7% dry weight), fructose (1.4%), glucose (1.2%), 
arabinose, and lactose (both unknown amounts). Raffinose, IF-fructosylsucrose, 
and 6G-fructosylsucrose are the three trisaccharides found in garlic. A 
tetrasaccharide called scorodose has been identified in garlic but reports on the 
content are conflicting. 
Cell wall polysaccharides present in garlic comprise galactan, a galacturonan, an 
arabinan, cellulose, and a xyloglucan. The dry scales of garlic also contain large 
amounts of the carbohydrate pectin. Pectin from garlic scales is used 
commercially to make jellies, cosmetics, and pharmaceuticals. The carbohydrate 
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content of garlic fluctuates throughout the growth of the plant, but reaches its 
highest levels in the mature bulb. 
1.4.2.2. Emymes in Garlic 
In addition to the unique abundance of the enzyme alliinase which is involved in 
the transformation of the cysteine sulphoxides to thiosulphinates, and the presence 
of y-glutamyl peptidases which hydrolyse y-glutamylcysteines to cysteine 
sulphoxides other enzymes have been characterised in garlic (Lawson, 1996). 
These include adenosine triphosphatase (AT? ase), which is present in all living 
organisms, polyphenol oxidase, which oxidises triphenols and is activated by 
magnesium and copper, jand phenylalanine-ammonia-1yase (PAL), which is 
involved in the synthesis of aromatic compounds in garlic and shows increased 
activity in the presence of allfin. The antioxidant enzymes peroxidase, catalase, 
and superoxide dismutase (SOD) are also found in garlic. 
In addition, alcohol dehydrogenase (ADH), esterase, and phosphoglucose 
isomerase have also been identified and their isoenzymes characterised. A whole 
range of enzymes involved in the synthesis, degradation, and metabolism of 
carbohydrates has been identified, as well as a species-specific deoxyribonuclease 
and a lysozyme. 
1.4.23. Protein, Free Amino Acids, and Dipeptides 
The protein content of garlic cloves is 1.5% fresh weight, which represents only 
30% of the total nitrogen. The remainder of the total nitrogen is present as free 
amino acids (25%), cysteine sulphoxides (23%), y-glutamylcysteines (20%), and 
y-glutamylphenylalanine (1.5%) (Lawson, 1996). The free amino acid content of 
garlic is exceptionally high and is about 65% greater than the total protein. The 
free amino acids of garlic include nearly all of the common amino acids present in 
protein (e. g. arginine, glutamic acid, lysine, and serine). The cysteine sulphoxides 
are equally abundant and the S-alkylcysteines are present in trace amounts. 
Garlic also contains a large amount of dipeptides, all of which have been shown to 
contain glutamic acid with a y-peptide linkage to the other amino acid. The y- 
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glutarnylcysteines (Table 1.3) accounts for the majority of these dipeptides; 
however y-glutamylphenylalanine, y-glutamylglycine, and oxidised. y- 
glutamylcysteine have also been found in garlic bulbs (Lawson, 1996). 
1.4.2.4. Upids 
Garlic contains only a very small amount of oil-soluble compounds and the lipid 
content of garlic cloves has been reported to be 1-2mg/g fresh weight (Lawson, 
1996). A high proportion of the lipids in garlic are polar (phospholipids and 
glycolipids). The polar lipids account for 37-60% of the total lipids, and the 
neutral lipids for 40-63%. The main fatty acid components are linoleic acid (60- 
65%), palmitic acid (20-300/o), oleic acid (3-10%), and (x-linolenic acid (3-6%). It 
is assumed that because of the type of lipids present they are used for structural 
purposes rather than for energy storage. 
1.4.2.5. Organoselenium Compounds 
The selenium content in fresh garlic is 0.02 mg/100g fresh weight and is 
drastically less than that of sulphur; however, because selenium belongs to the 
same family as sulphur it can substitute for sulphur in some organosulphur 
compounds with a strong preference of selenium binding to the methyl 
compounds of garlic (Lawson, 1996). Selenium is an important component of 
endogenous antioxidant systems and recent evidence suggests that low 
intake/bioavailability contributes to cancers, cardiovascular disease, and infertility 
(Rayman, 1997). Hence, there is considerable interest in growing garlic in 
selenium-enriched soils. The resulting increase in selenium concentration in 
garlic has been shown to provide selenium to selenium-depcndant enzymes in 
animals as well as to enhance the anticancer effects of garlic (Ip et al., 1992,1994, 
lp & Lisk, 1993,1994) 
1.4.2.6. Polyphenols: Flavonoids and Phenolic Acids 
Considerable interest has arisen in plant polyphenolic flavonoids and phenolic 
acids due to their antioxidant activity and protective effect against the 
development of cardiovascular disease and cancer (Rice-Evans, 1995, Visioli et 
al., 2000a). In spite of this and a recent study which demonstrated that garlic had 
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a relatively high phenolic content (12.9ýtmol/g wet weight, Vinson et al., 1998) 
relatively little work has been reported on the antioxidant activity of these 
polyphenols in garlic. 
Six phenolic acids have been found in peeled garlic cloves whose concentrations 
total 40pg/g fresh weight and include p-hydroxybenzoic acid (13gg/g), caffeic 
acid (I Olig/g), ferulic acid (7gg/g), vaniffic acid (6gg/g), sinapinic acid (2gg/g), 
and p-coumaric acid (2ptg/g) (Lawson, 1996). The scales were found to contain a 
similar concentration but p-coumaric acid was dominant and p-hydroxybenzoic 
acid was absent. Salicylic acid has also been found in trace amounts (Igg/g) 
(Swain et al, 1985). More recently the flavonoids apigenin, quercetin, and 
myricetin has been identified and quantified in whole garlic bulbs subjected to 
acid hydrolysis at concentrations of 217gg/g, 47ýtg/g, and 693gg/g, respectively 
(Miean & Mohamed, 2001). Lignin, a complex polymer of p-propenolphenols is 
found at 1.6% in garlic scales and serves to provide a rigid wall structure. 
1.4.2.7. Other Non-Sulphur Compounds 
Garlic contains phytosterols that are non-polar compounds with the solubility of 
lipids. The total sterol content appears to be 18pg/g fresh weight with the 
dominant sterol being P-sitosterol with lesser amounts of campesterol. and 
cholesterol. Saponins are also present in garlic at lmg/g. Saponins have strong 
surfactant (foaming) ability and have a variety of biological activities (Lawson, 
1996, Matsuura, 2001). 
A wide range of nutritional vitamins and minerals are present in garlic but the 
amounts are so small they are not important in evaluating the health benefits of 
garlic consumption. Garlic also contains adenosine, guanosine, and plant 
hormones such as auxin and gibberellins (Lawson, 1996). 
The chemical composition of garlic is extensively varied and interest is clearly 
focused on the sulphur components of garlic. It is these sulphur compounds and 
their transformation under different processing conditions that differentiate 
commercial garlic preparations. 
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1.5. COMMERCIAL GARLIC PREPARATIONS: PROCESSING AND 
COMPOSITION 
There are many types of commercially processed garlic formulations available. 
They include powdered dry garlic, oils produced upon treating chopped garlic 
with steam, vegetable oil, or ether, and aged garlic extracts. 
1.5.1. Extract of Garlic Aged in Dilute Alcohol (Aged Garlic Extract) 
Aged garlic extract (AGE, Kyolico) is formulated by soaking sliced raw garlic in 
15-20% aqueous ethanol for up to 20 months at room temperature. The extract is 
filtered and concentrated under reduced pressure at low temperature and is 
marketed in both dry (tablets and powder capsules) and liquid forms. The liquid 
form contains 10% (w/v) ethanol. 
Whole garlic contains mainly cysteine sulphoxides and y-glutamylcysteines and 
the main sulphur constituents of crushed garlic are y-glutamylcysteines and 
thiosulphinates (Table 1.3). In comparison, the ageing process described for AGE 
results in the complete hydrolysis of the main y-glutamylcysteines; y-glutamyl-S- 
allylcysteine and y-glutarnyl-S-1-propenylcysteine to S-allylcysteine (SAC) and S- 
I -propenylcysteine. The oxidation of these S-alkylcysteines to cysteine 
sulphoxides is prevented due to the absence of oxidase activity during the ageing 
process (Lawson & Wang, 1995). The SAC content is used to standardise 
commercial AGE. Two other sulphur compounds that are absent in fresh garlic 
are also greatly increased: cystine and S-allylmercaptocysteine (SAMC). 
Considerable amounts of allfin are also found and this is thought to be due to 
complete diff-usion of alliin into the medium with little diff-usion of the much 
larger allfinase. Because of this allicin and its oil-soluble transformation products 
are present only in trace amounts. AGE also contains a Maillard reaction 
compound; Na-(I-deoxy-D-frutos-1-yl)-L-arginine which is formed through a 
nonenzymatic reaction between reducing sugars and amino acids during the 
ageing process (Ryu et al., 2001). Numerous steroidal saponins have also been 
characterised in AGE (Matsuura, 2001). 
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Whereas other garlic preparations contain mainly the harsh and pungent oil- 
soluble thiosulphinates and their transformation products, AGE is concentrated in 
mild and odourless water-soluble sulphur compounds. The thiosulphinate allicin 
has many unwanted side effects, which include aggravation of the stomach, 
hepatotoxicity and strong oxidising properties particularly against red blood cells 
(Egen-Schwind et al., 1992a, 1992b, Freeman et al., 1995, Lawson et al., 1992). 
Raw garlic and some other garlic preparation have been shown to cause allergic 
skin reactions, stomach ulcers, other gastrointestinal problems, haemolytic 
anaemia and other symptoms (Burden et al., 1984, Hoshino et al., 2001, 
Nakagawa et al., 1980). However, AGE and SAC have not demonstrated such 
undesirable effects, even at excessive doses (Geng et al., 1997, Nakagawa et al., 
1980, Steiner et al., 1996, Steiner & Li, 2001, Yeh & Liu, 2001, Yeh et al., 1995). 
1.5.2. Garlic Powder Products 
Most commercial garlic powders are prepared by cutting the peeled garlic cloves 
into small pieces, followed by oven drying at 50-60'C and then pulverization. 
During this processing of garlic, conversion of some alliin and other cysteine 
sulphoxides to allicin and other thiosulphinates occur. The more alliin that is 
converted the greater the odour of the resulting powder. This odour is due to the 
subsequent conversion of the thiosulfinates to diallyl di- and trisulphides. Even 
though the sulphides are volatile, significant amounts remain in the powder. 
1.5.3. Oil of Steam-Distilled Garlic, Oil of Oil-Macerated Garlic, and Ether- 
Extracted Oil of Garlic 
Oil of steam-distilled garlic is produced upon steam treatment of crushed garlic. 
This oil contains purely allyl sulphides (allyl, methyl, and I -propenyl mono- and 
polysulfides), which are produced from the thiosulphinates during the steam 
distillation process. Commercial products sold for human consumption are 
diluted about 200-fold with vegetable oil. 
Oil of oil-macerated garlic is formulated by grinding garlic cloves in vegetable 
oil, followed by isolation of the clear oil. This product contains unique 
transformation compounds of allicin and other thiosulphinates: the vinyldithiins 
and the ajoenes, as well as allyl sulphides. 
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Extraction of the thiosulphinates of crushed garlic with ether followed by 
evaporation of the ether has been used to produce oil from garlic that has a 
composition similar to that of oil-macerated garlic preparations. 
1.6. THERAPEUTIC EFFECTS OF AGED GARLIC EXTRACT AND 
OTHER GARLIC PREPARATIONS 
1.6.1. Effects on the Cardiovascular System 
Epidemiological studies have identified a number of risk factors for the 
development of cardiovascular disease which include elevated serum lipids 
(cholesterol and triglycerides), increased plasma fibrinogen and coagulation 
factors, increased platelet activation, hypertension, alterations in glucose 
metabolism, and smoking (Frishman, 1998, Wood, 2001). Garlic has been used to 
treat a variety of cardiovascular problems in many countries for decades and a 
multitude,. of studies have been published examining the effect of garlic on the 
cardiovascular system with a view to preventing or reducing cardiovascular 
disease. 
1.6.1.1. Cholesterol and Lipid-Lowering Effects 
Blood lipids and lipoproteins circulating in the blood in the form of LDL are 
decreased in response to treatment with garlic, Various garlic extracts have been 
shown to reduce diet-induced hypercholesterolaernia in rats and rabbits (Bordia & 
Verma, 1980, Ismail et al., 1999, Kamanna & Chandrasekhara, 1982, Lata et al., 
1991, Slowing et al. 2001). AGE supplementation was effective in lowering 
plasma cholesterol and triglyceride and LDL-cholesterol in hyperlipidaemic 
subjects (Lau et al., 1987, Steiner et al., 1996, Yeh ct al., 1995). AGE 
supplementation in normolipidaernic subjects has been reported to have no effect 
on plasma lipids and lipoproteins (Rahman & Billington, 2000). Supplementation 
with garlic powder preparations has also been reported to reduce plasma 
cholesterol and LDL-cholesterol in hypercholesterolaernic subjects (Adler et al., 
1997, Jain et al., 1993, Kannar et al., 2001) although similar studies have reported 
no beneficial effects of garlic powder supplementation (Gardner et al., 2001, 
Isaacsohn et al., 1998, Simons et al., 1995, Superko & Krauss, 2000). Results for 
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the effect of dietary supplementation with garlic oil preparations on plasma lipid 
and lipoprotein levels have also been conflicting (Berthold et al., 1998, Bordia, 
198 1, Bordia et al., 1998). 
Several studies have indicated that the lowering of plasma cholesterol and 
triglycerides by extracts of garlic and its constituents is due to inhibition of key 
enzymes involved in cholesterol biosynthesis and fatty acid synthesis in cultured 
mt hepatocytes and human HepG2 cells (Gebhardt, 1993, Liu & Yeh, 2001, Yeh 
& Liu, 2001, Yeh & Yeh, 1994). Abuirmeileh et al. (1991) observed lipid- 
lowering activities of AGE and SAC in conjunction with a reduction in hepatic P- 
hydroxy-p-methylglutaryl coenzyme A (HMG-CoA) synthetase and reductase 
activities in hypercholesterolaemic chickens. Direct measurements of enzyme 
activity have identified that extract of garlic and various constituents inhibit 
human squalene monooxygenase and HMG-CoA reductase; enzymes involved in 
cholesterol biosynthesis (Gebhardt, 1993, Gupta & Porter, 2001). In addition, it 
has been shown that the more water-soluble sulphur compounds like SAC and S- 
propenylcysteine present in AGE are less cytotoxic and more efficient in 
inhibiting cholesterol biosynthesis than the lipid-soluble sulphur compounds like 
diallyl sulphide (DAS), DADS, and other sulphides (Yeh & Liu, 2001). 
1.6.1.2. Anti-Thrombotic andAnti-PlateletAggregatory Effects 
Platelet aggregation and subsequent thrombus formation is significantly and 
efficiently decreased by garlic and its constituents. At low intake (2.4g/d) 
supplementation with AGE has been shown to increase the threshold levels of 
collagen- and epinephrine-induced platelet aggregation and platelet adhesion to 
fibrinogen in healthy individuals (Steiner & Li, 2001). This study also 
demonstrated that high intake (7.2g/d) of AGE increased the threshold level of 
ADP-induced platelet aggregation and platelet adhesion to collagen and von 
Willebrand factor. This inhibition of ADP-induced platelet aggregation after 
dietary intervention with AGE (5ml/d (equivalent to 1.5g/d)) in normolipidemic 
subjects has also been observed in another study (Rahman & Billington, 2000). A 
reduction in collagen- and ADP-induced platelet aggregation was observed in 
hypercholesterolaernic chickens fed AGE or SAC (Abuirmeileh et al., 1991). 
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Dietary garlic oil has been shown to inhibit platelet aggregation induced by 
arachidonic acid, adrenaline, collagen, and calcium and has been shown to 
decrease the formation of the pro-aggregatory prostaglandin thromboxane-A2 
(TXA2) in platelets (measured as thromboxane-B2 (TXB2)) in coronary artery 
disease patients (Bordia et al., 1998). 
Aqueous extracts of fresh garlic, AGE, and SAC have been shown to reduce 
cyclooxygenase-mediated TXA2 (measured as TXI32) formation by platelets both 
in vivo and in vitro animal models of thrombosis and in hypercholesterolaernic 
chickens (Abuirmeileh et al., 1991, Thomson et al., 2000). Chloroform/acetone 
extracts of fresh garlic have been shown to inhibit cyclooxygenase activity 
directly in cell free assays with the acetone extract being more effective (Sendl et 
al., 1992). In contrast, in this study the chloroform extract of garlic was a more 
effective inhibitor of ADP- and platelet-activating factor (PAF)- induced platelet 
aggregation. 
1.6.13. Blood Coagulation, Fibrinolysis and Circulatory Effects 
Fibrinolysis is also enhanced by garlic resulting in dissolution of clots and 
thrombi. Dietary garlic oil has been reported to increase fibrinolytic activity 
(Bordia & Joshi, 1978, Bordia et al., 1998). Dietary intervention with garlic 
powder significantly reduces fibrinogen levels and prolongs the prothrombin 
clotting time of blood in patients with hyperlipoproteinaemia (Harenberg et al., 
1988). In vitro studies have identified that AGE improves microcirculation and 
blood properties by preventing lipid peroxidation and haernolysis in oxidised 
erythrocytes (Moriguchi et al., 2001). In contrast, garlic oil extracts and the allyl 
sulphides were unable to protect isolated erythrocytes from t-butyl hydroperoxide- 
induced hemolysis (Wu et al., 2001). 
1.6.1.4. Blood Pressure and Vascular Tone 
Dietary supplementation with AGE has been shown to have blood pressure- 
reducing effects in hypercholesterolaemic subjects (Steiner et al., 1996). A garlic 
extract has also been shown to modulate the production and function of both 
endothelium-derived relaxing factor (NO) and constricting factors (endothelin-1) 
in rat-isolated pulmonary arteries (Kim-Park & Ku, 2000). This observed effect 
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on NO production has been shown to be selectively regulated where AGE and 
SAC regulate NO production in macrophages by inhibiting inducible nitric oxide 
synthetase (NOS) expression while increasing NO production in endothelial cells 
(Kim et al., 2001). 
1.6.1.5 Anti-Atherosclerotic Effects 
Oxidation of LDL plays an important role in the initiation and progression of 
atherosclerotic vascular disease (Keaney, 2000). Oxidised LDL promotes 
vascular dysfimction by exerting direct cytotoxicity towards endothelial cells, by 
increasing chemotactic properties for monocytes, by transforming macrophages 
and smooth muscle cells to lipid-filled foarn cells, and by enhancing the 
proliferation of smooth muscle cells, endothelial cells, and monocytes; all of these 
events contribute to the development of the atherosclerotic lesion. As well as 
suppressing oxidation of LDL (Lau, 2001), garlic extracts have been shown 
reduce many of the pro-atherogenic properties of oxidised LDL- 
In a series of studies, Ide & Lau (1999a, 1999b, 2001) assessed the ability of AGE 
to protect endothelial cells against injury from oxidised LDL. Endothelial cell 
damage assessed using lactate dehydrogenase (LDH) release as an index of 
membrane damage, the methylthiazol tetrazoium (MTI) assay for cell viability, 
and TBARS indicating lipid peroxidation were all prevented by pre-treatment of 
the endothelial cells with AGE or SAC (Ide & Lau, 1999a, 1999b, 2001). 
Development of thickened, lipid-filled atherosclerotic lesions in the arteries of rats 
and rabbits fed a high-cholesterol diet was reduced when the diet was 
supplemented with AGE, garlic oil, or allicin (Abramovitz et al., 1999, Bordia & 
Verma, 1980, Campbell et al., 2001, Efendy et al., 1997, Eilat et al., 1995). 
Campbell et al. (2001) also demonstrated that the presence of AGE inhibited the 
accumulation of lipids in cultured macrophages and smooth muscle cell 
proliferation. Garlic powder extracts abolished atherogenic blood serum-induced 
accumulation of free cholesterol, triglycerides, and cholesteryl esters in smooth 
muscle cells (Orekhov & Tertov, 1997, Orekhov et. al., 1995). In cells isolated 
from atherosclerotic plaque, garlic powder extract lowered these lipids and 
inhibited lipid synthesis in normal cells and cells derived from atherosclerotic 
lesions. The extract inhibited cholesterol acyltransferase activity hence reducing 
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cholesterol ester formation and stimulated cholesterol ester hydrolase that 
degrades cholesterol esters. Garlic powder extract also inhibited the uptake of 
modified LDL in normal and atherosclerotic foam cells (Orekhov & Tertov, 
1997). 
1.6.2. Antioxidant Effects 
Free radicals and reactive species have been implicated in the pathogenesis of 
atherosclerotic vascular disease with the oxidation of LDL being an important 
mechanism (Keaney, 2000). The antioxidative actions of garlic and its 
constituents have been determined by their ability to scavenge reactive oxygen 
species (ROS), inhibit lipid peroxide formation and LDL oxidation, and enhance 
endogenous antioxidant systems. 
1.6.2.1. Scavenging qfROS 
AGE, a water-soluble extract of AGE, and its main constituents SAC, SAMC, and 
alliin demonstrated the ability to scavenge the ROS H202 using a cell free system 
(Ide & Lau, 1999a, Ide et al., 1996). The ability of AGE and SAC to scavenge 
H202 may explain the results of an earlier study that observed the presence of 
AGE and SAC protects vascular endothelial cells from H202-induced oxidant 
injury (Yamasaki et al., 1994). AGE and its main constituents have also been 
observed to scavenge the t-butyl hydroperoxide radical and hence prevent lipid 
peroxidation of liver microsomes (Imai et al., 1994). This study also reported that 
water extracts of raw and heat-treated garlic enhanced peroxidation of liver 
microsomes induced by t-butyl hydroperoxide. In contrast, a fresh garlic extract 
(heated or unheated) and allicin has been shown to scavenge the hydroxyl radical 
(OH*) generated by photolysis of H202 and reduce OH*-induced lipid 
peroxidation in rat liver homogenates (Prasad et al., 1995,1996). Heat treatment 
of garlic only slightly reduced its activity. Garlic powder extracts have also 
demonstrated the ability to scavenge reactive species such as OH* and peroxyl 
radicals (Aruoma et al., 1997). 
33 
1.6.2.2. Inhibiting Lipid Peroxidation ofLDL 
In vitro lipid peroxidation. of LDL induced by copper as assessed by the 
production of TBARS was significantly reduced by the presence of AGE and 
some of its constituents (SAC, SAMC, alliin, allixin) (Ho et al., 2001, Ide et al., 
1997). Dietary supplementation with AGE for seven days has been shown to 
significantly reduce the susceptibility of subsequently isolated LDL to Cu2+- 
mediated lipid peroxidation also (Munday et al., 1999, Steiner & Lin, 1998). 
Interestingly, in this study ingestion of raw garlic had no significant effect on the 
same perameters. Similar studies have also been performed using garlic powder 
extracts but results are inconsistent. Supplementation with garlic powder was 
found to significantly reduce the susceptibility of isolated LDL to oxidation 
induced by copper (Orekhov et al., 1996, Phelps & Harris, 1993). In contrast, 
other studies did not observe any effects on the oxidation resistance of LDL after 
supplementation with garlic powder (Byrne et al., 1999, Simons et al., 1995). 
1.6.2.3. Effects on Endogenous Antioxidant Defences 
In vitro studies have shown that incubation with oxidised LDL depletes 
intracellular glutathione (GSH) in endothelial cells and macrophages (Ide & Lau, 
1999a, 1999b, 2001). These studies demonstrated that pre-treatment of these cells 
with AGE or SAC prevented GSH depletion. A previous study observed that 
AGE increases GSH levels in vascular endothelial cells by modulation of the GSH 
redox cycle specifically increasing glutathione disulphide (GSSG) reductase 
activity, in addition, an increase in SOD activity was also reported (Geng & Lau, 
1997). Garlic supplementation has been shown to prevent the increase in 
oxidative stress associated with gentamicin-induced nephrotoxicity in rats. 
Oxidative stress was ameliorated by preserving superoxide dismutase (SOD) and 
glutathione peroxidase activities (Pedraza-Chaverri et al., 2000). In vivo animal 
studies have been used to investigate the effect of garlic oil supplementation on 
nicotine-induced lipid peroxidation in rats. Garlic oil supplementation reduced 
lipid peroxidation as assessed by numerous methods in all the major organs of the 
rat (heart, lung, liver, and kidney). This decrease in lipid peroxidation was 
associated with an increase in activity of antioxidant enzymes (catalase, SOD, and 
glutathione peroxidase) and increased levels of GSH (Helen et al., 1999). 
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In summary, the overall effects of garlic preparations on the cardiovascular 
system appear to be profound and varied and include reducing plasma lipids, 
preventing platelet aggregation and subsequent thrombus formation, and reducing 
blood pressure. However, the effects observed for commercial garlic powder and 
oil preparations were inconsistent. The evidence for antioxidant effects of various 
garlic preparations appears to be less convincing due to lack of in vivo human 
studies demonstrating direct antioxidant activity. In vitro and animal studies have 
demonstrated that AGE possesses substantial antioxidant activity compared with 
other garlic preparations and intake of AGE by humans is not associated with any 
undesirable effects as has been observed with other garlic preparations. 
1.7. OVERVIEW OF STUDY 
In vitro studies have identified the antioxidant properties of AGE with regards to 
scavenging reactive species, and inhibiting Cuýt-mediated lipid peroxidation of 
isolated human LDL (Ide et al., 1996,1997, Ide & Lau, 1999a, Imai et al., 1994). 
The ability of AGE to scavenge superoxide, inhibit Cu2-mediated protein 
oxidation of isolated human LDL, and reduce enzyme-mediated lipid peroxide 
formation and oxidative modification of LDL has yet to be demonstrated. In this 
study the ability of AGE to scavenge superoxide and inhibit lipid peroxide 
formation was investigated using cell-free assays. AGE was then assessed for its 
ability to inhibit Cuý+- and enzyme-mediated lipid peroxidation and protein 
oxidation of isolated human LDL. Cu2+-mediated lipid peroxidation of LDL is 
characterised by a lag phase when endogcnous antioxidants (tocopherols and 
carotenoids) become depleted and a propagation phase when rapid lipid 
peroxidation occurs (Esterbauer & Ramos, 1995). The ability of AGE to extend 
this lag phase was investigated and would suggest that preservation of 
endogenous LDL antioxidants might be occuring. 
Other studies have demonstrated that AGE and other plant extracts are able to 
prevent Cu2+-mediated oxidative modification of LDL, but have failed to address 
the possibility of the plant extract chelating Cu2' (Fuhrman et aL, 1997d, Hodgson 
et al., 1999b, Ide et al., 1997, Munday et al., 1999). The Cu2+ chelating properties 
of AGE were assessed using a novel approach based on restoration of xanthine 
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oxidase activity, which is completely inhibited in the presence of Cu2+ (Lowe et 
al., 1998). AGE may protect against Cu2-"-induced oxidation of LDL by sparing 
of endogenous antioxidants such as a-tocopherol and the carotenoids. This 
hypothesis was investigated by examining cc-tocopherol and carotenoid levels 
during Cu2+4nduced oxidation of LDL in the presence and absence of AGE. 
Plant polyphenols such as flavonoids are potent antioxidants. They have been 
shown to scavenge reactive species, chelate metal ions, and inhibit enzymes 
implicated in the pathogenesis of atherosclerosis (Brown et al., 1998, Chang, 
1993, Hanasaki et al., 1994, Miller et al., 1996, Robak, 1996). Their consumption 
by humans significantly reduces the susceptibility of subsequently isolated LDL 
to lipid peroxidation (Avirarn et al., 2000, Belinky et al., 1998, Fuhrman et al., 
1997d, Hayek et al., 1997, Hodgson et al., 2000), and the suggested binding of 
some plant extracts and flavonoids to LDL may explain their effectiveness in 
inhibiting the oxidation of LDL (Belinky et al., 1998, Grassmann et al., 2001, 
Hayek et al., 1997, Ivanov et al., 2001, Vinson et al., 1995,1998). Garlic has also 
been shown to be a rich source of polyphenols such as flavonoids (Miean & 
Mohamed, 2001, Vinson et al., 1998). The polyphenolic nature of AGE was 
investigated and the ability of components of AGE to bind directly to LDL and 
hence exert a protective effect against Cuý+-mediated lipid peroxidation was 
assessed. 
Human dietary supplementation studies have demonstrated that AGE attenuates 
many of the risk factors associated with cardiovascular disease and reduces the 
susceptibility of subsequently isolated LDL to oxidation (Munday et al., 1999, 
Rahman & Billington, 2000, Steiner et al., 1996, Steiner & Li, 2001). Evidence 
for direct antioxidant effects of AGE supplementation in humans is lacking. This 
may be due inadequate methods of assessing lipid peroxidation in vivo (Halliwell, 
2000, Jackson, 1999). F2-isoprostanes are a family of compounds formed from 
arachidonic acid through free radical-mediated lipid peroxidation of membranes 
and LDL particles (Morrow et al., 1990a, 1990b, Morrow et al., 1992, Pratico et 
al., 1998). They are increased in human conditions associated with increased 
oxidative stress and represent reliable and sensitive markers of lipid peroxidation 
in vivo (Davi et al., 1999, Meagher et al., 1999, Pratico, 1999, Reilly et al., 1996, 
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1998). Due to its potent biological properties the F2-isoprostane 8-iso- 
Prostaglandin F2 (8-iso-PGF2, ) has received much attention (Janssen, 2000, 
Minuz et al., 1998, Montero et al., 2000). A small clinical trial was constructed 
using non-smoking and smoking volunteers with the aim of identifying if smokers 
are subject to increased oxidative stress as evidenced by elevated levels of urinary 
and plasma 8-iso-PGF2,, and a decreased antioxidative capacity of plasma. The 
effect of AGE supplementation on both of these perameters was then investigated 
in both non-smokers and smokers. 
1.8. AIMS AND OBJECTIVES OF STUDY 
The first aim of the study was to investigate the antioxidant potential of AGE in 
vitro using whole AGE and a diethyl ether extract of AGE. 
m AGE was assessed for its ability to scavenge superoxide ions generated during 
the xanthine oxidase mediated breakdown of xanthine to uric acid. 
m The effect of AGE on 15-lipoxygenase-mediated lipid peroxidation of linoleic 
acid was also assessed. 
AGE was subsequently investigated for its ability to prevent oxidation of 
LDL. Human LDL isolated by density gradient ultracentrifugation was 
oxidatively modified by both enzymic (xanthine-xanthine oxidase and 15- 
lipoxygenase) and non-enzymic (Cu2) methods in the absence and presence 
of AGE. Measuring thiobarbituric acid reactive substances (TBARS) assessed 
lipid peroxidation and protein oxidation was assessed by increased 
electrophoretic mobility on agarose gels. 
In addition, a time course was performed to assess the effect of AGE on the 
lag phase of Cuý+-mediated lipid peroxidation of LDL. 
The second aim of this study was to investigate the properties and mechanisms of 
AGE using whole AGE and a diethyl ether extract of AGE. 
m AGE was assessed for its ability to chelate copper using a novel assay based 
on the complete inhibition of xanthine oxidase activity by Cu2+. 
In addition, the ability of AGE to preserve endogenous LDL antioxidants (cc- 
tocopherol. and carotenoids) during CJý-rnediated lipid peroxidation was 
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investigated by extraction of a-tocopherol and carotenoids and subsequent 
analysis by high-pressure liquid-chromatography (HPLC). 
m The polyphenolic nature of AGE was assessed using colorimetric assays and 
thin-layer chromatography (TLC) and high-pressure liquid chromatography 
(HPLQ. 
Incubation of whole plasma with AGE prior to LDL isolation and Cu2ý- 
mediated lipid peroxidation was performed to investigate the ability of 
components of AGE to bind directly to LDL and hence exert a protective 
effect. 
The third aim of this study was to investigate the antioxidant properties of whole 
AGE in vivo. 
wA human volunteer supplementation was performed using non-smokers and 
smokers. 
m The aims of this study was to confirm that increased oxidative stress due to 
cigarette smoking results in elevated levels of plasma and urinary 8-iso-PGFIý, 
and a decreased antioxidative capacity of plasma when compared to non- 
smokers, and secondly to investigate the antioxidant properties of aged garlic 
extract in vivo by monitoring the effects of AGE supplementation on plasma 
and urinary levels of 8-iso-PGF2. and the antioxidative capacity of plasma in 
both smoking and non-smoking individuals. 
w Plasma and urinary 8-iso-PGF2,, levels were measured using a competitive 
enzyme-linked immunoassay (ELISA) procedure. The antioxidant capacity of 
plasma was assessed using a chemiluminescent assay. 
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2. MATERIALS AND METHODS 
2.1. MATERIALS 
2.1.1. Chemicals and Enzymes 
'Kyolic 8' Aged Garlic Extract (AGE) was supplied by Wakunaga of America 
Company Ltd (Mission Viejo, CA, USA) and is formulated by soaking sliced raw 
garlic (Allium sativum) in 15-20% aqueous ethanol for up to 20 months at room 
temperature. The extract is filtered and concentrated under reduced pressure at 
low temperature. The content of water-soluble compounds is relatively high, 
while that of oil-soluble compounds is low. The AGE used in this study 
contained 30.5% extracted solids (305g/L) and S-allylcysteine, the most abundant 
water-soluble organosulphur compound in AGE, was present at 1.47g/L. 
OptiprepTm, a 60% (w/v) solution of iodixanol with a density of 1.32g/mL, was 
purchased from Nycomcd Pharma, Oslo, Norway. Triglyceride clinical diagnostic 
kits were purchased from Boehringer Mannheim, East Sussex, UK. Cholesterol 
and creatinine clinical diagnostic kits were purchased from Sigma-Aldrich 
Company Ltd., Dorset, UK. Lipoprotein and Lipoprotein (a) gels were purchased 
from Sebia Hydragels, Issy-les-Maulineaux, France. Optiseal", polyallomer 
tubes (I 1.2mL) were purchased from Beckman Instruments Ltd, 
Buckinghamshire, UK. Total and free 8-iso-Prostaglandin F2, Enzyme 
Immunoassay kits were purchased from Assay Design Inc. Ann Arbor, M148105, 
USA. Abelo Antioxidant Test kits for Superoxide and other Free Radicals with 
Pholasin@ were purchased from Knight Scientific Ltd., Plymouth, UK. Thin layer 
chromatography (TLC) plates and all solvents (HPLC grade) were purchased from 
Merck Ltd, Buckinghamshire, UK. Xanthine oxidase (Grade III from buttermilk), 
15-lipoxygenase (Type 1-13 from soybean) and all other reagents and chemicals 
were purchased from Sigma-Aldrich Company Ltd., Dorset, UK. 
2.1.2. Preparation of a Diethyl Ether Extract of AGE 
Due to the intense dark colouring of AGE, it was necessary to prepare a colourless 
extract, which did not interfere with some of the spectrophotometric assays. One 
part AGE was gently mixed with two parts diethyl ether and left to stand at room 
temperature for 5 minutes. The diethyl ether extract was removed and dried under 
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a stream of oxygen-free nitrogen gas. The residue was resuspended in phosphate 
buffered saline (PBS), pH 7.2 to its original volume for all assays unless 
otherwise stated. 
2.2. CELL-FREE ENZYME ANALYSES 
2.2.1. Determination of Superoxide Scavenging Ability of AGE 
Xanthine oxidase catalyses the oxidation of xanthine which leads to the 
production of uric acid. The by-products of this reaction are superoxide ions and 
hydrogen peroxide. Superoxide production and xanthine oxidase activity were 
measured as cytochrome C reduction and uric acid production, respectively. 
Xanthine oxidase was prepared to a concentration of 107mU/mL in PBS, pH 7.2, 
and xanthine was prepared as a 1.6mM solution also in PBS, pH 7.2. Superoxide 
ions were generated in a reaction volume of ImL containing 160[tM xanthine and 
1.25mg cytochrome C. The reaction was initiated by the addition of 10.7mU 
xanthine oxidase, and superoxide ion production was monitored at 550nm 
(Edwards et al., 1987). In a series of separate experiments, xanthine oxidase 
activity was monitored as the production of uric acid at 284nm (Mondal & Mitra, 
1994). Generation of superoxide ions was confirmed by the addition of 50U 
superoxide dismutase (SOD), which inhibited the reduction of cytochrome C 
without affecting xanthine oxidase activity (Figure 2.1). Whole AGE could not be 
used in experiments monitoring uric acid production due to excessive interference 
at 284run. If the diethyl ether extract of AGE should scavenge superoxide ions 
then the reduction of cytochrome C would be inhibited without affecting xanthine 
oxidase activity (i. e. uric acid production). AGE or the diethyl ether extract of 
AGE was added at 0-10% (v/v). The presence of 3mM ascorbic acid, a known 
scavenger of superoxide from this source (Nishikimi, 1975), completely inhibited 
the reduction of cytochrome C. Results for superoxide production are expressed 
as AA550nm/min, whilst, results for uric acid production are expressed as A 
A284nm/min. 
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2.2.2. Determination of Cu 2+ Chelation by AGE 
The Cu2-" chelating properties of AGE were assessed using a novel approach 
based upon restoring the activity of xanthine oxidase. This enzyme is completely 
inhibited in the presence of 50[tM CUS04 (Lowe et al., 1998). Monitoring either 
the production of the superoxide ions or the formation of uric acid can assess the 
activity of xanthine oxidase. If whole AGE or the diethyl ether extract of AGE 
should chelate Cuý+ then xanthine oxidase activity would be restored. AGE or the 
diethyl ether extract of AGE was added at 0-10% (v/v) along with 50ýLM CUS04- 
Additionally, in separate experiments 60pM EDTA (ethylenediamine tetraacetic 
acid) was added along with 50 gM CuSO4 as a positive control. Results for 
superoxide production are expressed as AA550nm/min, whilst, results for uric 
acid production are expressed as AA284nm/min. 
2.2.3. Assessment of Inhibition of Lipid Hydroperoxide Formation by AGE 
15-Lipoxygenase is an intracellular enzyme that adds oxygen to polyunsaturated 
fatty acids (PUFAs) to yield lipid peroxyl radicals (Yamamoto, 1992). This lipid 
peroxyl radical abstracts a hydrogen atom from an adjacent PUFA yielding a lipid 
hydroperoxide and a carbon-centred PUFA radical. This lipid peroxidation 
process can be monitored via molecular rearrangement of the carbon-centred 
radical to form a conjugated diene compound exhibiting UV absorbance at 
234nm. 
15-Lipoxygenase was prepared to a concentration of 10,000U/ML in 0.2M borate 
buffer (pH 9). Linoleic acid was solubilized in absolute ethanol and prepared as a 
0.6ýLM substrate solution in 0.2M borate buffer (pH 9) with the final ethanol 
concentration being 0.01% (v/v). The generation of hydroperoxy lipids was 
performed in a reaction volume of 3mL containing 50OU 15-lipoxygenase and 
2mL of 0.6gM linoleic acid. The reaction was monitored by the formation of 
conjugated dienes at 234nm (Esterbauer et al., 1989), and results are expressed as 
AA234nm/min. 
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Only the diethyl ether extract of AGE was added at 0-10% (v/v). The presence of 
1.5mM Troloe, a more polar analogue of vitamin E, completely inhibited the 
formation of lipid hydroperoxides. 
2.3. IN VITRO LDL OXIDATION ASSAYS 
2.3.1. Isolation of Human LDL 
Ethical approval for the use of human volunteers was obtained from the John 
Moores University Ethics Committee. Venous blood was drawn from healthy 
human volunteers and 9 volumes of blood were added into I volume of 3.8% 
(w/v) sodium citrate solution as anticoagulant. Plasma was obtained by 
centrifugation at 20OOg for 20 minutes. LDL was isolated using a method 
developed by Graham et al (1996) and subsequently modified by Lowe et al 
(1999). 
Plasma obtained was mixed with OptiprepTM (60% (w/v) iodixanol) to give a 12% 
(v/v) solution of iodixanol; 5mL of this was layered under 5mL of 6% (v/v) 
solution of iodixanol in saline in an 11.2mL OptisealTm tube. The tube was 
topped up with saline and the gradient was ultracentrifuged at 402,000g and 160C 
for 3h 10 minutes using a VTi 65.1 rotor. The brightly coloured LDL band was 
located approximately one third of the way down the tube and was removed with 
a cannula. LDL was characterised as previously described in Lowe et al (1999) 
by measuring the amount of protein, triglycerides, and cholesterol present and by 
measuring the electrophoretic mobility of lipoprotein fractions (Papadopoulos, 
1985). 
2.3.2. Assessment of the Ability of AGE to Inhibit Oxidation of Human LDL 
LDL was used at 200gg protein/nil and was oxidatively modified by both 
enzymic and non-enzymic methods. LDL was incubated for 5h at 370C in the 
presence of lOgM CUS04,, or 16mU xanthine, oxidase and 240PM xanthine. In 
another set of experiments LDL was incubated for 16h at 370C in the presence of 
50OU 15-lipoxygenase. These incubations and relevant controls were performed 
in the presence of 5% and 10% (v/v) whole AGE or 5% and 10% (v/v) diethyl 
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ether extract of AGE. In addition, a time course over Sh was performed for Cu2"- 
mediated oxidation of LDL in the presence and absence of the diethyl ether 
extract of AGE. Samples were removed every 30 minutes and the reaction was 
terminated by rapid freezing. Samples were stored at -200C for no longer than 
48h prior to analysis for TBARS, or stored at 4'C for no longer than 24h prior to 
electrophoretic analysis. 
2.3.2.1. Thiobarbituric Acid Reactive Substances (TBARS) Assay 
Malondialdehyde (MDA) is a product of lipid hydroperoxide decomposition and 
is subsequently used an as index of lipid peroxidation (Esterbauer & Cheeseman, 
1990). The MDA concentration of a sample can by measured using the TBARS 
assay (Mao et al, 1994). This assay is based on a reaction between MDA and 
thiobarbituric acid (TBA) which produces a pink complex with an absorbance 
maximum at 532nm. 
Protein was precipitated by the addition of O. 5mL of 20% (w/v) trichloroacetic 
acid (TCA) to ImL of LDL suspension. Following centrifugation ImL of 1% 
(w/v) thiobarbituric acid (TBA) was added to ImL of the supernatant; samples 
were then heated to 95'C for 10 minutes, and upon cooling the absorbance was 
read at 532nm. Hydrolysed tetraethoxypropane was used as the standard. This 
was prepared as a lOmM solution in 1% (v/v) H2SO4; following hydrolysis at 
room temperature for 2h; the solution was diluted accordingly in PBS and a 
calibration curve (0-10 rimoles MDA, Appendix I) was constructed using the 
TBARS assay described. TBARS production could not be used to assess the 
antioxidant potential of whole AGE as it interfered with this colorimetric assay. 
Results are expressed as nmoles of MDA/mg LDL protein. Where appropriate 
MDA production (nmoles/mg LDL protein) was plotted versus time and lag times 
were determined from the interception of linear trend lines drawn through the lag 
phase and propagation phase of Cuý+-mediated lipid peroxidation of LDL. Where 
there was no observable propagation phase the lag time was taken at the end of 
the experiment, this being 300 minutes. 
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2.3.2.2. Electrophoresis qfLDL 
On agarose gels, lipoproteins separate based on overall electronegative charge 
into the following fractions (in order of increasing mobility and increasing overall 
electronegative charge, see also figure 2.2): 
" The chylomicrons: these are very large lipoproteins with high triglyceride 
content. T'hey normally remain at the application point. 
" The beta lipoproteins or LDL. 
" The pre-beta lipoproteins or very low-density lipoproteins (VLDL). They 
have a molecular weight higher and a density lower than LDL. They are more 
mobile than LDL. 
" The fast pre-beta lipoproteins: this fraction is composed of lipoprotein (a) 
(Lp(a)) which is similar in size and composition to LDL. Lp(a) when present 
at a sufficiently high concentration, can be seen migrating between VLDL and 
HDL. 
" The alpha lipoproteins or high-density lipoproteins (HDL): they are the fastest 
fraction. 
The electrophoretic mobility of lipoproteins was in part used to characterise the 
LDL fraction (Papadopoulos, 1985). Electrophoretic mobility of LDL samples 
was also used as an indication of protein oxidation. Oxidised LDL has a greater 
electronegative, charge and a greater mobility than native LDL on agarose gels. 
This is primarily due to oxidative modification of the apo B protein in LDL- 
These analyses were performed using Sebia hydragel lipo + Lp (a) gels. Samples 
(2 or 4pQ were electrophoresed at a constant 27mA/gel for 80 minutes, then oven 
dried at 850C and stained with Sudan Black for 15 minutes. The electrophoretic 
mobility of LDL oxidatively modified in the presence and absence of whole AGE 
or the diethyl ether extract of AGE was compared to that of native LDL. 
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Figure 2.2. The Electrophoretic Profile of Plasma Lipoproteins. Depending on 
the sample composition, the following lipoprotein bands can be observed. 
Chylomicrons remain at the point of sample application and would not necessarily 
be observed if fasting samples were collected. LDL are the slowest fraction after 
chylomicrons and HDL are the fastest fraction. 
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2.3.3. Determination of LDL Binding Capacity of AGE 
Human plasma was incubated at 37'C for lh in the presence of ImM 
phenylmethyl-sulphonyl fluoride (PMSF) to inhibit any protease activity and 
whole AGE or the diethyl ether extract of AGE. Whole AGE was included at I%, 
3%, and 5% (v/v) and the diethyl ether extract of AGE was included at 5% and 
10% (v/v). Controls contained plasma and PMSF. After lh incubation plasma 
samples were removed and LDL was isolated. Isolated LDL used at 200ýtg 
protein/mL was subsequently oxidised with 10ýLM CUS04- Samples were 
removed every 30 minutes and the reaction was terminated by rapid freezing. 
Samples were stored at -20'C for no longer than 48h prior to TBARS and 
subsequent lag time analysis. 
2.3.4. Assessment of Endogenous LDL Antioxidant Preservation by AGE 
LDL was isolated as previously described. Whole LDL (0.5mL) was 
subsequently incubated for 4h at 37'C in the presence of 100ýM CUS04- These 
incubations and relevant controls were performed in the presence 10% (v/v) 
diethyl ether extract of AGE (this extract was re-suspended in 250ptL PBS). 
Samples were removed at Oh, lh, 1.5h 2h, and 4h and the reaction was tenninated 
by rapid freezing. Samples were stored at -200C for no longer than 48h prior to 
TBARS analysis or extraction of antioxidants. 
23.4.1. Extraction of a-Tocopherol and Carotenoidsfrom LDL 
a-Tocopherol and carotenoids were extracted from LDL as described by Lowe et 
al. (1999). LDL sample (O. SmL) was thoroughly defrosted followed by addition 
of I mL ethanol to precipitate protein. 1.5mL dried diethyl ether was then added, 
followed by addition of 1.5mL hexane. Samples were briefly vortexed in between 
addition of solvents. The sample-solvent mixture was then left to settle and the 
upper layer (slight orange colour) was removed with a glass pasteur pipette. The 
upper layer was then dried down slowly under a stream of oxygen-free nitrogen 
gas. Prior to HPLC analysis the residue was either stored at 4C in the dark or re- 
suspended in 200jiL ethanol: tctrahydrofuran (THF) (9: 1, v/v) and vortexed 
briefly. 
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2.3.4.2. Analysis of a-Tocopherol and Carotenoids by HPLC 
HPLC analysis of a-tocopherol and carotenoids was performed as described by 
Lowe et al (1999). A Rheodyne injection system (model 7125) was used to inject 
20ptl of sample onto an ODS2 reversed-phase column (Spherisorb 25.0 x 0.46cm, 
5pM particles). cc-Tocopherol and the carotenoids were eluted using an isocratic 
solvent system comprising acetontrile: THF: methanol (65: 22: 13 v/v/v), with 
0.33g/L ammonium acetate at ImL/min using a LKB Pharmacia 2165 pump 
(LKB Pharmacia, Uppsala, Sweden). A Spectra Physics (Mountain View, CA 
View, USA) Spectra Focus scanning wavelength detector detected a-tocopherol 
and carotenoids at 290nm and 460nm, respectively. Integration was performed 
using Spectra Physics Software. The arbitrary units (AU) determined for cc- 
tocopherol and carotenoids were standardised to LDL protein concentration. 
2.4. ANALYSIS OF PHENOLIC COMPOUNDS IN AGE 
2.4.1. The Folin-Ciocalteu Phenol Assay 
Folin-Ciocalteus' phenol reagent reacts with phenols and non-phenolic reducing 
substances to form chromagens that can be detected spectrophotometrically 
(Ohnishi & Barr, 1978). These chromagens exhibit an increased absorbance 
between 550-750mn. 
The dried down diethyl ether extract of AGE was re-suspended in 200gL PBS, pH 
7.2 for subsequent analysis. To measure free phenols in whole AGE or the diethyl 
ether extract of AGE, 0.5mL of either AGE or its extract was added to 5mL 50% 
(v/v) aqueous methanol. For estimation of total phenols whole AGE or the diethyl 
ether extract of AGE was subjected to acid hydrolysis with 3.75mL 50% (V/V) 
aqueous methanol + 1.25mL concentrated hydrochloric acid. Controls contained 
0.5mL whole AGE or the diethyl ether extract of AGE added to 5mL distilled 
water. All samples were then incubated at 90'C for 2h. The extracts were 
allowed to cool, filtered through a 0.45gM pore, stored at 4'C and used the same 
day. 
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The whole AGE filtrate (100gL) was made up to 0.5mL volume with distilled 
water and the diethyl ether extract of AGE filtrate was used neat for subsequent 
analysis. The filtrates (0.5mL) of whole AGE and the diethyl ether of AGE were 
incubated for 10 minutes at room temperature with 5. OmL alkaline reagent 
(alkaline reagent = ImL 0.5% (w/v) CUS04.5H20 in 1% (w/v) aqueous sodium 
citrate added to 50mL 2% (w/v) NaC03 in O. IM aqueous NaOH). Folin- 
Ciocalteu reagent was diluted 10-fold with distilled water and 0.5mL was added 
to the samples. The samples were gently mixed and incubated at room 
temperature for 30 minutes and the absorbance read at 660nm. Catechin was used 
as the standard. This was prepared as a lmg/mL solution and a calibration curve 
was constructed (Appendix II). The phenolic content of AGE extracts was 
expressed as mg/mL. To calculate the amount of conjugated phenols present in 
the AGE extracts the amount of free phenols was subtracted from the amount of 
total phenols present. 
2.4.2. TLC Analysis 
Whole AGE was used as supplied and the dried diethyl ether extract of AGE was 
re-suspended in 200tiL methanol. In addition, acid hydrolysed extracts were 
prepared. Whole AGE was incubated with 2M hydrochloric acid (1: 1, v/v) for Ih 
at 1000C. The extracts were allowed to cool, filtered through a 0.45ýLM pore, 
stored at 4T and used the same day. A diethyl ether extract of this acid- 
hydrolysed whole AGE was also prepared as previously described and re- 
suspended in 20ORL methanol. 
The untreated and acid-hydrolysed AGE extracts were used for TLC analysis. 
Standard compounds were dissolved in methanol to a concentration of lmg/mL. 
Whole AGE (101Q, 30pL diethyl ether extract of AGE, and I OgL standards were 
loaded onto silica gel 60 F254 TLC plates and left to dry. The plates were run for 
-lh in an ethylacetate: methanol: water (10: 2: 1, v/v/v) solvent system. The plates 
were then dried for 15 minutes at II 5'C. 
The plates were left to cool then visualised using UV light or ferric chloride spray 
reagent (2.7% w/v in 2M HCI). Viewing the plates under UV light displays 
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phenolic compounds with various fluorescence colours, the most common being 
blue and violet. Fine spraying of the TLC plate with ferric chloride and then 
heating the plate at 950C for 15 minutes displays phenolic compounds with 
brown, pink, and blue colours. In both instances, the distance moved by the 
solvent front and the sample/standard bands (centre of the band) were measured in 
millimetres. The distance moved by the sample/standard was divided by the 
distance moved by the solvent front to obtain the Rf value. 
2.4.3. HPLC Analysis 
HPLC analysis of phenolics was performed using whole AGE diluted 1150 with 
methanol and diethyl ether extract of AGE re-suspended in ImL methanol. A 
Waters 2960 Separation Model HPLC (injection system and pump) was used to 
inject 10[d of sample onto a Waters symmetry C18 column (15.0 x 0.46cm, 
3.51iM particles). Column temperature was 30'C. Phenolic compounds were 
eluted at ImUmin using an gradient solvent system comprising which started 
with 5% solution A (acetonitrile + 0.1% (w/v) trifluoroacetic acid) and 95% 
solution B (water + 0.1% (w/v) trifluoroacetic acid) gradually changing to 80% 
solution A and 20% solution B over 20 minutes. A Waters 996 photo diode array 
detector was used to analyse phenolic compounds at 280nm or 200nm4OOnm. 
Integration was performed using Waters Millennium software package. 
2.5. IN VIVO HUMAN STUDIES 
2.5.1. Clinical Trial Design and Subjects 
Apparently healthy subjects who were not taking medication for any known 
disease participated in the study which had the prior approval of the Ethics 
Committee of Liverpool John Moores University. The information sheet used to 
recruit volunteers is displayed in Appendix III. They were divided into two 
groups, non-smokers (n = 10; 5 men, 5 women, mean age 41.6 ± 4.0) and smokers 
(n =10; 5 men, 5 women, mean age 41.0 ± 4.1). All subjects answered a simple 
questionnaire about their age, height, weight, average weekly alcohol 
consumption, and number of cigarettes smoked per day (Appendix IV). Body 
mass index (BMI) was determined as weight (kg)/height2 (m2). On day 0 all 
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subjects provided 10mL samples of mid-stream urine and venous blood between 
10.00h and 12.00h. Subjects then consumed 5mL of AGE daily for 14 days 
between 0700h and 0900h; otherwise, subjects followed their usual diet and 
lifestyle, including alcohol intake. On day 14 blood and urine samples were 
collected in exactly the same way. All subjects then discontinued taking AGE and 
a final set of blood and urine samples were collected on day 28 of the trial (i. e. 14 
days after cessation of AGE supplementation). All blood samples were collected 
into I OOU heparin and plasma was obtained by centrifugation at 20OOg for 20 
min. Plasma and urine was stored at -700C as 0.5mL aliquots. Plasma and urine 
samples specifically used for 8-iso-PGF2,, analysis also included l0Pg/mL 
meclofenamic; acid to prevent any in vitro isoprostane formation. 
Plasma and/or urinary samples were subsequently analysed for protein, 
cholesterol, triglycerides, creatinine, and 8-iso-Prostaglandin F2,,, (8-iso-PGF2, x) 
concentration. Plasma samples were also analysed for its antioxidant capacity to 
scavenge superoxide. 
2.5.2. Enzyme Immunoassay of Plasma and Urinary 8-iso-PGF2. 
Plasma total (i. e. esterified plus free) and urine free 8-iso-PGF2,, concentrations 
were assayed using a competitive enzyme-immunoassay (Figure 2-3). 
Essentially, plasma samples were thawed and incubated at 420C for 10 min to 
melt any lipid or salt crystals. To release 8-iso-PGF2 esterified to plasma lipids, 
4 volumes of plasma were subjected to alkaline hydrolysis with I volume of I OM 
NaOH for 2h at 45'C. The hydrolysis mixture was allowed to cool and 
neutralised by adding an equal volume of 2M HCL The samples were then 
centrifuged at 500g for 5 min to remove any particulate matter. All analyses were 
carried out in duplicate as described in the kit manufacturers instructions; 25 gI of 
either sample and standards (range 0-50,000 pg 8-iso-PGF2,,, /mL) were incubated 
in 96 well plates coated with a goat antibody specific to rabbit IgG followed by 
addition of solutions of alkaline phosphatase conjugated 8-iso-PGF2a and a 
polyclonal rabbit antibody to 8-iso-PGF2a- Wells were then washed thoroughly 
and incubated with a p-nitrophenyl phosphate substrate solution for 45 min at 
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room temperature. A stop solution was added to all wells and the absorbance was 
read immediately at 405nm using a microtiter plate reader. Results were 
expressed as nmol/L plasma ± standard error of the mean (SEM) (pg/mL x 0.003 
= nmol/L). A typical standard curve is displayed in Appendix V. 
Urine samples were thawed and incubated at 42'C for 10 min to melt any lipid or 
salt crystals, centrifuged at 500g for 5 min to remove any particulate matter and 
diluted 1: 10 with Tris-buffered saline, pH 7.4. All samples and standards (range 
0-100,000 pg 8-iso-PGF2. /mL) were assayed in duplicate as described previously. 
Because 24 hour urine collections were not possible, urinary creatinine 
concentrations (mg/mL) were used to standardise urinary 8-iso-PGF2,, output. 
Results are expressed as pmol/mmol of creatinine, ± SEM (pg/mg creatinine, x 
0.32 = pmol/mmol creatinine). A typical standard curve is displayed in Appendix 
V1. 
53 
C 
c-) 
-0 
_c 
C- 
Jzý 1 
in 0 
CA 
-0 
CL. 
0 
, Z: 
Ln 
cl 
U 0 C, 4 
r- 
. j- 
CD CD ce -0 . , 
-I-- 
-0 
-c u2 
54 
-a 
cj 
IN 
ý4 
(C 
.i 
oo 
oc cn 
4- _Z CU 
_O C 
ý: 0m 
6. u 
-0 :1 "0 0-Eý... 
ýc :3 
1-. c2. rA 73 
, r_ 73 
ZZ 
CD :Z A-- 
- $zý U Q) 
uý Z60 
, r- 45 2 rz C. ce ce 2 
2.53. Antioxidant Capacity of Plasma 
The antioxidant capacity of plasma was determined using the Abel'8' antioxidant 
test kit for superoxide and other free radicals with Pholasin"'. This assay is based 
on the generation of superoxide in the presence of Pholasino. If Pholasino is 
present when superoxide is generated light will be emitted. If there are 
antioxidants (other than Pholasite) present capable of scavenging superoxide then 
these will compete with Pholasino for the superoxide and less light will be 
detected. 
Antioxidant capacity of plasma was determined as in the kit manufacturer 
instructions. Sample (251Q was transferred to a luminometer cuvette and the 
following were then added and mixed: 50ptL assay buffer, 100ýtL Pholasino, and 
275gL solution A. Solution B (50[tL) was then added and the light emission was 
recorded using a BioOrbit tube luminometer for -20 seconds and the peak light 
emission was recorded. When solution B is mixed with solution A superoxide is 
generated. The antioxidant capacity of the sample was expressed as the 
percentage reduction in peak light emission compared to controls without sample. 
The percentage reduction was then converted to equivalent ascorbate antioxidant 
units by constructing an ascorbate standard curve ranging from 0-80ýLmol/L 
(Appendix VII). Due to constraints made by the company the precise constituents 
of the solutions in this kit cannot be divulged. 
2.6. GENERAL BIOCHEMICAL ANALYSES 
2.6.1. Protein Assay 
The Bradford protein assay is based upon the Coomassie Blue technique for 
estimation of protein (Bradford, 1976). This assay depends on the change in the 
absorbance spectra of Coomassie Blue when it binds to proteins. The complex 
formed from the binding of protein and dye causes a shift in the dye absorption 
maximum from 465nm to 595nm. 
For protein determination 5pL of sample (diluted if required with saline) was 
transferred into a 96-well microtitre plate and 150pL Bradford reagent was added. 
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The plate %%-as incubated for 10 minutes at room temperature and the absorbance 
read at 550run. Protein concentration was determined by constructing a standard 
curve using human scrum albumin (IISA) from 0 to ImgImL (Appendix VIII). 
Plasma protein concentration was expressed as g/L and all other samples were 
expressed as mg/mL 
2.6.2. Cholesterol Assay 
Total plasma and lipoprotein cholesterol concentration was determined 
enzymatically using InfinityTu Cholesterol Reagent kit. This assay is based on 
enzymatic hydrolysis of cholesterol esters followed by oxidation of free 
cholesterol and subsequent chromophorc formation (Katterman et al, 1984), 
which can be measured spectrophotometrically at 500-550nm (Figure 2.4). 
For cholesterol dctcmination 10pl, of sample was transferred into a 96-well 
microtitrc plate and 200pL cholesterol reagent (containing lOOU/L cholesterol 
oxidasc; 1250U/L cholesterol estcrase; 80OU/L horseradish peroxidase; 
0.25mmol/L 4-aminoantipyrinc; I Ommol/L hydroxybenzoic acid) was added. The 
plate -mas incubated for 15 minutes at room temperature and the absorbance read 
at 540run. Plasma and lipoprotein cholesterol concentration was determined by 
constructing a standard curve using cholesterol calibrators from 0-300mg/dL 
(Appendix W. Total plasma and lipoprotein cholesterol concentrations were 
converted to mmol/L (mg/dL x 0.0259 = mmoVL) 
2.63. Triglyceride Assay 
Total plasma and lipoprotcin triglyccridc concentration was determined 
enzymatically using Peridochrom'O Triglyccridcs GPO-PAP kit. This assay is 
based on enzymatic hydrolysis of triglyccrides followed by phosphorylation, and 
oxidation of glyccrol and subsequent chromophore formation (Nagele et al., 
1984), which can be measurcd spcctrophotometrically at 492nm (Figure 2.5). 
For tfiglyceride dctcrmination lOpL of sample was transferred into a 96-wcll 
microtitrc platc and 200pL triglyccride rcagent (containing 0.5mmol[L ATP; 
0.35mmol/L 4-aminophcnazonc; 300OU/L lipasc; 250OU/L glyccrol phosphatc 
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oxidase; 20OU/L glycerol kinase; 15OU/L peroxidase; 3.5mmol/L 4-chlorophenol) 
%-as added. The plate was incubated for 10 minutes at room temperature and the 
absorbance read at 492run. Plasma and lipoprotein triglyceride concentration was 
determined by constructing a standard curve using triglyceride calibrators from 0- 
300mg/dL (Appendix X). Total plasma and lipoprotein triglyceride 
concentrations %rere converted to mmoUL (mgIdL x 0.0115 = mmol/L). 
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Figure 2.4. Enzymatic Determination of Cholesterol 
CE 
Step 1. Cholesterol Esters -)I Cholesterol + Fatty acids 
CO 
Step 2. Cholesterol + 02 -+ Cholest4-en-3-one + H202 
POD 
Step 3.21120z + HBA Quinoneimine dye + 4H20 
+ 4AAP 
Step 1: Cholesterol esters arc hydrolysed by cholesterol esterasc (CE) to cholesterol and 
free fatty acids. Step 2: Free cholesterol, including that originally present, is then 
oxidised by cholesterol oxidase (CO) to cholest-4-en-3-one and hydrogen peroxide 
(11202). Step 3: The hydrogen peroxide combines with hydroxybenzoic acid (HBA) and 
4-aminoantipyrine (4AAP) in the presence of peroxidase (POD) to form a chromophore 
(quinoneimine dye) which may be quantitated at 500-550nm. 
Figure 2.5. Enzymatic Determination of Triglycerides 
lipase 
Step 1. Triglycerides + 31120 -* -+ Glycerol + Fatty acids 
GK 
Step 2. Glycerol + ATP Glycerol-3-phosphate + ADP 
GPO 
Step 3. Glycerol-3-phosphate + 02 -Jý Dihydroxyacetone phosphate + H202 
POD 
S(ep4.11202+4AP+4CP -+ -+ 4-(p-benzoquinone-mono-imino)- 
phenazone + 21120 + IICI 
Step 1: Triglyccridcs arc hydrolyscd by lipase to glycerol and free fatty acids. Step 2: 
Glycerol is then phophorylatcd by glycerol kinase (GK). Step 3: Glycerol-3-phosphate is 
then oxidised by glycerol phosphate oxidase (GPO) to dihydroxyacetone phosphate and 
hydrogen peroxide (1120ý). Step 4: The hydrogen peroxide combines with 4- 
aminophcnawnc (4AP) and 4-chlorophcnol (4CP) in the presence of peroxidase (POD) to 
form a chromophore (4-(p-bcnzoquinone-mono-imino)-phcnazonc) which may be 
quantitated at 492nm. 
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2.6.4. Creatinine Assay 
Plasma and urinary creatinine were determined using a creatinine clinical 
diagnostic kit. This method is based upon creatinine reacting with alkaline picrate 
to form an orange/yellow coloured complex. Iffie colour derived from creatinine 
is then destroyed at acidic pH (Heinegard & Tiderstrom, 1973). The difference in 
colour intensity measured at or near 500nm before and after acidification is 
proportional to the creatinine concentration. 
For creatinine determination 150p. L of sample (diluted if required with saline) was 
transferred into a cuvette and I. 5mL of alkaline picrate solution (prepared by 
mixing 5 volumes of creatinine colour reagent (0.6% picric acid) with I volume of 
IM NaOl-0 was added then mixed and incubated at room temperature for 10 
minutes. The absorbance at 500nm was then recorded (Initial A). 50ýLL of acid 
reagent (mixture of sulphuric acid and acetic acid) was then added, mixed 
thoroughly and allowed to stand at room temperature for 5 minutes. Tle 
absorbance at 500run %%-as then recorded (Final A). Final A was then subtracted 
from Initial A to give actual absorbance. Plasma and urinary creatinine 
concentration was determined by constructing a standard curve using creatininc 
calibrators from 0-10mg/dL (Appendix XI). Plasma and urinary creatinine 
conccntration'%Vrc converted to tunol/L (mg/dL x 88.4). 
Urinary creatinine concentration was used to standardise urinary concentrations of 
8-iso-Prostagiandin F2.. Plasma crcatinine concentration (mgIdL) was used to 
estimate crcatinine clearance (mUmin) which is a measure of glomerular filtration 
rate. This %kms determined using the following calculation were creatinine is 
related to lean body mass (Cockcroft & Gault, 1976): 
Crcatininccleamec(mUmin) - (140-age in years) x (weight in kg) 
72 x plasma creatinine in mgIdL 
Note. For women multiply above calculation by 0.85. 
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2.7. STATISTICAL ANALYSIS 
Results are expressed as means ± standard error of the mean (SEM). The 
significance of differences was assessed using the student's two-tailed, 
paircd/unpaircd west, p<0.05 was considered statistically significant. Analysis of 
correlation vms performed using the Pearson correlation test, which generates an 
r-value. R-values close to I denote good correlation. A negative r-value denoted 
inverse correlation. Analyses were performed using Microsoft Excel-97 statistical 
package. 
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CHAPTER3 
THE IN VITRO ANTIOXIDANT NATURE 
OF AGED GARLIC EXTRACT 
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3. THE IN P7TRO ANTIOXIDANT NATURE OF AGED GARLIC 
EXTRACT 
3.1. INTRODUCrION 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced 
metabolically by the human body have been implicated in the pathogenesis of 
several human diseases, including atherosclerosis (Halliwell & Gutteridge, 1998). 
Endogcnous human defences against ROS- and RNS-induced damage include 
antioxidant enzymes such as the superoxide dismutases, glutathione peroxidases, 
and catalase, and antioxidant compounds such as bilirubin, uric acid, and 
glutathione (Becker et al., 1991, Mates & Sanchez-Jimenez, 1999, Stocker et al, 
1990). This defence system is supported by dietary antioxidants such as vitamin 
F, vitamin C, carotenoids, and flavonoids (Bendich & Langseth, 1995, 
Evstignccva ct A, 1998, Krinsky, 1998, Ricc-Evans, 1995). Mechanisms and 
evaluation of antioxidant action can include scavenging of reactive species, 
inhibiting the formation of reactive species, recycling of other antioxidants, 
upregulation of cndogcnous antioxidant defences, and binding catalytic metal ions 
(Halliwcll et al, 1995, Halliwell, 1997). 
An important mechanism in the development of atherosclerosis is the oxidation of 
low-density lipoprotcins; (LDL), which due to its pro-atherogenic properties 
results in atherosclerotic plaque formation, progression, and subsequent coronary 
complications (Keaney, 2000). Because the oxidative modification of LDL 
appears to be a central mechanism for the development of atherosclerosis many 
studies have focused on the ability of nutritional antioxidants to directly inhibit 
this oxidation process in vitro or following dietary supplementation (Bowen et al., 
1998, Fuhrman ct al, 1997b, 1997d, Fuller et al, 2000). 
Over the last decade many studies have focused on the antioxidant nature of garlic 
and it's numerous preparations and constituents. Fresh garlic and garlic powder 
extracts have been demonstrated to scavenge hydroxyl and peroxyl radicals in cell 
free assays and prevent hydroxyl radical-induccd lipid peroxidation in rat liver 
homogcnatcs (Aruoma ct al., 1997, Prasad et al., 1995,1996). Supplementation 
with garlic extracts has been shown to preserve or increase antioxidant enzyme 
62 
activity in animal models of oxidative stress (Helen et al., 1999, Pedraza-Chaverri 
et al., 2000). These latter studies noted preserved or increased activities of the 
antioxidant enzymes superoxide dismutase (SOD), glutathione pcroxidase, and 
catalase. Dietary supplementation studies with garlic powder extracts have 
proven inconsistent with regards to reducing the susceptibility of subsequently 
isolated LDL to oxidative modification (Byrrie et al., 1999, Orekhov et al., 1996, 
Phelps & Harris, 1993, Simons et al., 1995). 
Similar antioxidant properties have been published for AGE. AGE and one of its 
constituents S-allylcysteine (SAC) have been shown to scavenge the ROS 
hydrogen peroxide and t-butyl-hydroperoxide and hence prevent oxidant injury to 
endothclial cells, liver microsomes, and erythrocytes (Ide & Lau, 1999a, Ide et al., 
1996, Imai et al., 1994, Moriguchi et al., 2001, Yamasaki ct al., 1994). 
Interestingly, one of these studies reported that water extracts of raw and heat- 
=tcd garlic enhanced pcroxidation of liver microsomes induced by t-butyl- 
hydroperoxide (Imai et al., 1994). Studies have shown that AGE and SAC protect 
endothclial cells from oxidant-induced injury by increasing the activity of SOD 
and preventing depiction of the endogenous antioxidant compound glutathione 
(GSII) (Gcng & Lau, 1997, Ide & Lau, 1999a, 1999b, 200 1). This preservation of 
GSII levels by AGE is due to increased activity of glutathione disulphide (GSSG) 
rcductase and hence modulation of the glutathione redox cycle (Geng & Lau, 
1997). In vitro lipid peroxidation of LDL induced by Cu2' was significantly 
reduced in the prcscncc of AGE and some of its constituents and dietary 
supplementation with AGE %-as shown to significantly reduce the susceptibility of 
subsequently isolated LDL to CJ'ýmcdiatcd lipid peroxidation (Ho et al., 2001, 
Ide ct al., 1997, Munday et al., 1999). This latter study observed that dietary 
supplementation with raw garlic had no effect on the susceptibility of 
subsequently isolated LDL to Cu2+-mediatcd lipid pcroxidation. 
Oxidation of apolipoprotcin B-100 in LDL appears to be important for scavenger 
receptor recognition and subsequent uptake of oxidiscd LDL by macrophages, this 
uptake by macrophages can occur in the absence of lipid pcroxidation (Hunt ct al., 
1994). With most studies focusing on lipid peroxidation of LDL the effect of 
AGE and other garlic prcparations on inhibiting protein oxidation of LDL are 
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lacking. While AGE and other garlic preparations have been shown to increase 
the activity of certain antioxidant enzymes and reduce metal ion-induced 
oxidation of LDL (Geng & Lau, 1997, Hclcn et al., 1999, Ide et al., 1997, 
Pcdraza-Chaverri et al., 2000), to date the ability of garlic preparations to prevent 
enzyme-mediated oxidation of LDL has not been examined. 
The aim of this study NNras to investigate the in vitro antioxidant potential of aged 
garlic extract (AGE). Initial studies examined the ability of AGE to scavenge 
superoxide ions and inhibit lipid hydropcroxide formation in cell-free systems. 
Subsequent studies utilized isolated human LDL, which was challenged with 
Cu2". xanthine-xanthine oxidasc, or 15-lipoxygenase, and AGE was examined for 
its ability to prevent the oxidative modification of LDL. These studies are 
schematically represented in Figure 3.1. 
3.1.1. Overview of Study 
Superoxide ions %verc generated during the xanthine oxidase-catalyzed breakdown 
of xanthinc to uric acid. This enzymatic reaction can be monitored by two 
methods, namely superoxide production via cytochrome C reduction at 550run 
and xanthinc oxidase activity via uric production at 284nm (Edwards et al., 1987, 
Mondal & Mitra, 1994, see Chapter 2, pp 41-42 for detailed methods). The ability 
to monitor this reaction by using two methods is important in assessing the 
mechanism by which AGE interferes with this assay i. e. direct scavenging of 
superoxide or inhibition of xanthine oxidase itself 
In another set of experiments lipid hydroperoxides were generated during the 15- 
lipoxygenase-mediated oxygenation of the PUFA linoleic acid. This reaction 
begins with the formation of a lipid peroxyl radical, which in turn abstracts a 
hydrogen atom from a neighbouring PUFA to yield a lipid hydroperoxide and a 
carbon ccntrcd radical. This lipid peroxidation process is monitored via molecular 
rearrangement of the carbon-ccntrcd radical to a conjugated dicne compound at 
234nm (Estcrbaucr ct al, 1989, see Chapter 2, pp 43-44 for detailed methods). 
AGE was aSsCssCd for its ability to prevent lipid hydroperoxide formation. 
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In the final series of experiments human lipoproteins were isolated by density 
ultracentrifugation and LDL was differentiated from other lipoprotein fractions by 
measuring the amount of cholesterol, triglycerides, and protein present and 
observing its electrophorctic mobility on agarose gels. LDL was oxidatively 
modified by both enzymic (xanthine oxidase/xanthine and 15-lipoxygenase) and 
non-enzymic methods (Cu2) in the absence and presence of AGE. Measuring 
TBARS production assessed lipid peroxidation (Mao et al., 1994) and protein 
oxidation %ras assessed by increased clectrophorctic mobility on agarose gels. 
The effect of AGE on the characteristic lag phase and propagation phase of CU2+- 
mediated lipid pcroxidation (Esterbauer & Ramos, 1995) was also assessed. For 
detailed methods see Chapter 2, pp 44-47. 
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31. RESULTS 
31.1. Superoxide Scavenging Ability of AGE 
Superoxide production by xanthine-xanthine oxidase measured by the reduction 
of cytochrome gave a reaction rate of 0.040 ± 0.001 AA550nm/min. The 
inclusion of 3mM ascorbic acid, a known superoxide scavenger (Nishikimi, 
1975), inhibited the reduction of cytochrome C by approximately 98% (Table 
3.1). Similarly, the presence of 50U of superoxide dismutase inhibited the 
reduction of cytochrome C by 98%; this confirms the production of superoxide in 
the enzyme reaction. Xanthine oxidase activity measured by the production of 
uric acid gave a reaction rate of 0.060 ± 0.002 AA284nm/min and was not 
significantly affected by the presence of superoxide dismutase (Table 3.1). 
At 10% (v/v) of the reaction volume, both whole AGE and the diethyl ether 
extract of AGE signiflcantly inhibited superoxide production i. e. the reduction of 
cytochromc C by 100% and 34% respectively. Superoxide production was 
inversely related to the concentration of AGE or the diethyl ether extract of AGE 
(r = -0.96 and -0.97 respectively, Figure 3.2). Uric acid production was not 
signiricantly affected in the presence of the dicthyl extract of AGE. Tlese results 
suggest that components of AGE present in the diethyl ether extract of AGE do 
not inhibit xanthinc oxidasc, rather they scavenge superoxide generated in this 
reaction as evidenced by their inhibition of cytochrome C reduction (Figure 3.2). 
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Table 3.1. The effect of SOD. ascorbic acid, whole AGE and a diethyl ether 
extract of AGE on superoxide and uric acid production by xanthine-xanthine 
oxidase. Values are means of three experiments ± SEM. Significant differences 
(p < 0.05) from control' (xanthine-xanthine oxidase only) are indicated by *. 
Extract/Agent Superoxide Production 
(AA550rim/min) 
Uric Acid Production 
(AA284nm/min) 
None 1 0.040 0.001 0.060 ± 0.002 
50U SOD 0.001 0.001* 0.057 ± 0.003 
3mM ascorbic acid 0.001 0.001* N. D. 
10% whole AGE 0* N. D. 
10% diethyl ether extract 0.027 ± 0.001 0.053 ± 0.005 
of AGE 
N. D.: not determined. 
100 
00 
60 
40 
-0 10 - v 
0 
0 2468 10 
AGE Preparation (% v/v) 
Figure 3.2. Concentration dependant inhibition by whole AGE (*) and a diethyl 
ether extract of AGE (0) used at 0-10% (v/v) on reduction of cytochrome C by 
superoxide ions generated by xanthine-xanthine oxidase. Values are means of 
three separate experiments ± SEM. Pearson correlation coefficient (r) for AGE 
and diethyl ether extract of AGE was -0.96 and -0.97 respectively. Significant 
differences (p < 0.05) from control (0% AGE preparation) are indicated by *. 
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3.2.2. Inhibition of Lipid Hydroperoxide Formation by AGE 
Lipid hydroperoxide formation by 15-lipoxygenase/linoleic acid measured as the 
production of conjugated diene compounds gave a reaction rate of 0.30 ± 0.01 
AA234mn/min. The inclusion of 1.5mM Troloxe, a synthetic analogue of the 
lipophilic chain-breaking antioxidant vitamin E, completely inhibited conjugated 
diene formation (Table 3.2). The presence of the diethyl ether extract of AGE at 
10% (v/v) significantly reduced conjugated diene formation by 50%. The 
concentration of the diethyl ether extract of AGE was inversely correlated (r =- 
0.86) the amount of conjugated dienes formed (Figure 3.3). These results suggest 
that components of AGE present in the diethyl ether extract of AGE reduce lipid 
hydroperoxide formation by scavenging of lipid peroxyl radicals and/or inhibition 
of 15-liPOxygenase activity. 
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Table 3.2. The effect of Troloxo and a diethyl ether extract of AGE on lipid 
hydroperoxide formation measured as conjugated diene formation by 15- 
lipoxygenase/linoleic acid. Values are means of three experiments ± SEM. 
Significant differences (p < 0.05) from control' (15-lipoxygenase/linoleic acid 
only) are indicated by *. 
Extract/Agent Conjugated Diene Formation 
(AA234mn/min) 
N- - 
None' 0.30 ± 0.01 
1.5mM Trolox& 0* 
10% diethyl ether extract of AGE 0.15 ± 0.01* 
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Figure 3.3. Concentration dependant effect of a diethyl. ether extract of AGE used 
at 0-10% (v/v) on lipid hydroperoxide formation measured as conjugated diene 
formation by 15-lipoxygenase/linoleic acid substrate solution at 234nm. Values 
are means of three experiments ± SEM. Pearson correlation coefficient (r) was - 
0.086. Significant differences (p < 0.05) from control (0% diethyl ether extract 
of AGE) are indicated by 
*. 
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3.2.3. The Ability of AGE to Inhibit Oxidative Modification of Human LDL 
3.2.3.1. Charaderisation ofHuman LDL 
Human lipoprotein fractions isolated by density ultracentrifugation were 
differentiated from each other by measuring the amount of protein, cholesterol, 
and triglycerides present and observing their electrophoretic mobility on agarose 
gels as described by Lowe et al, 1999 and Papadopoulos, 1985. The amount of 
protein present was determined using the Bradford assay and constructing a 
standard curve using human serum albumin (HSA) as the standard (appendix 
VIII). Cholesterol and triglyceride content was determined enzymatically and by 
constructing a standard curve using cholesterol and triglyceride calibrators 
(appendices IX & X, respectively). 
LDL was distinguished from VLDL by its significantly higher cholesterol (3.54 ± 
0.87 mmol/L vs. 1.20 ± 0.31 mmol/L) and protein concentration (0.65 ± 0.08 
mg/mL vs. 0.29 ± 0.05 mg/mL) and its significantly lower triglyceride 
concentration (0.21 ± 0.11 mmol/L vs. 1.48 ± 0.75 mmol/L) (Figure 3.4). VLDL 
also had a slightly greater electrophoretic mobility than LDL on agarose gels 
(Figure 3.5). LDL was distinguished from HDL by its significantly lower protein 
concentration (0.65 ± 0.08 mg/mL vs. 2.34 ± 0.34 mg/mL) and HDL also had a 
much greater electrophoretic mobility than LDL on agarose gels (Figures 3.4 & 
3.5). 
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3.2.31. En2yme Mediated Oxidation ofLDL 
LDL was used at 0.2 mg protein/mL as determined by the Bradford protein assay 
(appendix VIII). Lipid pcroxidation of LDL was monitored by the production of 
TBARS at 532nm. This was converted to mnoles of MDA by constructing a 
standard curve using hydrolyzed tetraethoxypropane as the standard (appendix I). 
LDL incubated in PBS only produced 3.29 ± 0.27 rimol MDA/mg LDL protein 
(Figure 3.6). No significant lipid peroxidation as assessed by the formation of 
TBARS or protein oxidation as assessed by increased electrophoretic mobility of 
LDL was observed in the presence of xanthine-xanthine oxidase (Figures 3.6 & 
3.7). 
LDL incubated in borate buffer only produced 0.19 ± 0.10 nmol MDA/mg LDL 
protein (Figure 3.6). The extent of lipid peroxidation induced in LDL by 15- 
lipoxygenase was significantly increased by 34-fold to 6.46 ± 0.40 nmol 
MDA/mg LDL protein when compared to the LDL in borate buffer control 
(p=0.002, Figure 3-6). This was reduced by approximately 17% (5.39 ± 0.77 
nmol MDA/mg LDL protein) in the presence of 5% (v/v) diethyl ether extract of 
AGE, and significantly reduced by approximately 37% (4.10 ± 1.35 nmol 
MDA/mg LDL protein) in the presence of 10% (v/v) diethyl ether extract of AGE 
(p=0.03, Figure 3.6). There was no alteration in the electrophoretic mobility of 
LDL incubated in the presence of 15-lipoxygenase (Figure 3.7). 
74 
a) 
-0 
CIS 
* 
* 
** 
> 
C 
-* 
0 
coo \C CIA C) 
(ulalo. id -1(1-1 Ow/salowu) VCjW 
Ljý a 
N -, = tr) 
c cz 
LQ -0 E 
N 
cts 
n -0 
c1.4 _O 
0 
CD 
ýE -c, 
ce r». 
-0 rz CD 
zi "Ci 
c- 
> Eý -a 
CD 
aZ 
ý: ) Q) Im zi Z 
72 
-0 k2 r_ 
75 
(1. ) 1) lj Cý 
cn --"::; 
cl, ý G -0 
r-, =--0 
F3 C) 
r- 
M ý, c * 
rA 
(X -cu 
cn C, 
u 
'1) 0- , =0 
cn U---v u 
kn -C. " xE 
CL 0 cn .-= X 
CL 
uj 
cr 
a 
>- 
m 
o3 x 
-= C --ý 0 
76 
3.2.3.3. CU2"ýMediated Oxidation qfLDL 
Lipid peroxidation of LDL incubated in the presence of Cu2' was significantly 
increased by approximately 20-fold in comparison with LDL incubated in PBS 
only (3.29 ± 0.27 nmol MDA/mg LDL protein vs. 60.39 ± 7.55 nmol MDA/mg 
LDL protein, p=0.017). The presence of 5% or 10% (v/v) diethyl ether extract of 
AGE significantly inhibited lipid peroxidation by approximately 70% and 81%, 
respectively (18.38 ± 2.28 runol MDA/mg LDL protein and 11.22 ± 3.64 nmol 
MDA/mg LDL protein, respectively, p=0.019 and 0.006, respectively) (Figure 
3.8). 
Oxidation of the LDL lipoprotein by Cu2+ greatly increased its electrophoretic 
mobility (Figure 3.7). This increase in clectrophoretic mobility was completely 
abolished in the presence of 10% (v/v) whole AGE (Figure 3.7). However, this 
effect was not observed with 10% (v/v) diethyl ether extract of AGE (Figure 3.7). 
While the diethyl ether extract of AGE displayed a concentration dependent 
decrease in electrophoretic mobility of LDL even at concentrations of 10% the 
extract had not abolished the Cu 2+_induced increase in electrophoretic mobility. 
The kinetics of Cu2+ mediated oxidation of LDL is characterized by two phases, a 
lag phase and a propagation phase (Esterbauer & Ramos, 1995). The presence of 
the diethyl ether extract of AGE extended the lag phase to such an extent that 
there was no observable propagation phase (Figure 3.9). 
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3.3. DISCUSSION 
Free radicals have been implicated in the pathogenesis of atherosclerosis with the 
free radical initiated oxidative modification of LDL playing a key role (Keaney, 
2000). This oxidative hypothesis of atherosclerosis is supported by several lines 
of evidence: (i) The presence of oxidation products in human and animal 
atherosclerotic lesions (Breuer et al., 1996, Leeuwenburgh et al., 1997, Oguogho 
et al., 1999, Suarna et al., 1995), (ii) LDL extracted from atherosclerotic lesions, 
but not plasma derived LDL, resembles LDL oxidised in vitro (Yla-Herttuala et 
al., 1989), (iii) antibodies raised against oxidized LDL react with atherosclerotic 
lesions but not with normal arterial tissue (Palinski et al., 1989), (iv) patients with 
carotid atherosclerosis have higher levels of autoantibodies to oxidized LDL than 
normal subjects and the degree of atherosclerosis correlates with the concentration 
of autoantibodies present (Chiesa et al., 1998, Inoue et al., 2001, Lehtimaki et al., 
1999, Salonen et al., 1992), and (v) antioxidant treatment is consistent with 
preventing the progression of atherosclerosis (Parker et al., 1995, Sasahara et al., 
1994, Sun et al., 1997, Williams et al., 1992). 
Xanthine oxidase-mediated breakdown of hypoxanthine to xanthine and then to 
uric acid is a key source of the ROS superoxide and hydrogen peroxide in the 
vascular endothelium and increasing evidence suggests that ROS generated from 
this source may contribute to the development of atherosclerosis. In vitro studies 
have identified that circulating plasma xanthine oxidase binds to vascular 
endothelial cells and impairs cell function via oxidative mechanisms (Houston et 
al., 1999) and xanthine oxidase type activity has been identified in human 
atherosclerotic lesions (Swain & Gutteridge, 1995). 
The effect of AGE on superoxide ions generated from this source has been 
investigated in the experiments reported here and results suggest that AGE may 
contain components that actively scavenge superoxide (Table 3.1). These active 
components were present in the diethyl ether extract of AGE and while whole 
AGE was more efficient in inhibiting the reduction of cytochrome C by 
superoxide (Figure 3.2) the possibility that it may directly inhibit xanthine oxidase 
itself and not scavenge superoxide could not be excluded. These results 
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contradict other studies, which have demonstrated that AGE does not possess any 
significant superoxide scavenging ability (Ide et al., 1996). More comparative 
observations cannot be made between the methods and results presented here and 
those reported by Ide et al. (1996) due to absence of methods and data. However, 
this group has repeatedly demonstrated that AGE can scavenge the ROS hydrogen 
peroxide (Ide & Lau, 1999a, Ide et al., 1996). The results from the experiments 
presented here suggest that superoxide generated by xanthine-xanthine oxidase 
alone is not sufficient to induce oxidative modification of LDL (Figures 3.6 & 
3.7) and it may be that superoxide interacts with other reactive species such as 
nitric oxide to produce extremely potent free radicals (i. e. peroxynitrite) capable 
of inducing LDL oxidation (Hogg & Kalyanaraman, 1998, Violi et al., 1999). 
15-Lipoxygenase oxygenates PUFAs such as linoleic acid resulting in the 
formation of lipid peroxyl radicals. These lipid peroxyl radicals are capable of 
initiating the chain propagating process of lipid peroxidation by abstracting 
hydrogen from an adjacent PUFA generating a lipid hydroperoxide and a new 
PUFA radical. This PUFA radical propagates the lipid peroxidation process and 
the lipid hydroperoxide decomposes into a wide range of products capable of 
modifying proteins (Yamamoto, 1992). Substantial evidence now exists 
implicating 15-lipoxygenase in the pathogenesis of atherosclerosis. Using animal 
models of atherosclerosis increased expression of 15-lipoxygenase mRNA and 
protein and colocalization with oxidised LDL has been demonstrated in 
atherosclerotic lesions (Harats et al., 2000, Hiltunen et al., 1995, Yla-Herttuala et 
al., 1990). 15-lipoxygenase inhibitors and disruption of 15-lipoxygenase gene 
expression attenuates atherosclerosis in animal models of atherosclerosis (Bocan 
et al., 1998, Cyrus et al., 1999). Activation of 15-lipoxygenase by oxidised LDL 
has been demonstrated to be one of the mechanisms by which vascular endothelial 
cells may contribute to oxidation of LDL and lipoxygenase-type activity has been 
demonstrated in macrophages capable of oxidising LDL (Derian & Lewis, 1992, 
Rankin et al., 199 1). 
This present study demonstrates that AGE is an efficient inhibitor of 15- 
lipoxygenase-mediated peroxidation of linoleic acid using a cell free system and 
lipid peroxidation of isolated human LDL (Table 3.2 & Figures 3.3 & 3.6). 
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Oxidation of the protein component of LDL was not observed with 15- 
lipoxygenase (Figure 3.7). These inhibitory effects were observed using the 
diethyl ether extract of AGE and could be due to either to inhibition of 15- 
lipoxygenase itself or scavenging of lipid peroxyl radicals. In both cases the chain 
propagation process of lipid peroxidation mediated by 15-lipoxygenase would be 
terminated. The results presented here are one of the first studies that have 
examined the effect of AGE on 15-lipoxygenase mediated lipid peroxidation of 
linoleic acid and LDL. 
Although there is little evidence for the actual involvement of Cu2' in modifying 
LDL in vivo, atherosclerotic lesions have been shown to contain detectable 
amounts of redox reactive copper (Evans et al., 1995, Smith et al., 1992, Swain & 
Gutteridge, 1995). This catalytic copper may contribute to the pro-oxidant 
environment of the atherosclerotic lesion where extensive LDL oxidation takes 
place. In vitro studies have demonstrated that Cu2' induces LDL oxidation by 
binding to discrete sites on apolipoprotein B-100 of LDL (Gieseg & Esterbauer, 
1994, Kuzuya et al., 1992) where it becomes reduced by abstraction of a hydrogen 
atom from apolipoprotein B-100 itself (Lynch & Frei, 1995), or from preformed 
lipid hydroperoxides (Patel et al., 1997), or from a-tocopherol Qwatsuki et al., 
1995, Yoshida et al., 1994). The most important of these being lipid 
hydroperoxides, which decompose into products capable of initiating rapid lipid 
peroxidation and protein oxidation. Thus, the initial amount of lipid 
hydroperoxides present in LDL is important when examining oxidative 
modification induced by Cu2+. Lengthy centrifugation processes requiring 
additional salt removal by dialysis is utilised in many LDL isolation procedures 
and this may result in artificially high levels of lipid hydroperoxides. In an effort 
to overcome this problem a novel method was employed where LDL was isolated 
within 3.5 h using iodixanol as the centrifugation medium. The presence of 
iodixanol which is inert and non-toxic in the LDL sub-fraction did not interfere 
with any of the subsequent assays therefore no dialysis step was required and the 
LDL was not subjected to harsh salt solutions (Graham et al., 1996, Lowe et al., 
1999). This method has proven to be a less harsh and more rapid procedure for 
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the isolation of lipoprotein subfractions because the centrifugation step is only 3.5 
h and a dialysis step was not required. 
Oxidation of LDL by Cu2+ has become a routine method for assessing the 
antioxidant potential of dietary phytochemicals and the studies reported here 
confirm the efficacy of AGE in inhibiting this oxidation process. Whole AGE 
completely abolished the Cuý+-induced electrophoretic shift in LDL, indicating 
there was no oxidative modification of the LDL lipoprotein (Figure 3.7). 
However, the diethyl ether extract of AGE only partially reversed the 
electrophoretic shift in LDL (Figure 3.7). The diethyl ether extract of AGE 
significantly reduced Cu2+-induced lipid peroxidation of LDL as assessed by 
TBARS production to the extent that the propagation phase characteristic of CU2+- 
mediated lipid peroxidation of LDL (Esterbauer & Ramos, 1995) was completely 
abolished (Figure 3.9). These observations may reflect a different mechanism for 
whole AGE and the diethyl ether extract of AGE. The diethyl ether extract may 
act to preserve the lipid soluble antioxidants of LDL and hence prolong the lag 
phase of Cu2+-mediated lipid peroxidation of LDL. These results are in agreement 
with other studies that have shown AGE to be an efficient inhibitor of Cu2+- 
induced lipid peroxidation of LDL in vitro and following dietary supplementation 
(Ide et al., 1997, Munday et al., 1999). In contrast to these previous studies, the 
results presented here also confirm that AGE is an efficient inhibitor of Cu2+- 
mediated protein oxidation of apolipoprotein B- 100 in isolated LDL. 
Collectively these results have demonstrated that AGE may inhibit the 
atherogenic oxidation of LDL by (i) scavenging of superoxide, (ii) inhibiting the 
formation of lipid hydroperoxides, and (iii) inhibiting Cu2+-mediated oxidative 
modification of LDL by possibly two different mechanisms. 
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CHAPTER 4 
THE ANTIOXIDANT MECHANISMS OF 
AGED GARLIC EXTRACT 
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4. THE ANTIOXIDANT MECHANISMS OF AGED GARLIC EXTRACT 
4.1. INTRODUCTION 
Epidemiological evidence, although inconclusive suggests that a diet rich in 
antioxidants such as vitamin E, vitamin C, P-carotene and flavonoids may play a 
role in preventing the development and progression of atherosclerosis (Ascherio et 
al., 1999, Geleijnse et al., 1999, Hennekens et al., 1996, Hertog et al., 1993, 
Klipstein-Grobusch et al., 1999, Knekt et al., 1994,1996, Kushi et al., 1996, 
Rimm et al., 1993, Stampfer et al., 1993). The anti-atherogenic properties 
exhibited by these compounds may be attributed to their ability to prevent LDL 
oxidation. Many biochemical studies have focused on this using single dietary 
antioxidants and there is evidence to show that their presence increases the in 
vitro resistance of LDL to oxidation (Aviram & Fuhnnan, 1998, Bowen et al., 
1998, Jialal & Fuller, 1995). 
Studies suggest that plant polyphenols such as the flavonoids are potent anti- 
atherosclerotic and antioxidant compounds both in vitro and in vivo. They have 
been shown to scavenge reactive species, chelate metal ions, and inhibit enzymes 
implicated in the pathogenesis of atherosclerosis (Brown et al., 1998, Chang, 
1993, Hanasaki ct al., 1994, Miller ct al., 1996,16bak, 1996). Their consumption 
by humans and atherosclerosis-prone mice significantly reduces the susceptibility 
of isolated LDL to lipid peroxidation (Avirarn et al., 2000, Belinky et al., 1998, 
Fuhrman et al., 1997d, Hayek et al., 1997, Hodgson et al., 2000), and the 
suggested binding or absorption of plant extracts and plant flavonoids to LDL 
may explain their cffectiveness in inhibiting the oxidation of LDL (Belinky ct al., 
1998, Grassmann et al., 2001, Hayek et al., 1997, Ivanov et al., 2001, Vinson et 
al., 1995,1998). 
Garlic is a rich source of phenolic compounds (Vinson et al., 1998). Numerous 
phenolic acids have been identified which include p-hydroxybenzoic acid, caffeic 
acid, ferulic acid, vanillic acid, sinapinic acid, p-coumaric acid, and salicylic acid 
(Lawson, 1996, Swain et al., 1995). The concentration of these phenolic acids 
ranges from 1-13pg/g fresh garlic. More recently, flavonoids; have been identified 
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and quantified in whole garlic bulbs following acid-hydrolysis pre-treatment 
(Miean & Mohamed, 2001). The flavonoids identified include quercetin 
(47pg/g), apigenin (217pg/g), and myricetin (693pg/g). There is considerable 
interest in plant polyphenolic flavonoids and phenolic acids due to their 
antioxidant activity and protective effect against the development of 
cardiovascular disease (Rice-Evans, 1995, Visioli et al, 2000a). In spite of this, 
and the relatively high and varied phenolic content of garlic, little work has been 
reported which attributes any of the antioxidant effects of garlic and its 
preparations to its phenolic components. 
Many studies have focused on the efficacy of plant extracts in inhibiting oxidative 
modification of LDL by Cu2+. However, with regards to whole plant extracts 
identifying how these extracts interfere with Cu2+-mediated oxidation of LDL is 
rarely assessed. AGE and one of its antioxidant constituents S-allylcysteine 
(SAC) inhibit the in vitro lipid peroxidation of isolated LDL by Cu 2+ (Ho et al., 
2001, Ide et al., 1997). Dietary intervention with AGE or garlic powder extracts 
has been shown to reduce the susceptibility of isolated LDL to undergo lipid 
peroxidation by extending the lag time of Cu2+-induced lipid peroxidation 
(Munday et al., 1999, Orekhov et al., 1996, Phelps & Harris, 1993). This 
observed elongation of the lag time of Cu2+-induced oxidation suggests that garlic 
extracts may act to prevent depletion of endogenous LDL antioxidants. Other 
studies have assessed the ability of pure plant phenolic: -- compounds to bind Cu2+ 
and hence prevent any initiation of LDL oxidation using spectroscopic assays 
which are unsuitable for whole plant extracts (Brown et al., 1998, Miller et al., 
1996). However, the role of garlic extracts in chelating unbound Cu2+ or 
preventing the depletion of endogenous LDL antioxidants has yet to be addressed. 
The aim of the study reported in this chapter was to investigate the antioxidant 
properties of AGE, and the mechanisms by which AGE exerts its antioxidant 
effects. Initial studies addressed the role of AGE in chelating unbound Cu2+. 
Subsequent studies analysed the phenolic content of AGE using acid-hydrolysed 
extracts, spectrophotometric assays, thin-layer chromatography (TLC), and high- 
pressure liquid-chromatography (HPLQ. Finally, the role of AGE in inhibiting 
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Cuý'ý-mediated oxidation of LDL by preventing the depletion of endogenous LDL 
antioxidants and binding directly to LDL was addressed. The studies are shown 
schematically in Figure 4.1. 
4.1.1. Overview of Study 
The copper chelating properties of AGE were assessed using a novel approach 
based on restoring the activity of xanthine, oxidase. Xanthine oxidase activity 
monitored via the production of superoxide or uric acid is completely inhibited in 
the presence of 50ptM CUS04- If whole AGE or the diethyl ether extract of AGE 
should chelate Cu2+ then xanthine oxidase activity would be restored (see Chapter 
2, pp 43 for detailed methods). 
AGE was assessed for its ability to prevent the depletion of endogenous LDL 
antioxidants during Cuý+-mediated oxidation. Prior to extraction of antioxidants, 
LDL was oxidised in the presence and absence of the diethyl ether extract of AGE 
and samples were removed between 0-4 h and subsequently analysed for TBARS. 
cc-Tocopherol and carotenoids were extracted from LDL and analysed by HPLC 
at 290nm and 460nm, respectively (see Chapter 2, pp 48-49 for detailed methods). 
The nature of the phenolic content of AGE was assessed using quantitative and 
qualitative methods. Acid-hydrolysed extracts were compared with untreated 
extracts. The amount of phenolics in AGE was assessed using the Folin-Ciocalteu 
phenol assay and more qualitative information on the phenolics in AGE was 
assessed by TLC analysis using ferric chloride/UV detection systems. Phenolic 
compounds have a characteristic absorbance at 280mn and AGE was examined at 
this wavelength by HPLC (see Chapter 2, pp 49-51 for detailed methods). 
AGE was assessed for its ability to directly bind to LDL and hence reduce the 
oxidative susceptibility of LDL to Cu2+ mediated oxidation. Whole plasma was 
inc7ubated in the presence and absence of whole AGE and the diethyl ether extract 
of AGE prior to LDL isolation. Isolated LDL was subsequently oxidized by Cu2+ 
and samples were removed every 30 min and subsequently analysed for TBARS. 
(see Chapter 2, pp 45,48 for detailed methods). 
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4.1. RESULTS 
4.2.1. The Cu 2+ Chelation Properties of AGE 
Superoxide production by xanthine-xanthine oxidasc measured as the reduction of 
cytochrome C gave a reaction rate of 0.040 ± 0.001 AA550nm/min. Xanthine 
oxidase activity measured by the production as uric acid gave a reaction rate of 
0.06 ± 0.002 AA284nm/min (Table 4.1). The production of superoxide, and uric 
acid by xanthine-xanthine oxidase was inhibited 100% and 63% respectively in 
the presence of 50jiM CUS04 (Table 4.1). The concomitant addition of 60gM 
EDTA restored both superoxide production and xanthine oxidase activity, 
presumably by chelating Cuý+. 
The addition of 2% whole AGE in the presence Of CUS04 restored xanthine 
oxidase activity (measured as superoxide production) to comparable rates 
exhibited in the presence of 2% (v/v) AGE only (Table 4.1, Figure 4.2). This 
observation was true at all AGE concentrations (Figure 4.2). In contrast, 2% or 
10% (v/v) diethyl ether extract of AGE failed to restore xanthine oxidase activity 
(measured as either superoxide or uric acid production) (Table 4.1). These results 
strongly suggest that whole AGE possess Cu2+ binding capabilities, whilst the 
diethyl ether extract of the aged garlic does not. 
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Table 4.1. The effect of whole AGE, a diethyl ether extract of AGE, and EDTA 
on superoxide and uric acid production by xanthine-xanthine oxidase (X-XO) in 
the presence of Cu2+ * 
Values are means of three experiments SEM. Significant 
differences (p < 0.05) from control' (X-XO) are indicated by and from control 2 
(X-XO + 50jiM CUS04) are indicated by *. 
Extract/Agent CUS04 (50ýLM) Superoxide Uric Acid 
Production Production 
(AA550nin/min) (AA284mn/min) 
NONE' 0.040 0.001 0.060 ± 0.002 
2% Whole AGE 0.024 0.001 ND 
NONE2 +00.022 0.002* 
60ýLM EDTA + 0.039 ± 0.004 0.062 0.003** 
2% Whole AGE + 0.026 ± 0.002*, ND 
2% Diethyl Ether 0 IF 0.025 ± 0.001* 
Extract of AGE 
10% Diethyl Ether 0 0.025 ± 0.003* 
Extract of AGE 
ND: Not Octerinined 
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4.2.2. The Effect of AGE on Cu 2+-Mediated Lipid Peroxidation of LDL and 
CU2+-Mediated Depletion of Endogenous LDL Antioxidants 
Isolated human LDL was oxidised by Cu2+ in the presence and absence of the 
diethyl ether extract of AGE and samples were removed at pre-determined time 
points (0,1,1.5,2, and 4 h). The antioxidants present in LDL were subsequently 
extracted and analysed by HPLC using methods previously described (Lowe et 
al., 1999). Formation of TBARS and depletion of the LDL antioxidants a- 
tocopherol, P-carotene, and lycopene during Cu2+-mediated oxidation was 
compared in the presence and absence of the diethyl ether extract of AGE. 
TBARS production and content of antioxidants were all standardised to LDL 
protein concentration. In order to extract sufficient amounts of endogenous LDL 
antioxidants for HPLC analysis, it was necessary to increase the amount of LDL, 
Cu2', and diethyl ether extract of AGE present per incubation compared to what 
had been used in previous LDL oxidation experiments. LDL was used neat 
(MmL, protein concentration ranged from 0.4-0.5mg/mL), the concentration of 
Cu2+ was increased to 1001iM whilst the diethyl ether extract of AGE used at 10% 
(v/v) was resuspended in 25OgL PBS. 
4.2.2.1 . The Effect ofA GE on C42"ýMediated Upid Peroxidation of LDL 
LDL samples previously oxidised with Cu2' in the presence and absence of 10% 
(v/v) diethyl ether extract of AGE were analysed for TBARS production as an 
index of lipid peroxidation (Mao et al., 1994). This was converted to rimoles of 
MDA by constructing a standard using hydrolysed tetraethoxypropane as the 
standard (appendix 1) and standardised to LDL protein concentration (Bradford, 
1976, appendix VIII). Although it was previously demonstrated that the diethyl 
ether extract of AGE reduced Cu2+-mediated lipid peroxidation of LDL it was 
necessary to reconfirm this because the concentrations of LDL, Cu2+, and the 
diethyl ether extract had been changed to facilitate this particular experiment. 
Under these experimental conditions Cu2' was still an effective initiator of lipid. 
peroxidation of LDL when compared to LDL in PBS only (Figure 4.3). The 
presence of 10% (v/v) diethyl ether extract of AGE significantly reduced Cu2'- 
mediated lipid peroxidation by 23% at 2 hours (15.17 ± 2.21 nmol MDA/mg LDL 
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protein vs. 12.09 ± 0.89 nmol MDA/mg LDL protein, p<0.05), and 44% at 4 
hours (30.37 ± 4.04 runol MDA/mg LDL protein vs. 17.06 ± 2.48 nmol MDA/mg 
LDL protein, p<0.05) (Figure 4.3). This inhibition of lipid peroxidation observed 
in the presence of the diethyl ether extract of AGE and Cu2+ remained 
significantly different from LDL in PBS only (p<0.05, Figure 4.3). 
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4.2.21. The Effect of AGE on C42-'ýMediated Depletion of a-Tocopherol in 
LDL 
LDL samples previously oxidised with Cu2+ in the presence and absence of 10% 
(v/v) diethyl ether extract of AGE were analysed for their cc-tocopherol content by 
HPLC using methods described by Lowe et al. (1999). a-Tocopherol 
concentration was calculated using a standard solution of cc-tocopherol. In brief, 
the absorbance maximum for (x-tocopherol was determined using 
UV/visible spectroscopy. The concentration of the a-tocopherol standard was 
calculated using published extinction coefficients. Different concentrations of the 
cc-tocopherol standard were analysed by HPLC and one concentration from the 
linear range of the concentrations analysed was chosen and repeatedly analysed 
ten times. The concentration of this cc-tocopherol standard and the arbitrary units 
measured by HPLC analysis were used to determine the cc-tocopherol content of 
LDL samples. The a-tocopherol concentration of LDL (Wnol) was standardised 
to the protein concentration of the LDL sample ([tmol/mg LDL protein). cc- 
Tocopherol concentrations of LDL were similar to published values (Lowe et al., 
1999). 
a-Tocopherol levels monitored at 290nm were significantly decreased at 0 hours 
in all LDL samples incubated with Cu2' regardless of the presence of the diethyl 
ether extract of AGE when compared to LDL in PBS only (Figure 4.4, p<0.05). 
At 0h ot-tocopherol levels in LDL were decreased by 28% in the presence of Cu" 
when compared to LDL in PBS only (2.81 ± 0.45 ptmol/mg LDL protein vs. 3.95 
± 0.15 jimol/mg LDL protein, p<0.05) and decreased by 41% in the presence of 
Cu2' and 10% (v/v) diethyl ether extract of AGE when compared to LDL in PBS 
only (2.36 ± 0.67 jimol/mg: LDL protein vs. 3.95 ± 0.15 pmol/mg LDL protein, 
p<0.05) (Figure 4-4). 
Significant decreases in cc-tocopherol content were observed at 0 hours in all LDL 
samples containing Cu2+. The reason for this observation at this present time is 
unknown and may be an artefact of the experiments. Possible explanations may 
be that rapid freezing did not result in rapid termination of Cu2+-induced oxidation 
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of LDL and/or Cu2+ may have reacted extremely rapidly with preformed lipid 
peroxides present in LDL. This initial depletion of a-tocopherol observed at 0 
hours in all samples containing Cu2+ was also true for P-carotene and lycopene, 
(Figures 4.6 & 4.8). Further analysis will be required to explain the reason for 
this observation. The addition of a Cu2+ chelating agent such as EDTA may have 
been more suitable for these experiments were high concentrations of Cu2' were 
employed to induce oxidation of LDL. For these reason all results are also 
presented as percentage change compared to respective controls at 0h (Figures 
4.5,4.7 & 4.9). 
a-Tocopherol levels were decreased at all other time points in all LDL samples 
incubated with Cu2+ again regardless of the presence of the diethyl ether extract of 
AGE when compared to LDL in PBS only (Figure 4.4, p<0.05). At 2 hours a- 
tocopherol levels were significantly depleted by 70% in the presence of Cu2' 
(p=0.03) and even more significantly depleted by 92% when the diethyl ether 
extract of AGE was present (p=0.01). At 4 hours depletion of a-tocopherol was 
maximal in the presence of the diethyl ether extract of AGE and/or Cu2+. When 
values were presented as percent change compared to respective controls at 0 
hours cc-tocopherol levels were depleted in the presence of Cu2+ and this depletion 
appeared to be slightly enhanced by the presence of a diethyl ether, extract of 
AGE. (Figure 4.5). These results suggest that although the diethyl ether extract of 
AGE is an efficient inhibitor of Cu2+-mediated lipid peroxidation of LDL the 
mechanism of this protection does not involve preservation of the LDL 
antioxidant cc-tocopherol. In fact, the diethyl ether extract of AGE appears to 
enhance C2'ý-induced depletion of cc-tocopherol (Figures 4.4 & 4.5). 
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4.2.23. The Effect ofAGE on C42"-Mediated Depletion of fl-Carotene in LDL 
LDL samples previously oxidised with Cu2+ in the presence and absence of 10% 
(v/v) diethyl ether extract of AGE were analysed for their P-carotene content 
using HPLC and methods described by Lowe et al. (1999). The P-carotene 
concentration of standard solutions was determined using UV/visible 
spectroscopy and published extinction coefficients as previously described for cc- 
tocopherol. The P-carotene concentration of LDL (ýtrnol) was standardised to the 
protein concentration of the LDL sample (ttrnol/mg LDL protein). P-Carotene 
concentrations of LDL were similar to published values (Lowe et al., 1999). 
P-Carotene levels monitored at 460nm were decreased at 0 hours in all LDL 
samples incubated with Cu2+ regardless of the presence of the diethyl ether extract 
of AGE when compared to LDL in PBS only (Figure 4.6, p>0.05). At 0 hours 0- 
carotene levels in LDL were decreased by 21% in the presence of Cu2' when 
compared to LDL in PBS only (0.023 ± 0.002 pmol/mg LDL protein vs. 0.029 ± 
0.005 gmol/mg LDL protein) and decreased by 24% in the presence of Cu2+ and 
10% (v/v) diethyl ether extract of AGE when compared to LDL in PBS only 
(0.022 ± 0.002 pmol/mg LDL protein vs. 0.029 ± 0.005 pmol/mg LDL protein) 
(Figure 4.6). 'niese results suggest that initial depletion of P-carotene observed at 
0 hours in the presence of Cu 2+ was not alleviated by the presence of the diethyl 
ether extract of AGE. 
P-Carotene levels were significantly decreased from I hour onwards in all LDL 
samples incubated with Cu2+ regardless of the presence of the diethyl ether extract 
of AGE when compared to LDL in PBS only (Figure 4.6, p<0.05). However, 
significantly higher p-carotene levels were observed in the LDL samples 
incubated with Cu2+ and the diethyl ether extract of AGE compared to the samples 
containing LDL and Cu 2+ from 1.5 hours onwards (Figure 4.6). At 1.5 hours and 
2 hours LDL P-carotene levels were 21% and 16% higher in the presence of the 
diethyl ether extract of AGE and Cu2+ when compared to Cu2+ alone (p<0.05). At 
4 hours virtually all LDL P-carotene had been depleted in the presence of Cu2+ but 
was 82% higher when the diethyl ether extract of AGE was present (0.004 ± 0.001 
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jimol/mg LDL protein vs. 0.001 ± 0.001 )imol/mg LDL protein, p<0.05) (Figure 
4.6). When values were presented as percent change compared to respective 
controls at 0 hour's P-carotene was gradually depleted from I hour onwards but 
this depletion was significantly prevented by the diethyl ether extract of AGE 
from 1.5 hours onwards (Figure 4.7). These results suggest that the diethyl ether 
extract of AGE was an efficient inhibitor of Cu2-ý-mediated lipid peroxidation of 
LDL and the mechanism of this protection may involve preservation of the LDL 
antioxidant P-carotene. 
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4.2.2.4. The Effect ofA GE on Cu2t-Mediated Depletion ofLycopen e in LDL 
LDL samples previously oxidised with Cuý+ in the presence and absence of 10% 
(v/v) diethyl ether extract of AGE were analysed for their lycopene content using 
HPLC and methods described by Lowe et al. (1999). The lycopene concentration 
of standard solutions was determined using LTV/visible spectroscopy and 
published extinction coefficients as previously described for a-tocopherol. The 
lycopene concentration of LDL (pmol) was standardised to the protein 
concentration of the LDL sample (Mol/mg LDL protein). Lycopene 
concentrations of LDL were similar to published values (Lowe et al., 1999). 
Lycopene levels in LDL monitored at 460nm were significantly decreased at 0 
hours in the presence of Cu 2+. However there was no significant decrease in the 
presence of the diethyl ether extract of AGE and Cu2+ when compared to LDL in 
PBS only (Figure 4.8). At 0 hours lycopene levels in LDL were decreased by 
43% in the presence of Cu2+ when compared to LDL in PBS only (0.031 ± 0.002 
pmol/mg LDL protein vs. 0.054 ± 0.006 pmol/mg LDL protein, p<0.05) and 
decreased by 37% in the presence of Cu2+ and 10% (v/v) diethyl ether extract of 
AGE when compared to LDL in PBS only (0.034 ± 0.004 pmol/mg LDL protein 
vs. 0.054 ± 0.006 Molling LDL protein, p>0.05) (Figure 4.8). 
Lycopene levels were also significantly decreased from I hour onwards in all 
LDL samples incubated with Cu2+ regardless of the presence of the diethyl ether 
extract of AGE when compared to LDL in PBS only (Figure 4.8, p<0.05). The 
presence of the diethyl ether extract of AGE had no significant effects on Cu2, ý- 
mediated depletion of LDL lycopene levels at any of the time points investigated 
(p>0.05, Figure 4.8). When values were presented as percent change compared to 
respective controls at 0 hours lycopene, levels were significantly depleted from 1.5 
hours onwards in the presence of Cuý+ and the diethyl. ether extract of AGE had no 
effect on this depletion except at 4 hours when slightly higher levels were 
observed (Figure 4.9). The diethyl ether extract of AGE did not enhance the 
depletion of lycopene as observed with a-tocopherol (Figure 4.4 & 4-5) or 
significantly prevent the depletion of lycopene as observed with P-carotene 
(Figure 4.6 & 4.7). 
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4.23. The Phenolic Nature of AGE 
4.2.3.1 The Phenolic Content ofAGE 
In chapter 3 it was demonstrated that the diethyl extract of AGE possesses 
antioxidant properties using cell free assays and in vitro LDL oxidation studies. 
Because the S-alkylcysteines in AGE are extremely polar compounds it was 
hypothesised that the antioxidant nature of the diethyl ether extract of AGE would 
not be due to the presence of these compounds. This was confirmed by blotting a 
sample of the diethyl ether extract of AGE on filter paper, which was 
subsequently sprayed with ninhydrin (0.2% w/v in ethanol). Ninhydrin reacts 
with amino acids, amines, and amino sugars to produce reddish-purple 
derivatives, except for proline and hydroxyproline where yellow derivatives are 
produced. None of the components of AGE extracted with diethyl ether reacted 
with ninhydrin and reddish-purple or yellow spots were not seen, therefore amino 
acid-containing compounds were not extracted. A pure sample of SAC, the main 
sulphur compound present in whole AGE was analysed and this reacted with 
ninhydrin to produce a pink derivative. This confirms that the components of 
AGE present in the diethyl ether extract were not amino acid based compounds 
like the S-alkylcysteines. The diethyl ether extract of AGE was subsequently 
analysed for its phenolic content. 
The phenolic content of whole AGE and the diethyl ether extract of AGE was 
determined using a colourimetric assay, namely the Folin-Ciocalteu assay 
(ohnishi & Barr, 1978) and by constructing a standard curve using catechin as the 
standard (appendix 11). Because phenolic compounds such as flavonoids are 
generally present in plant extracts in their conjugated forms as glycosides it was 
necessary to perform an acid-hydrolysis step with the AGE extracts. This allowed 
determination of the total phenolic content of whole AGE and the diethyl ether 
extract of AGE. In comparison, treating the extracts with methanol or measuring 
the amount present in untreated AGE samples determined the free phenolic 
compounds in AGE. 
The total amount of phenolic compounds present in whole AGE was found to be 
22.70 ± 1.57 mg/mL (Fable 4.2). Conjugated phenolic compounds accounted for 
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77% of the total Phenolic content of whole AGE, the remaining 23% being free 
phenolic compounds. As expected, the amount of phenolic compounds detected 
in untreated whole AGE was not significantly different from the values obtained 
with the methanol-treated whole AGE (6.10± 0.22 mg/mL vs. 5.26 ± 0.98 mg/mL, 
p>0.05) (Table 4.2). The total amount of phenolic compounds present in the 
diethyl ether extract of AGE was determined to be 1.10 ± 0.05 mg/mL and was 
much less than that observed for whole AGE (Table 4.2). Conjugated phenolic 
compounds accounted for 72% and free phenolic compounds accounted for the 
remainder of the total phenolic content (28%). As observed with whole AGE the 
amount of phenolic compounds detected in untreated diethyl ether extract of AGE 
was not significantly different from the values obtained with the methanol-treated 
diethyl ether extract of AGE (0.24 ± 0.04 mg/mL vs. 0.30 ± 0.05 mg/mL, p>0.05) 
(Table 4.2). 
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Table 4.2. The phenolic content of whole AGE and a diethyl ether extract of 
AGE. In order to measure total phenolics in the extracts, acid hydrolysis at 90'C 
for 2h was required. Free phenolics were measured in extracts treated with 
methanol at 90'C for 2h and in untreated extracts for comparison. Values arc the 
means of three experiments ± SEM. 
Phenolic Compounds Whole AGE Diethyl Ether Extract of 
(mg/mL) AGE (mg/mL) 
Free phenolics in untreated samples 6.10 ± 0.22 0.24 ± 0.04 
Free phenolics in methanol treated 5.26 ± 0.98 0.30 ± 0.08 
samples (A) 
Total phenolics in acid-hydrolysed 22.70 ± 1.57 1.10 ± 0.05 
samples (B) 
Conjugated phenolics (B-A) 17.46 ± 1.27 0.80 ± 0.04 
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4.23.2. Analysis of Phenolic Compounds in AGE By TLC 
Thin-layer chromatography (TLC) analysis was performed to compare the 
properties of the phenolic compounds present in AGE with a battery of known 
standard phenolic compounds. The Folin-Ciocalteu assay confirmed that the 
majority of the phenolic compounds in whole AGE and the diethyl ether extract of 
AGE were present in their conjugated form. For a comparative TLC analysis 
acid-hydrolysed whole AGE and a diethyl ether extract of this were employed as 
well as untreated whole AGE and its diethyl ether extract. Silica gel 60 plates and 
an organic solvent system (ethylacetate: methanol: water (10: 2: 1, v/v/v)) were 
employed for TLC analysis and phenolic compounds were visualised with UV 
light and ferric chloride reagent. 
Whereas untreated whole AGE did not display any separation of phenolic 
compounds under this system, the diethyl ether extract of AGE contained three 
well-resolved bands detected with ferric chloride and four well-resolved blue 
fluorescent bands detected with UV light (Table 4.3 & Figure 4.10). In contrast, 
the acid-hydrolysed whole AGE and its diethyl ether extract displayed a much 
greater mobility of phenolic compounds to the extent that that a smear of 
compounds were detected with ferric chloride. This smear contained a pink band 
and a brown band separated by a discreet brown band which were more 
concentrated in the diethyl ether extract suggesting a more efficient extraction 
under these acidic conditions (Table 4.3 & Figure 4.10). However, a small group 
of bands identified in the acid-hydrolysed whole AGE with Rf values of 1.8-2.2 
were not present in the diethyl ether extract (Figure 4.10). Numerous phenolic 
compounds present in the acid-hydrolysed AGE sample and its diethyl ether 
extract were also detected under UV light. Five bands were detected in the acid- 
hydrolysed whole AGE and six bands were detected in its diethyl ether extract 
(Table 4.3). These compounds exhibited blue, white, and purple fluorescence 
indicating they were phenolic in nature. 
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Table 43. The Rf values for standard phenolic compounds and AGE samples. Er 
designates acid-hydrolysed AGE samples. The Rf values for samples/standards 
were calculated by measunng the distance of the compound moved (measured to 
the centre of spot/smear) and dividing this value by the distance moved by the 
solvent front in millimetres. All experiments were repeated three times and 
values shown are typical of the results obtained. 
Sample/Standard Ferric 
Chloride 
Rf values 
Sample/Standard Uv 
Light 
Rf values 
Standards Standards 
_ 
Caffeic acid (grey) 0.67 Caffeic acid (white) 0.65 
Catechin (grey-brown) 0.70 Catechin (dull) 0.71 
p-Coumaric acid (brown) 0.72 p-Coumaric; acid (blue) 0.71 
Ferulic acid (pink-brown) 0.70 Ferulic acid (blue) 0.67 
Kaempferol (brown) 0.81 Kaempferol (dull) 0.84 
Quercetin (grey) 0.77 Quercetin (dull) 0.80 
Salicylic acid (pink) 0.39 Salicylic acid (white) 0.38 
Diethyl extract of AGE Diethyl extract of AGE 
Band I (brown) 0.55 Band I (blue) 0.52 
Band 2 (brown) 0.64 Band 2 (blue) 0.62 
Band 3 (brown) 0.71 Band 3 (blue) 0.69 
Band 4 - Band 4 (blue) 0.77 
Whole Age-LHLI Whole Age (W) 
Distinct group of 3 brown 0.18 Band I (white) 0.17 
bands 0.20 Band 2 (white) 0.40 
0.22 Band 3 (blue) 0.65 
Band 4 (blue-purple) 0.73 
Pink band 0.58 Band 5 (blue-purple) 0.81 
Discreet brown band 0.61 
Brown Smear 0.62-0.77 
Diethyl Ether Extract of Ag Diethyl Ether Extract of 
an Age (W) 
Pink band 0.56 Band I (white) 0.18 
Discreet brown band 0.61 Band 2 (white) 0.40 
Brown Smear 0.62-0.75 Band 3 (white) 0.54 
Band 4 (blue) 0.65 
Band 5 (blue-purple) 0.73 
Band 6 (blue-purple) 0.81 
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4.2.3.3. Analysis of Phenolic Compounds in AGE by RPLC 
High-pressure liquid-chromatography (HPLQ analysis is a useful technique for 
investigating complex mixtures of phenolic compounds. The acetonitrile/water 
gradient system used allowed separation of phenolic compounds present in AGE 
by polarity with the most polar compounds eluted first. A Waters photo diode 
array detection system was employed and AGE extracts were initially analysed 
for absorbance at 280nm. All phenolic compounds exhibit some absorbance at 
this wavelength. As displayed in Figure 4.11 whole AGE was far too complex an 
extract for HPLC analysis. The diethyl ether extract however was much more 
suitable for HPLC analysis because the baseline remained relatively level with a 
better resolution of peaks (Figure 4.12). 
The largest peaks present in the diethyl ether extract were selected for further 
analysis. In total, four peaks were selected and an absorbance scan was 
performed on these peaks between 200400nm. Three of these peaks appeared to 
be simple phenolic compounds with characteristic single UV maxima at 275nm, 
280nm, and 285mn (Figure 4.13a, b&4.14a, respectively). These three 
compounds were well separated with retention times of 2.23 min, 4.17 min, and 
11.45 min, respectively, the longest retention time indicating the least polar of 
these compounds. The last of these peaks had a retention time of 8.12 and 
appeared to be a more complex phenolic compound with UV maxima at 320nm 
with a broad shoulder at 285nm (Figure 4.14b). These retention times were 
compared to standard plant phenolic compounds namely catechin, caffeic acid, 
and quercetin. These standards had retention times of 5.87 min, 6.64 min, and 
11.07 min, respectively. The UV maximum for catechin was 279nm, the UV 
maxima for caffeic acid was 320nm with a broad shoulder at 295nm, and 
quercetin had a LTV maxima at 370mn with a small shoulder at 300nm. 
These results in conjunction with the results from the Folin-Ciocalteu assay and 
TLC analysis suggest that whole AGE is a rich source of phenolic compounds 
with numerous different types of phenolic compounds present and these phenolic 
compounds were extracted with diethyl ether. 
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4.2.4. The LDL-Binding Properties of AGE 
In previous experiments utilising isolated human LDL the results have shown that 
the diethyl ether extract of AGE is an efficient inhibitor of Cu2+-mediated lipid 
peroxidation and the mechanism behind this inhibition may be in part due to the 
partial preservation of the endogenous LDL antioxidant 0-carotene. In this part of 
the study these in vitro LDL oxidation experiments are taken one step further 
where LDL was isolated from whole plasma previously incubated with AGE. 
These experiments permitted the use of whole AGE and the diethyl ether extract 
of AGE and identified if the antioxidant components present in AGE were 
retained in the LDL fraction when isolated and subsequently oxidised with Cu2+. 
Whole plasma was incubated with whole AGE at 1%, 3%, and 5% (v/v) or the 
diethyl ether extract of AGE at 5% and 10% (v/v). The effect of this incubation 
step with AGE was then assessed on Cu2+-mediated lipid peroxidation of 
subsequently isolated LDL. Samples were removed every 30 minutes with the 
time course starting at 0 hours and ending at 5 hours. LDL was used at 200pg 
protein/mL as determined from the Bradford assay (Bradford, 1976) using human 
serum albumin (HSA) as the standard (appendix VIII). CUS04 was used at 10ýIM 
and lipid peroxidation was assessed using the TBARS assay (Mao et al., 1994) 
and converted to nmoles of MDA by constructing a standard using hydrolysed 
tetraethoxypropane (MDA) as the standard (appendix I) and standardised to LDL 
protein concentration. MDA (nmoles/mg LDL protein) was plotted versus time 
and lag times were determined from the interception of linear trend lines drawn 
through the lag phase and propagation phase of Cu2+-mediated lipid peroxidation 
of LDL. Where there was no observable propagation phase the lag time was 
taken at the end of the experiment, this being 300 minutes. 
Incubation of whole plasma with 1% or 3% (v/v) whole AGE extended the lag 
time of Cu2+-mediated lipid peroxidation of LDL by 24% and 26%, respectively. 
Lag time was non-significantly increased from 96.0 ± 4.9 minutes to 123.0 ± 17.4 
minutes in the presence of 1% whole AGE and 87.0 ± 4.8 minutes to 118.0 ± 3.8 
minutes in the presence of 3% whole AGE (Table 4.4). There was a trend 
towards significance with 3% whole AGE (p=0.07, Table 4.4). 
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Incubation of whole plasma with 5% (v/v) whole AGE significantly extended the 
lag time of Cu2+-mediated lipid peroxidation. of LDL by 71%. Lag time was 
increased from 86.0 ± 9.5 minutes to 300 minutes in the presence of 5% whole 
AGE (p=0.017, Table 4.4). In all experiments incubation of plasma with 5% 
whole AGE consistently extended the lag time of Cu2+-mediated lipid 
peroxidation. of LDL to the final time point (300 minutes, Figure 4.15). 
Incubation of whole plasma with 5% or 10% (v/v) diethyl ether extract of AGE 
extended the lag time of Cu2+-mediated lipid peroxidation of LDL by 20% and 
32%, respectively. Lag time was non-significantly increased from 71.0 ± 8.1 
minutes to 89.0 ± 7.2 minutes in the presence of 5% diethyl. ether extract of AGE 
(Table 4.4) and significantly increased from 62.0 ± 3.5 minutes to 90.0 ± 4.2 
minutes in the presence of 10% diethyl ether extract of AGE (Table 4.4, Figure 
4.16). 
In summary, these results demonstrate that the antioxidant properties of AGE with 
regards to inhibiting lipid peroxidation. induced by Cu2+ remain even when AGE 
is not directly incubated with LDL i. e. LDL is isolated from plasma incubated 
with AGE. These results suggest that components of AGE that are also present in 
the diethyl ether extract bind to or become incorporated within the LDL particle. 
118 
Table 4.4. The effect of incubation of whole plasma with whole AGE or a diethyl 
ether extract of AGE on the lag time of Cu2+-mediated lipid peroxidation of 
subsequently isolated LDL. Values are means of three experiments ± SEM. 
Significant differences (p < 0.05) from control (LDL + Cu2+) are indicated by *. 
LDL Sample Lag Time (minutes) P value 
LDL + Cu 2+ 96.0 ± 4.9 
LDL + Cu2+ + 1% whole AGE 123.0±17.4 0.21 
LDL + Cu 2+ 87.0 ± 4.8 
LDL + Cu2+ + 3% whole AGE 118.0 ± 3.8 0.07 
LDL + Cu 2+ 86.0 ± 9.5 
LDL + Cu2+ + 5% whole AGE 300 0.017* 
LDL + Cu 2+ 71.0± 8.1 
LDL + Cu2+ + 5% diethyl ether 89.0 ± 7.2 0.18 
extract of AGE 
LDL + Cu 2+ 62.0 ± 3.5 
LDL + Cu2+ + 10% diethyl ether 90.0±4.2 0.016* 
extract of AGE 
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43. Discussion 
AGE is a complex mixture of phytochemicals. Therefore, it is not surprising that 
several mechanisms may exist for the inhibition of Cuý+-induced oxidation of 
LDL and two possibilities are chelating Cu2+ thereby preventing any initiating 
events or preventing the depletion of lipid soluble LDL antioxidants. This study 
has demonstrated that whole AGE can alleviate the inhibition by Cu2+ of xanthine 
oxidase by chelating this metal ion (Table 4.1). These Cu2+-chelating properties 
of AGE would thus significantly decrease the oxidative modification of isolated 
LDL. In support of this, the results presented in Chapter 3 demonstrated that 
whole AGE completely abolished the Cu2+-induced electrophoretic shift in LDL, 
indicating there was no oxidative modification of the LDL. However, the diethyl 
ether extract of AGE did not demonstrate any Cu2+-chelating properties (Table 
4.1), but reduced Cu2+-mediated lipid peroxidation, and partially reversed the 
electrophoretic shift in LDL (Chapter 3). In this latter case, the diethyl ether 
extract of AGE was not as efficient as the whole AGE and this may reflect a 
different mechanism where the diethyl. ether extract may act to preserve the lipid 
soluble antioxidants of LDL during peroxidation. 
Other studies have investigated the effects of AGE or other phytochernicals on 
Cul-'ýmediated oxidation of isolated human LDL, but have failed to address the 
possibility of the plant extract chelating Cuý+ (Fuhrman et al., 1997d, Hodgson et 
al., 1999b, Ide et al., 1997, Munday et al., 1999). Several studies have assessed 
the ability of pure plant phenolic compounds to bind Cu2+ using spectroscopic 
assays and concluded that the chelating ability of polyphenols is dependent upon 
the localisation of functional hydroxyl groups (Brown et al., 1998, Miller et al., 
1996). This study has identified the Cu2+-chelating properties of AGE using a 
novel approach namely, the reversal of Cu2+4nduced enzyme inhibition (Table 
4.1). This approach allows the chelating properties of whole plant extracts as well 
as pure phenolic compounds to be assessed. 
As mentioned earlier the diethyl ether extract of AGE did not demonstrate any 
Cuý'-chelating properties (Table 4.1), but reduced Cu2+-mediated lipid 
peroxidation, and partially reversed the clectrophoretic shift in LDL (Chapter 3). 
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If this diethyl ether extract reduces Cu2+ý-mediated oxidation of LDL and this 
effect was not due to chelation of Cuý+ it can be hypothesised that this antioxidant 
effect may be due to preservation of endogenous LDL antioxidants such as a- 
tocopherol, P-carotene, and lycopene. Before rapid lipid peroxidation occurs, 
LDL becomes depleted of its antioxidants, with a-tocopheroI being consumed 
first and P-carotene last (Esterbauer & Ramos, 1995); this is the lag phase of the 
process. It is not until the LDL has lost most of its antioxidant compounds that 
the propagation phase commences and the PUFAs in LDL are rapidly oxidised to 
lipid hydroperoxides. This is followed by the decomposition phase, when the 
lipid hydroperoxides break down and/or rearrange to form a wide range of 
products, including aldehydes, ketones, alcohols, and epoxides (Bhadra et al., 
199 1, Brown et al., 1997, Esterbauer et al, 1991 a). 
Interestingly, the diethyl ether extract of AGE did not prevent the depletion of a- 
tocopherol or lycopene during Cu2+-mediated lipid peroxidation of LDL (Figures 
4.4 & 4.8) even though there was substantial inhibition of lipid peroxidation 
during the same experiments (Figure 4.3). More importantly, the diethyl ether 
extract of AGE actually appeared to enhance depletion of cc-tocopherol during 
Cu2+-mediated lipid peroxidation of LDL (Figures 4.4 & 4.5). The reason for this 
is currently unknown, although other studies have also observed a similar effect 
(Belinky et al., 1998, Hayek et al, 1997). The in vitro oxidation of LDL isolated 
from atherosclerotic mice in the presence of the licorice flavonoid glabridin failed 
to protect a-tocopherol although oxidation was reduced (Belinky et al., 1998). 
Hayek et al (1997) observed that LDL isolated from atherosclerotic mice who had 
consumed the red wine flavonoids catechin and quercetin was more resistant to 
oxidation although this LDL had -50% less cc-tocopherol than the placebo group. 
A more recent study has shown that LDL isolated from human plasma previously 
incubated with lemon oil was more resistant to oxidation and this was independent 
of preservation of cc-tocopherol (Grassmann et al., 200 1). 
In contrast, preservation of P-carotene was observed during Cu2+-mediated lipid 
peroxidation of LDL in the presence of the diethyl ether extract of AGE (Figure 
4.6 & 4.7). Because P-carotene is located within the core of LDL particles it is 
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improbable that there is direct interaction between the antioxidant components 
present in AGE and P-carotene. This suggests that the antioxidant components 
present in AGE extracted with diethyl ether may act to inhibit the chain 
propagation process of lipid peroxidation by scavenging of lipid peroxyl radicals 
and subsequently inhibiting the formation of lipid hydroperoxides; a role assigned 
to c(-tocopherol. Under these circumstances preservation of P-carotene, the last 
antioxidant to be depleted during Cu2-mediated lipid peroxidation of LDL, may 
be observed. This preservation of P-carotene has also been observed in other 
studies where the in vitro oxidation of LDL isolated from atherosclerotic mice in 
the presence of the licorice flavonoid glabridin or LDL isolated from human 
plasma previously incubated with lemon oil inhibited the consumption of P- 
carotene and lycopene (Belinky et al., 1998, Grassmann et al., 2001). 
Garlic is a rich source of plant polyphenols such as flavonoids and phenolic acids 
(Lawson, 1996, Miean & Mohamed, 2001, Swain et al., 1995, Vinson et al., 
1998). The results presented in this study suggest the same is true for AGE. 
Using numerous methods of analysis this study has shown that AGE has a high 
phenolic content (Table 4.2) with many different types of polyphenols present in 
both whole AGE and the diethyl ether extract of AGE (Table 4.3, Figures 4.10, 
4.12,4.13, & 4.14). The antioxidant effect of the diethyl ether extract of AGE 
with regards to scavenging of superoxide, inhibiting lipid peroxide formation, and 
inhibiting oxidative modification of LDL may be attributed to these polyphenolic 
components. The high and varied polyphenolic content of AGE would not be true 
for all cornmercial garlic preparations due to processing and extraction methods. 
Polyphenolic compounds are relatively polar molecules but some do exhibit 
lipophilic tendencies, so their concentration and variability in different garlic 
extracts (aged extracts, oil-based preparations, and powdered extracts) would be 
expected to vary. 
The potent effects of plant flavonoids in reducing the susceptibility of LDL to 
undergo oxidative modification may be related to the absorption or binding of 
these antioxidants to LDL (Belinky et al., 1998, Hayek et al., 1997). These 
studies have shown that LDL from plasma previously incubated with red wine, 
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catechin, quercetin, and glabridin is enriched with these polyphenols. Studies 
with whole plant extracts have also shown that antioxidant components present in 
these extracts exhibit lipoprotein-bound antioxidant activity (Grassmann et al., 
2001, Ivanov et al., 2001, Vinson et al., 1995,1998). Similar experiments were 
also performed with AGE. LDL isolated from whole plasma previously incubated 
with whole AGE or the diethyl ether extract of AGE significantly extended the lag 
time of Cu2-mediated lipid peroxidation (Tables 4.4 & 4.5). These results 
suggest that the potent effects of AGE with regards to inhibiting CU2'-mediated 
lipid peroxidation may in part be due to the ability of components of AGE to bind 
to or become absorbed by LDL. Identifying how these antioxidant components 
present in AGE become bound to or incorporated within LDL may help to explain 
the partial preservation of P-carotene observed in earlier experiments. 
In summary, the results presented here have demonstrated that AGE may inhibit 
the atherogenic oxidation of LDL by Cu2+ by two different mechanisms: (i) by 
chelation of Cuý+ and hence preventing any initiation events and (ii) by preventing 
depletion of the LDL antioxidant P-carotene. This latter effect suggests that AGE 
may directly scavenge lipid peroxyl radical and subsequently prevent lipid 
hydroperoxide formation. The efficacy of AGE in inhibiting LDL oxidation may 
also in part be due to its ability to bind to or become absorbed by LDL and its 
high concentration of polyphenolic antioxidants. 
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5. THE IN VIVO ANTIOXIDANT NATURE OF AGED GARLIC 
EXTRACT 
5.1. INTRODUCTION 
Cigarette smoking is one of the highest risk factors for the development of 
atherosclerotic vascular disease and may be the most important risk factor as it 
contributes to a third of all deaths from this condition (Feeman, 1999, Tierney et 
al., 2000). As cigarette smoke is known to contain a large number of oxidants, it 
has been hypothesised that the adverse effects of smoking may result from 
oxidative damage to lipids, proteins, and DNA (Halliwell & Gutteridge, 1999). 
This damage could result from oxidants present in cigarette smoke or from 
activation of phagocytic cells that generate reactive species. Oxidation of LDL is 
an important mechanism in the development of atherosclerosis and exposure of 
LDL to cigarette smoke results in oxidative modification in vitro and in vivo, 
however evidence for this is controversial primarily due to different and 
unreliable methods of assessing lipid peroxidation (Chen & Loo, 1995, Valkonen 
& Kuusi, 1998, Yamaguchi et al., 2000). 
The hypothesis that smokers are subject to increased oxidative stress is supported 
by more direct evidence: lower plasma levels of the antioxidants a-tocopherol 
(vitamin E), ascorbic acid (vitamin Q and glutathione have been observed in 
smokers when compared to non-smokers, increased plasma levels of lipid 
peroxides have been identified in smokers when compared to non-smokers 
although some results for this are conflicting, and smokers risk of cardiovascular 
disease correlates inversely with their intake of the antioxidants vitamin E and P- 
carotene (Ayaori et al., 2000, Banedee et al., 1998, Liu et al., 1998, Nowak et al., 
1999, Rimm et al., 1993). 
Free radical-mediated peroxidation of membrane and lipoprotein lipids plays a 
pivotal role in the pathogenesis of many diseases including atherosclerosis 
(Esterbauer et al., 1993). Traditional methods of assessing lipid peroxidation in 
vivo have included the measurement of thiobarbituric acid-reactive substances 
(TBARS) or lipid peroxides both of which suffer from ex vivo artifactual 
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generation, instability and non-specificity of analytes (Halliwell, 2000, Jackson, 
1999). Another common method of monitoring lipid peroxidation and assessing 
the efficacy of antioxidants in vivo is to estimate the susceptibility of isolated low- 
density lipoprotein (LDL) to Cu2+-induced oxidation in vitro, the obvious problem 
with this method is that it does not directly relate to oxidant stress in vivo and the 
effect of non-lipoprotein associated antioxidants is removed (Fruebis et al., 1997). 
For these reasons monitoring lipid peroxidation in vivo and assessing the effects 
of dietary intervention with antioxidants on lipid peroxidation has been 
problematic. 
F2-isoprostanes are increased in human conditions thought to be associated with 
increased oxidative stress such as smoking, hypercholesterolemia, hypertension, 
diabetes, and alcoholic liver disease (Cracowski et al., 2001, Davi et al., 1997, 
1999, Devaraj et al, 2001, Gopaul et al., 1995, Meagher et al., 1999, Morrow et 
al., 1995, Reilly et al., 1996,1998). They are formed in situ from arachidonic 
acid through a non-enzymatic process of lipid peroxidation catalyzed by free 
radicals on cell membranes and LDL particles (Morrow et al., 1992, Pratico et al., 
1998). They are cleaved presumably by phospholipases, and circulate in the 
plasma as the free form or esterified to phospholipids whilst the free form is 
excreted in urine (Morrow et al., 1990a, 1990b). F2-isoprostanes are thought to be 
reliable and sensitive markers of lipid peroxidation in vitro and in vivo, which can 
be monitored non-invasively in the urine and are not confounded by lipid-rich 
diets (Gopaul ct al., 2000a, 2000b, Pratico, 1999). 
Due to its vasoconstrictor, platelet activation, and mitogenic properties the F2- 
isoprostane 8-iso-Prostaglandin F2a (8-iso-PGF2a) also known as 8-epi-PGF2 or 
iPF2a-III has received much attention (BaneiJee et at., 1992, Fukunaga et al., 
1993, Janssen, 2000, Kang et al., 1993, Kromer & Tippins, 1996, Minuz et al., 
1998, Takahashi et al., 1992). Elevated plasma and urinary levels of total F2' 
isoprostanes and specifically 8-iso-PGF2 have been demonstrated in smokers 
(Bachi et al., 1996, Morrow et al., 1995, Oguogho et al., 2000, Reilly et al., 1996). 
These studies also noted that upon cessation of smoking or supplementation with 
vitamin C alone or in conjunction with vitamin E the levels of total F2- 
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isoprostanes or 8-iso-PGF2,, dramatically decreased (Morrow et al., 1995, Reilly 
et al., 1996). Also, in support of smoking as a mediator of oxidative stress and 8- 
iso-PGF2,, as marker for increased oxidative stress plasma and urinary levels of 8- 
iso-PGF2,, normalise within two-four weeks of quitting cigarette smoking 
(Morrow et al., 1995, Oguogho et al., 2000, Pilz et al., 2000, Reilly et al., 1996). 
Garlic has attracted considerable interest as a cardioprotective agent (Agarwal, 
1996, Rahman, 2001). Its effects on risk factors for cardiovascular disease 
include reducing plasma lipids, preventing platelet aggregation and subsequent 
thrombus formation, enhancing fibrinolytic activity, and reducing blood pressure 
(Abuirmeileh et al., 1991, Bordia et al., 1998, Kannar et al., 2001, Rahman & 
Billington, 2000, Steiner & Li, 2001, Steiner et al., 1996, Thompson et al., 2000). 
The majority of the studies are human supplementation trials. The antioxidant 
property of garlic has also been well demonstrated but this has mainly been 
concentrated on in vitro studies or in vivo animal studies. These studies have 
demonstrated the AGE possesses substantial antioxidant activity in comparison 
with other garlic preparations, which includes scavenging of reactive species, 
preventing oxidative damage of lipoproteins and endothelial cells, and 
preservation of endogenous antioxidant defences (Geng & Lau, 1997, Ide & Lau, 
1999a, 2001, Ide et al., 1997, Imai et al., 1994). Direct evidence for the 
antioxidant properties of AGE in vivo in humans is insubstantial with AGE 
supplementation reducing the in vitro susceptibility of LDL to oxidation (Steiner 
et al., 1996, Munday et al., 1999). 
The aim of the study reported here was to investigate the in vivo antioxidant 
potential of AGE in human subjects. Initially it was identified whether increased 
oxidative stress due to cigarette smoking results in elevated levels of plasma and 
urinary 8-iso-PGF2. and a decreased antioxidative capacity of plasma to scavenge 
superoxide when compared to non-smoking individuals. The antioxidant 
properties of AGE were then examined by monitoring the effects of AGE 
supplementation on plasma and urinary levels of 8-iso-PGF2,, and the 
antioxidative capacity of plasma to scavenge superoxide in both smoking and 
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non-smoking individuals. These studies are schematically represented in Figure 
5.1. 
5.1.1. Overview of Study 
Apparently healthy subjects recruited for this study (n = 20) were divided into two 
age- and sex-matched groups, 10 non-smokers and 10 smokers. All volunteers 
answered a simple questionnaire about their age, height, weight, average weekly 
alcohol consumption, and number of cigarettes smoked per day (Appendix W). 
The duration of the trial was 28 days in total, starting with 14 days of AGE 
consumption followed by a 14 day washout period. The volume of AGE was 5 
mIJday and blood and urine samples were collected at the start of the trial (day 0), 
on the last day of AGE consumption (day 14), and at the end of the washout 
period (day 28). Plasma and urine samples were stored at -70'C until analysis. 
Routine biochemical measurements included total plasma cholesterol, 
triglycerides, and protein concentrations. Plasma and urinary creatinine 
concentrations were also monitored to assess kidney function and to standardise 
urinary concentrations of 8-iso-PGF2(x, respectively. Total plasma and free 
urinary concentrations of 8-iso-PGF2,, were analysed using a competitive enzyme- 
linked immunoassay (ELISA) and the antioxidant capacity of plasma to scavenge 
superoxide was assessed using a chemiluminescence assay (see Chapter 2, pp 51- 
59 for detailed methods). 
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51. RESULTS 
5.2.1. The Clinical and Biochemical Characteristics of Subjects 
All non-smoking and smoking subjects were asked to complete a simple 
questionnaire (Appendix IV), which provided information relating to age, height, 
weight, alcohol consumption, and smoking habits. Both groups consumed similar 
amounts of alcohol and were similar in age, height and weight. In fact the only 
difference observed between the two groups of subjects was in smoking habits 
(Table 5.1). 
The biochemical characteristics of non-smoking and smoking groups were 
monitored throughout the study and are given in Table 5.2. Plasma protein 
concentration was measured using the Bradford assay (Bradford, 1976) and HSA 
as the standard (Appendix VIII). Total plasma cholesterol and triglycerides were 
measured using enzymatic methods (Katterman et al., 1984, Nagele et al., 1984) 
and relevant cholesterol and triglyceride standards (Appendices IX & X). Plasma 
and urinary creatinine were monitored using a colourimetric assay (Heinegard & 
Tiderstrom, 1973) and creatinine standards (Appendix XI). Plasma creatinine 
concentrations were subsequently used to determine creatinine clearance; a 
measure of kidney function (Cockcroft & Gault, 1976). This latter measurement 
was performed to ensure dietary supplementation with AGE had no effect on 
kidney function. 
All subjects had normal plasma protein concentrations, were normolipidaernic, 
and had normal kidney function as assessed by creatinine clearance (Table 5.2). 
These perameters did not differ significantly between non-smokers and smokers. 
No significant differences were observed before and after supplementation with 
AGE or after the washout period. All individual subject's clinical and 
biochemical characteristics are presented in Appendix XIL 
132 
Table 5.1. Clinical Characteristics of Non-Smoking and Smoking Volunteers. All 
values are the means ± SEM. Analysis for significance was performed using the 
two-tailed unpaired t-test; significant differences (p<0.05) are indicated by *. 
Characteristic Non-smokers 
(n= 10) 
Smokers 
(n= 10) 
T-test (non-smokers 
vs. smokers) 
Gender (male: female) 5: 5 5: 5 
Age (years) 41.60±4.01 41.00±4.08 p=0.57 
Weight (kg) 72.76±5.07 67.51±4.05 p=0.37 
Height (m) 1.69±0.04 1.68±0.03 p=0.75 
Body Mass Index 25.20±1.54 23.71±0.72 p=0.42 
(BMI, kg/m) 
Alcohol Consumption 14.05±4.01 17.60±6.12 p=0.65 
(units/week) 
Number of Cigarettes 0 18.50±1.83 P=0.00* 
smoked/day 
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5.2.2. The Effect of AGE Supplementation in Non-smokers and Smokers on 
Plasma and Urinary Levels of 8-iso-PGF2(,, 
Plasma and urinary levels of 8-iso-PGF2., were determined using a competitive 
enzyme-linked immunoassay and sample values were interpolated from a standard 
curve using 8-iso-PGF2,, (Appendices V& VI). Whereas plasma concentrations 
of 8-iso-PGF2c, were given as nmol/L plasma urinary concentrations were 
standardised to urinary creatinine concentrations and were given as pmol/mmol 
creatinine. 
The level of total 8-iso-PGF2., in plasma from smokers was significantly higher 
when compared to that measured in non-smokers (1.25 ± 0.19 nmol/L vs. 1.98 ± 
0.18 nmol/L, p--0.04) (Figure 5.2). After 14 days of aged garlic extract 
supplementation plasma levels of 8-iso-PGF2., were significantly reduced by 29% 
in non-smokers (1.25 ± 0.19 nmol/L vs. 0.88 ± 0.12 mnol/L, p=0.03) and 35% in 
smokers (1.98 ± 0.18 nmol/L vs. 1.28 ± 0.19 nmol/L, p=0.0001) (Figure 5.2). 
Interestingly, the significant difference seen in the concentration of plasma total 8- 
iso-PGF2c, between non-smokers and smokers prior to the ingestion of AGE was 
reduced after two-weeks of dietary supplementation (p=0.04 vs. p=0.07, Figure 
5.2). After the two-week washout period plasma concentrations of total 8-iso- 
PGF2 increased by 26% in non-smokers (0.88 ± 0.12 nmol/L vs. 1.12 ± 0.18 
nmol/L) and 34% in smokers (1.28 ± 0.19 nmol/L vs. 1.71 ± 0.19 nmol/L). In 
fact, plasma total 8-iso-PGF2,, concentrations were now similar to those prior to 
ingestion of AGE (Figure 5.2). 
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The concentration of free 8-iso-PGF2,,, in the urine of smokers was approximately 
twice that of non-smokers (272 ± 53 pmol/mmol creatinine vs. 504 ± 85 
pmol/mmol creatinine, p=0.06, Figure 5.3). The changes observed in the urinary 
concentrations of 8-iso-PGF2(x in non-smokers and smokers after dietary 
supplementation with AGE followed a similar pattern to those observed with 
plasma total 8-iso-PGF2,, concentrations. Tlius, after 14 days of aged garlic 
extract supplementation urinary levels of 8-iso-PGF2,, were significantly reduced 
by 37% in non-smokers (272 ± 53 pmol/mmol creatinine vs. 172 ± 28 pmol/mmol 
creatinine p--0.02) and 48% in smokers (504 ± 85 pmol/mmol creatinine vs. 265 ± 
57 pmol/mmol creatinine p=0.0003) (Figure 5.3). The urinary concentration of 8- 
iso-PGF2.. increased by 21% in non-smokers (172 ± 28 pmol/Mmol creatinine vs. 
208 ± 41 pmol/mmol creatinine) and 60% in smokers (265 ± 57 pmol/mmol 
creatinine vs. 424 ± 72 pmol/mmol creatinine) after the two-week washout period. 
Indeed, no significant differences were observed in the concentration of urinary 
free 8-iso-PGF2. in the smoking and non-smoking group before supplementation 
with AGE and after the two-week washout period i. e. day 0 vs. day 28 (Figure 
5.3). All individual subject's plasma and urinary 8-iso-PGF2,, concentrations are 
presented in Appendix XII. 
These results suggest that smokers are sub ect to increased oxidative stress and j 
associated lipid peroxidation as evidenced by increased plasma and urinary 
concentration of 8-iso-PGF2,,, when compared to non-smokers. AGE 
supplementation for two-weeks dramatically reduced the concentration of these 
biologically active lipid peroxidation products in the plasma and urine of smokers. 
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5.23. The Effect of AGE Supplementation in Non-smokers and Smokers on 
the Antioxidant Capacity of Plasma to Scavenge Superoxide 
The antioxidant capacity of plasma to scavenge superoxide was assessed using a 
chemiluminescence assay. Superoxide ions were generated in the presence of 
Pholasin, which scavenges superoxide resulting in emission of light. if 
antioxidants, which scavenge superoxide other than Pholasin were present i. e. in 
the plasma samples, then the light emission would be reduced. The antioxidant 
capacity was expressed as percentage reduction in peak light emission compared 
to controls and this was subsequently converted to equivalent ascorbate units 
(pmol/L) by constructing an ascorbate standard curve (Appendix VII). 
The plasma antioxidant capacity of non-smokers was approximately twice that of 
smokers (18.35 ± 1.36 pmol/L vs. 9.64 ± 1.24 pmol/L, p=0.001) (Figure 5.4). 
After 14 days of dietary supplementation with AGE there was a minimal non- 
significant change in the plasma antioxidant capacity in non-smokers (18.35 ± 
1.36 pmol/L vs. 19.56 ± 1.03 pmol/L). In contrast, the plasma antioxidant 
capacity of smokers had significantly increased by 53% following 
supplementation with AGE for 14 days (9.64 ± 1.24 pmol/L vs. 20.48 ± 4.22 
gmol/L, p=0.04) (Figure 5.4). Interestingly, the significant difference observed in 
the plasma antioxidant capacity between non-smokers and smokers prior to 
ingestion of AGE was reduced after two-weeks of dietary supplementation 
(p=0.001 vs. p=0.83) (Figure 5.4). The plasma antioxidant capacity of non- 
smokers remained unaffected by the two-week washout period (19.56 ± 1.03 
pinol/L vs. 19.30 ± 1.42 pmol/L). However, after the two-week washout period 
plasma antioxidant capacity decreased by 49% in smokers (20.48 ± 4.22 gmol/L 
vs. 10.44 ± 2.00 limol/L, p=0.001); in fact, plasma antioxidant capacity was now 
similar to that prior to ingestion of AGE (10.44 ± 2.00 pmol/L vs. 9.64 ± 1.24 
ýtinol/L) (Figure 5.4). All individual subject's plasma antioxidant capacity values 
are presented in Appendix XII. 
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These results suggest that smokers have a reduced plasma antioxidant capacity, 
which was alleviated following two-week dietary supplementation with AGE. In 
fact, the plasma antioxidant capacity was increased to those observed in non- 
smokers. 
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53. DISCUSSION 
Smoking is a risk factor for cardiovascular disease (Fecman, 1999, Tierney et al., 
2000) and although the mechanisms behind this association are unclear it is 
thought to be primarily due to the increased oxidative stress associated with 
cigarette smoking. This increased oxidative stress is evidenced in smokers by 
lower levels of antioxidants (Ayaori et al., 2000, Baneýee et al., 1998) and 
increased levels of oxidation products (Baneýee et al., 1998, Lapenna ct al., 1995, 
Lee et al., 1999, Morrison et al., 1999). There is also increased susceptibility of 
LDL isolated from smokers and passive smokers to oxidative modification and 
subsequent uptake by cultured macrophages (Scheffler et al., 1992, Valkonen & 
Kuusi, 1998), and increased plasma levels of autoantibodies against oxidiscd LDL 
(Heitzer et al., 1996). In agreement with these studies, the presence of oxidatively 
modified LDL in rabbits injected with aqueous extracts of cigarette smoke has 
been demonstrated (Yamaguchi et al., 2000). 
The results from this study are in agreement with the hypothesis that smoking is 
associated with increased oxidative stress. Smokers had increased levels of the 
lipid peroxidation product 8-iso-PGF2,, and a decreased plasma antioxidant 
capacity to scavenge free radicals. The antioxidant capacity of plasma as assessed 
by the ability to scavenge superoxide was significantly lower (48%) in smokers 
when compared to non-smokers (p--0.001, Figure 5.4). This decreased 
antioxidant capacity of plasma from smokers has also been observed in another 
study (Morrison et al., 1999). Plasma levels of the free radical mediated oxidation 
product 8-iso-PGF2,, were significantly higher (36%) in smokers when compared 
to age and sex matched controls (non-smokers) (p=0.04, Figure 5.2). Urinary 
levels of 8-iso-PGF2,, were also raised by 48% in smokers when compared to non- 
smokers (Figure 5.3). These results are in agreement with other similar studies 
that have noted significantly increased levels of F2-isoprostanes or more 
specifically 8-iso-PGF2. in smokers when compared to age and sex matched 
controls (Bachi et al., 1996, Morrow et al., 1995, Oguogho et al., 2000, Reilly et 
al., 1996). Urinary excretion of 8-iso-PGF2, showed elevations between 42% - 
69% in smokers (Oguogho ct al., 2000, Reilly et al., 1996) and rate of urinary 
excretion of 8-iso-PGF2(,, was also 56% higher in these subjects (Bachi et al., 
142 
1996). Plasma levels of 8-iso-PGF2 were 50% higher and elevations of 57% and 
39% have been demonstrated for free and esterified 172-isoprostanes, respectively 
in the plasma of smokers (Morrow et al., 1995, Oguogho et al., 2000). The 
observation in these previous studies that smokers have elevated levels of 172- 
isoprostanes esterified to plasma lipids supports the hypothesis that the link 
between and risk of coronary artery disease may be attributed to enhanced LDL 
oxidation. 
After 14 days of aged garlic extract supplementation, plasma and urinary levels of 
8-iso-PGF2,, decreased significantly by 29% and 37% respectively, in non- 
smokers (p=0.03 and p--0.02, respectively, Figures 5.2 & 5.3). In comparison, 
this observation was significantly greater in smokers following 14 days of aged 
garlic extract supplementation. Plasma levels of 8-iso-PGF2,, significantly 
decreased by 35% (p--0.0001, Figure 5.2) and urinary levels significantly 
decreased by 48% (p=0.0003, Figure 5.3) in conjunction with a significantly 
increased antioxidant capacity of plasma to scavenge superoxide (p=0.04, Figure 
5.4). Plasma and urinary 8-iso-PGF2cc levels in both non-smokers and smokers 
following the 14 day washout period when aged garlic extract supplementation 
had ceased, increased and were not significantly different from 8-iso-PGF2,, levels 
observed at the beginning of the study (day 0, Figure 5.2 & 5.3). The increased 
antioxidant capacity of plasma observed in smokers after 14 days of AGE 
supplementation also decreased to that observed at the beginning of the clinical 
trial (day 0, Figure 5.4). 
A similar human volunteer supplementation study also demonstrated that dietary 
intervention with the antioxidant vitamin C alone or in conjunction with vitamin E 
reduces urinary 8-iso-PGF2,, excretion by 30% in smokers (Reilly et al., 1996). 
Interestingly, this study noted that supplementation with vitamin E alone had no 
effect. Vitamin C and/or vitamin E supplementation has also been shown to 
reduce 8-iso-PGF2a levels in other syndromes associated with increased oxidative 
stress such as diabetes, hypercholesterolemia, and alcoholic liver disease (Davi et 
al., 1997,1999, Gopaul et al., 1995, Meagher et al., 1999, Reilly et al., 1998). 
50%-80% higher levels of urinary 8-iso-PGF2,, were reported in these syndromes 
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when compared to age and sex matched controls which were reduced by 37%- 
58% following supplementation with vitamin E or vitamin C. Levels of 8-iso- 
PGF2,, esterified to LDL were 63% higher in hypercholesterolemic patients when 
compared to normocholesterolemics (Reilly et al., 1998). Consistent with 8-iso- 
PGF2,,, formation as a consequence of oxidative stress in vivo this study and others 
have demonstrated increased levels of 8-iso-PGF2. in syndromes associated with 
increased oxidative stress with a reduction observed following dietary 
intervention with antioxidant supplements. Due to time constrictions and number 
of samples analysed an enzyme immunoassay was used in this study, although the 
most popular method for analysing isoprostane levels is a gas chromatography- 
mass spectrometry method. %ile both of these methods provide quantitatively 
distinct results, qualitatively the information provided is similar (Pratico et al., 
1999). This study provides the first direct evidence to suggest that AGE acts as an 
antioxidant in vivo by reducing the formation and excretion of these free radical- 
catalyzed lipid peroxidation products and increasing the antioxidant capacity of 
plasma to scavenge free radicals. 
8-iso-PGF2. has been shown to enhance platelet activation, vasoconstriction and 
smooth cell proliferation and has also been shown to be present in increased 
amounts in human atherosclerotic vascular tissue when compared to healthy 
vascular tissue (Fukunaga et al., 1993, Hoffman et al., 1997, Kang et al., 1993, 
Kromer & Tippins, 1996, Lahaie et al., 1998, Mehrabi ct al., 1999, Minuz et al., 
1998, Oguogho et al., 1999, Pratico et al., 1996). These pro-atherogenic 
properties of 8-iso-PGF2,, together with the findings that elevated levels of 8-iso- 
PGF2. are associated with traditional risk factors associated with the development 
of cardiovascular disease suggests that dietary supplementation with a preparation 
such as AGE that reduces the levels of these free radical catalysed products 
possibly by enhancing the antioxidant capacity of plasma to scavenge free radicals 
and hence prevent initiation of oxidative events may be beneficial in reducing the 
development and progression of atherosclerosis. 
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6. GENERAL DISCUSSION 
Atherosclerosis associated cardiovascular disease is a major cause of mortality 
and morbidity in the western society. Many epidemiological studies have 
identified certain risk factors, which are associated with the development of 
cardiovascular disease. These traditional risk factors are numerous and include 
elevated plasma lipids (cholesterol and triglycerides), alterations in glucose 
metabolism (insulin-dependent and non-insulin-dependent diabetes), 
hypertension, increased platelet aggregation and decreased fibrinolytic activity in 
blood, advanced age, male gender, obesity, and smoking (Frishman, 1998, Wood, 
2001). Reactive oxygen species (ROS) and reactive nitrogen species (RNS) have 
been strongly implicated in the pathogenesis of atherosclerosis in that they initiate 
the oxidative modification of low-density lipoprotein. It is this oxidised LDL that 
is recognised by scavenger receptors expressed by macrophages and smooth 
muscle cells present in the sub-endothelial space, which subsequently leads to 
unregulated uptake by these cells (Keaney, 2000). 
ROS/RNS-mediated oxidative modification of LDL is also an important risk 
factor for the development and progression of atherosclerotic disease and many of 
the more traditional risks factors associated with this disease are linked to the 
oxidative modification of LDL hypothesis. Oxidation of LDL is central to this 
hypothesis because as well as facilitating foam cell formation oxidised LDL 
elicits numerous atherogenic properties, which enhance development and 
progression of the atherosclerotic lesion (Keaney, 2000). One of the associations 
between increased risk of cardiovascular disease and alterations in glucose 
metabolism is the atherogenic glycation of LDL that occurs in the presence of 
elevated glucose levels (Menzel et al., 1997, Moro et al., 1999, Napoli et al., 
1997). This in vitro or in vivo glycated LDL is more susceptible to in vitro 
oxidative modification. The strong implication of ROS/RNS in the pathogenesis 
of atherosclerosis supports the link between smoking and an increased risk for the 
development of cardiovascular disease as cigarette smoke is a rich source of 
potentially damaging reactive species which are capable of modifying LDL 
(Halliwell & Gutteridge, 1999). Increased plasma cholesterol and the 
concomitant increase in LDL cholesterol is also a risk factor because increased 
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circulating plasma levels of LDL increase the risk of LDL becoming either 
minimally oxidised in the plasma and/or trapped in the sub-endothelial spaces of 
arteries where it becomes progressively oxidised and ultimately progresses to 
foam cell formation and atherosclerotic lesion development. 
The protective effects of garlic with regards to promoting a healthy cardiovascular 
system have long been recognised but it is only recently that interest has focused 
on identifying the active components of garlic responsible for its beneficial 
effects. Garlic in its numerous commercial forms has been shown to attenuate 
many of the traditional risk factors associated with cardiovascular disease 
(Agarwal, 1996, Rahman, 2001). These have included lowering of plasma lipids 
and the atherogenic lipoprotein LDL, increasing fibrinolytic activity, decreasing 
platelet aggregation and reducing blood pressure. Although, some dietary 
supplementation studies have suggested that some garlic preparations have no 
beneficial effects the general consensus of opinion is that garlic and its 
preparations are effective in attenuating many of the risk factors associated with 
cardiovascular disease. In contrast, the evidence supporting the role of garlic as 
an antioxidant is less convincing. Many studies have identified the antioxidant 
potential of garlic and its commercial preparations in vitro and a few studies have 
shown antioxidant activity in vivo using animal models. To date, evidence 
demonstrating the antioxidant activity of garlic and its preparations in vivo in 
humans has yet to be presented. 
The mechanisms and evaluation of antioxidant action are varied and include 
scavenging of reactive species, inhibiting the formation of reactive species, 
recycling of other antioxidants, upregulation of endogenous antioxidant defences, 
and binding catalytic metal ions (Halliwell et al., 1995, Halliwell, 1997). With 
reference to identifying a potential antioxidant or an anti-atherosclerotic 
preparation, the ability of the potential compound or plant extract to prevent 
oxidative modification of LDL is a routinely used methodology to assess its 
antioxidant and anti-atherogenic potential. In the work Presented here an attempt 
was made to define the antioxidant potential and the antioxidant mechanisms of 
AGE using cell free assays, in vitro LDL oxidation studies, and 
147 
chromatographical analyses, and finally an attempt was made to observe the 
antioxidant effects of AGE supplementation in vivo in humans. 
Superoxide is a ROS and enhanced production of this free radical due to increased 
activity of xanthine oxidase has been implicated in the pathogenesis of 
atherosclerosis (Houston et aL, 1999, Swain & Gutteridge, 1995). Using a cell 
free system AGE was assessed for its ability to scavenge or inhibit the generation 
of superoxide generated during the xanthine oxidase-mediated breakdown of 
xanthine to uric acid (Chapter 3). Whole AGE was capable of reducing the 
formation of superoxide in a concentration dependent manner using this system. 
A diethyl ether extract of AGE also demonstrated the ability to reduce the 
formation of superoxide in a concentration dependant manner and in addition the 
mechanism of action of this extract was confirmed to be superoxide scavenging. 
The demonstration of superoxide scavenging ability observed with the diethyl 
ether extract of AGE could not be determined with whole AGE due to 
interference with the particular, part of the assay that monitors xanthine oxidase 
activity. Therefore, although compounds present in AGE extracted with diethyl 
ether displayed the ability to scavenge superoxide the possibility that other 
compounds present in whole AGE may act to directly inhibit xanthine oxidase 
activity could not be excluded (Figure 6.1). The role of superoxide in mediating 
LDL oxidation in the presence and absence of AGE was also examined but it was 
concluded that in this study superoxide alone was not sufficient to induce 
oxidation of LDL (Chapter 3). This is in agreement with another study which also 
concluded that superoxide alone cannot induce lipid peroxidation of LDL (Garner 
et al., 1994). 
Other studies that have examined the ability of garlic to scavenge reactive species 
have shown that fresh garlic and garlic powder extracts scavenge hydroxyl and 
peroxyl radicals using cell free systems (Aruoma et al., 1997, Prasad et al., 1995). 
AGE has also been shown to scavenge the ROS hydrogen peroxide and t-butyl 
hydroperoxide (Ide & Lau, 1999a, Ide et al., 1996, Imai et al., 1994). In contrast 
to results presented here, Ide et al (1996) did not observe any significant 
superoxide scavenging by AGE. The conflict between these two results may be 
due to different methodologies used, although the methods cannot be compared 
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due to insufficient information provided by Ide et al (1996). As well as the ROS 
scavenging observed in this study and others, AGE and other garlic preparations 
have been shown to enhance the activity of the antioxidant enzymes superoxide 
dismutase and catalase, which act to scavenge superoxide and hydrogen peroxide 
(Geng & Lau, 1997, Helen et al., 1999, Pedraza-Chaverri et al., 2000). 
Superoxide is a reactive species that may be involved in oxidation of lipids and 
proteins either directly or by interacting with other reactive species to generate 
more potent radicals, thus the ability of AGE to scavenge or reduce the formation 
of superoxide and hence prevent any oxidative events would be advantageous in 
human diseases associated with increased oxidative stress such as atherosclerosis. 
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15-lipoxygenase is an enzyme that oxygenates polyunsaturated fatty acids 
(PUFA) resulting in the initiation and subsequent propagation of lipid 
peroxidation. This then results in the decomposition of lipid hydroperoxides into 
products capable of modifying proteins (Yamamoto, 1992). Evidence has now 
been accumulated that strongly implicates 15-lipoxygenase in the pathogenesis of 
atherosclerosis (Bocan et al., 1998, Cyrus et al., 1999, Harats et al., 2000, 
Hiltunen et al., 1995, Yla-Herttuala et al., 1990). One study has demonstrated 
increased 15-lipoxygenase mRNA expression in early atherosclerotic lesions of 
hyperlipidaemic rabbits (Hiltunen et al., 1995), whilst another study demonstrated 
colocalisation of 15-lipoxygenase mRNA and protein with oxidised LDL in the 
atherosclerotic lesions of these hyperlipidaernic rabbits (Yla-Herttuala et al., 
1990). The most convincing of these studies are recent publications that have 
demonstrated that 15-lipoxygenase inhibitors or disruption of 15-lipoxygenase 
gene expression attenuates lesion development in atherosclerosis-prone rabbits 
and mice (Bocan et al., 1998, Cyrus et al., 1999), and overexpression of 15- 
lipoxygenase in the vascular endothelium accelerates early atherosclerosis in mice 
(Harats et al., 2000). 
The work presented here shows that compounds present in whole AGE extracted 
with diethyl ether reduced 15-lipoxygenase-mediated peroxidation of linoleic acid 
in a ccll-free system (Chapter 3). In addition, 15-lipoxygenasc was able to induce 
significant lipid peroxidation of isolated human LDL, which was reduced in the 
presence of the diethyl ether extract of AGE (Chapter 3). In contrast, protein 
oxidation of LDL was not observed in this study. This was not unexpected as 15- 
lipoxygenase is directly involved in the peroxidation of lipids, not the oxidation of 
proteins. Due to interference with these assays the effect of whole AGE could not 
be observed. The reduction of lipid peroxidation observed in the presence of 
AGE may be due to direct inhibition of 15-lipoxygenase activity or scavenging of 
lipid hydroperoxides and hence prevention of the chain propagating process of 
lipid peroxidation. Although both mechanisms seem plausible the precise 
mechanism responsible could not be determined and was beyond the scope of this 
study. The mechanism could be clarified using a method described by Robak et 
al., (1988). This study investigated the effect of numerous plant flavonoids on 
oxygen consumption during 15-lipoxygenase-mediated peroxidation of 
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arachidonic acid. Any inhibition of oxygen consumption would suggest that 
direct inhibition of 15-lipoxygcnase itself was taking place. 
This is one of the first studies to demonstrate that a garlic preparation such as 
AGE reduces 15-lipoxygenase-mediated peroxidation. of linoleic acid and isolated 
human LDL and hence may reduce the involvement of the enzyme in the lipid 
peroxidation process. AGE and other garlic preparations may also reduce lipid 
peroxidation by modulating the glutathione redox cycle. In vitro studies with 
AGE and in vivo supplementation studies in animals with other garlic preparations 
have shown that in response to an oxidative stress stimulus these garlic extracts 
increase the activity of glutathione peroxidase and glutathione disulphide 
rcductase and the levels of glutathionc (Geng & Lau, 1997, Helen et al., 1999, Ide 
& Lau, 1999a, Pcdraza-Chaverri et al., 2000). This would result in an increased 
capacity to reduce hydrogen peroxide and damaging lipid hydroperoxides to 
harmless alcohols and water. 
Although there is little evidence supporting a role for Cu2' in the development and 
progression of atherosclerosis, increased amounts of Cu2+ have been identified in 
atherosclerotic tissue when compared to normal arterial tissue (Evans et al., 1995, 
Smith et al., 1992, Swain & Gutteridge, 1995). The results presented in this study 
demonstrate that Cu2+ was able to induce significant oxidation of both the lipid 
and protein moiety of isolated human LDL (Chapter 3). The presence of the 
diethyl ether extract of AGE reduced both Cu2-"-mediated protein oxidation and 
lipid peroxidation of LDL. Whilst the effect of whole AGE on Cu2'-mediated 
lipid pcroxidation could not be assessed due to interference with the TBARS 
assay, it was observed that Cu2+ýmediated protein oxidation of LDL was 
completely inhibited in the presence of whole AGE. These results demonstrated 
that whilst the diethyl ether extract of AGE exerted an appreciable protective 
effect against Cu2+-induccd oxidation of LDL this protection was greater when 
whole AGE was employed. In addition, the protection AGE exerted against Cu2+- 
mediated protein oxidation of LDL has not been demonstrated before with AGE 
or any other garlic preparation, which is surprising as it is the oxidation of the 
protein moiety in LDL that facilitates recognition by scavenger receptors 
expressed on macrophages (Hunt et al., 1994). 
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Cu2"-mediated oxidation is a well-used and traditional method of assessing the 
ability of possible antioxidant compounds or plant extracts for their protective 
effect with regards to reducing lipid peroxidation. Esterbauer extensively studied 
the characteristics of Cu2+ýmediated lipid peroxidation and observed that the 
process is charactcrised by three phases, which begins with the lag phase when 
endogenous LDL antioxidants become depleted. Once antioxidant depletion has 
occurred the propagation phase follows when rapid lipid peroxidation occurs, this 
is then followed by the decomposition phase when lipid hydroperoxides 
decompose and/or rearrange to form a wide range of products (e. g. aldehydes, 
ketones, alcohols) capable of modifying proteins (Esterbauer & Ramos, 1995, 
Esterbaucr et al., 1991a, 1993, Klatt & Esterbauer, 1996). The ability of an 
antioxidant plant extract to extend the lag phase of Cu2+-mediated lipid 
peroxidation i. e. the time before rapid lipid peroxidation occurs, suggests that 
preservation of endogenous antioxidants may be happening. In fact, the results 
presented here clearly demonstrate that compounds present in AGE extracted with 
diethyl ether extend this lag time to such an extent that there was no observable 
propagation phase (Chapter 3). A similar in vitro study has shown that AGE 
protects against Cu2-mediated lipid peroxidation of LDL (Ide et al., 1997). In 
addition, dietary supplementation with AGE in humans has been shown to extend 
the lag time of Cu 2+-mediated lipid peroxidation in vitro (Munday et al., 1999), 
with similar observations demonstrated for garlic powder extracts (Orekhov ct al., 
1994, Phelps & Harris, 1993), although more recent observations with regards to 
garlic powder extracts have been conflicting (Byrrie et al., 1999, Simons et al., 
1995). 
Although many other studies have shown that AGE and other garlic and plant 
extracts are able to reduce Cu2+-mediated oxidative modification of LDL these 
studies have failed to address the mechanism of this reduction (Fuhrman et a]., 
1997d, Hodgson et al., 1999b, Ide et al., 1997, Orekhov et al., 1994). Multiple 
mechanisms could be involved in the protection of LDL against Cu2+-induced 
oxidation of LDL and these could include chelation of Cuý+, scavenging of lipid 
hydroperoxides, and recycling of endogenous LDL antioxidants. In this study the 
Cu2+ chelation properties of AGE were identified using a novel approach based on 
the inhibition of xanthine oxidase activity by Cu2+ (Lowe et al., 1998) and the 
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restoration of this activity in the presence of a Cu2+ chelator (Chapter 4). This 
approach was confirmed using a common Cu2+ chelating agent, namely EDTA. 
While whole AGE was shown to be an efficient chelator of Cuý+, the diethyl ether 
extract of AGE displayed no such properties (Figure 6.1). In conjunction with 
earlier studies this suggests that at least two mechanisms might be responsible for 
the protection of LDL against Cu2+-mediated oxidation. One of these mechanisms 
being the chelation of Cu2* exhibited by whole AGE, and hence prevention of any 
initiation events resulting in LDL oxidation. This is supported by the observation 
that whole AGE completely inhibited Cu2+-mcdiated protein oxidation of LDL. 
The dicthyl ether extract of AGE did not display any Cu2+ chelating properties and 
hence was not as efficient in preventing protein oxidation of LDL induced by Cu2' 
suggesting another mechanism such as recycling of endogenous antioxidants may 
be involved in this situation. 
Earlier results demonstrated that the dicthyl ether extract of AGE prevented Cu2'- 
mediated lipid peroxidation of LDL by extending the lag phase of this process 
when cndogenous LDL antioxidants become depleted (Chapter 3). This 
observation and the demonstration of no significant chelation properties suggest 
that the mechanism of protection against Cu2+-mediated oxidation of LDL might 
be due to preservation of endogenous LDL antioxidants. To test this hypothesis 
the depletion of the LDL antioxidants a-tocopherol, P-carotene, and lycopene 
were observed during Cu2+-mcdiated oxidation of LDL in the presence and 
absence of the diethyl ether extract of AGE (Chapter 4). This study confirmed 
that rapid depletion of these antioxidants occurs in the presence of Cu2+ with a 
concomitant increase in lipid peroxidation. In this part of the study rapid freezing 
of samples was used to terminate the oxidative modification of LDL induced by 
Cu2+ in the presence or absence of the diethyl ether extract of AGE. The 
significant depletion of ct-tocopherol, P-carotene, and lycopene that occurred at 0 
hours in all samples containing Cu2+ when compared to control (LDL only) 
suggested that rapid freezing was not sufficient to halt this process and a more 
efficient approach may have been the use of a Cu2' chelator such as EDTA. This 
may be of importance when considering any future studies of this kind. In this 
study to overcome this problem all arbitrary values obtained from the antioxidant 
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depletion studies were also expressed as a percentage of their respective controls 
at 0 hours (Chapter 4). 
'Me diethyl ether extract of AGE did not act to preserve a-tocopherol levels and 
in fact appeared to slightly enhance its depletion even though lipid peroxidation 
was reduced in the same experiments. In contrast, Cu2+4nduced depletion of 
lycopene was unaffected and depletion of P-carotene was significantly reduced in 
the presence of the diethyl ether extract of AGE (Chapter 4). One possible 
explanation for the partial preservation of P-carotene during Cu2+ý-mediated 
oxidation of LDL is that compounds present in AGE may act as chain-breaking 
antioxidants, which scavenge lipid hydroperoxides and hence prevent the 
propagation of lipid peroxidation, a similar role to that of a-tocopherol. In this 
situation preservation of the carotcnoids may be observed. Interestingly, other 
studies utilising plant polyphenols have observed similar effects on cc-tocoPherol 
levels even though the isolated LDL was more resistant to oxidation (Belinky et 
al., 1998, Hayek et al., 1997). These studies showed that the presence or 
consumption of the licorice and red wine polyphenols glabridin, catechin, and 
quercetin failed to protect or increase the depletion of oc-tocopherol during 
oxidation of LDL isolated from atherosclerotic mice. Belinky et al (1998) also 
observed that glabridin partially preserved P-carotene and lycopene levels during 
oxidation of LDL. A more recent study has shown that oxidation of human LDL 
isolated from plasma previously incubated with lemon oil is more resistant to 
oxidation and this was attributed to the partial preservation of P-carotene and 
lycopcne (Grassmann et al., 2001). These observations are similar to the findings 
of the study presented here which demonstrated that Cu2+-induced lipid 
peroxidation of LDL was reduced in the presence of components of AGE and this 
reduction was not due to preservation of a-tocopherol levels but may in fact be 
due to partial preservation of P-carotene levels in LDL. 
Garlic is a rich source of polyphenolic compounds and there is currently a large 
amount of interest in the antioxidant properties of these plant compounds, 
although few studies have investigated the phenolic content of commercial garlic 
preparations. This study prevents evidence to suggest that AGE has a high 
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phenolic content with different types of phenolic compounds mainly present in 
their conjugated form (Chapter 4). Whole AGE as well as the diethyl ether 
extract of AGE contained phenolic compounds although the phenolic content was 
considerably greater in whole AGE and it may be that the antioxidant effects of 
the diethyl ether extract of AGE may be attributed to the presence of these plant 
antioxidants. This high and varied phenolic nature of AGE is also true for fresh 
garlic (Mican & Mohamed, 2001, Vinson et al., 1998), but would not be 
necessarily be true for all commercial garlic preparations due to extensive 
processing and extraction methods although this has yet to be determined. Plant 
extracts, and plant polyphenols such as the flavonoids have been shown to exhibit 
lipoprotein-bound activity, which may explain their efficacy in preventing 
oxidation of LDL (Belkiky et al., 1998, Grassmann et al., 2001, Hayek et al., 
1997, Ivanov et al., 2001, Vinson et al., 1995, -1998). The results presented here 
also suggest that compounds present in AGE may also bind to or become 
incorporated within LDL and hence reduce the pro-atherogenic oxidation of LDL 
(Chapter 4). A more detailed analysis of how AGE binds to or becomes 
incorporated within LDL may help to elucidate the earlier finding of partial 
preservation of P-carotene and not oc-tocopherol during Cu2+4nduced lipid 
peroxidation of LDL. 
Monitoring lipid peroxidation in vivo has been problematic which has led to 
inconsistent results with regards to monitoring the effects of dietary intervention 
with antioxidant nutrients. In this study, the F2-isoprostane 8-iso-PGF2,, was used 
as a biomarker of lipid peroxidation in vivo as it has been shown to be reliable and 
specific endpoint of the non-enzymatic free radical-catalysed oxidation of 
arachidonic acid (Pratico, 1999). Another method of assessing the efficacy of 
antioxidant supplementation is to measure the capacity of plasma to scavenge 
reactive species in comparison with known antioxidants such as ascorbic acid 
(vitamin Q and a-tocopherol (vitamin E). This present study utilised a novel 
index of lipid peroxidation, namely 8-iso-PGF2,, and the capacity of plasma to 
scavenge superoxide compared to ascorbic acid to assess the effects of AGE 
supplementation. These analyses were performed in smokers and non-smokers 
before and after supplementation with AGE, and after a two-week washout period 
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(Chapter 5). Smokers were subject to increased oxidative stress as they had 
increased total plasma and free urinary 8-iso-PGF2,, concentrations and a 
decreased antioxidant capacity to scavenge superoxide when compared to non- 
smokers. 
Dietary supplementation with AGE significantly reduced plasma and urinary 8- 
iso-PGF2. concentrations in both smokers and non-smokers although the 
reduction was more pronounced in smokers, and also increased the antioxidant 
capacity of plasma in smokers. After the two-week washout period plasma and 
urinary levels of 8-iso-PGF2. in smokers and smokers and the antioxidant 
capacity of plasma in smokers returned to that observed prior to AGE 
supplementation. Numerous studies have also demonstrated that smoking is 
associated with increased oxidative stress by measuring 8-iso-PGF2,,, or total F2- 
isoprostanes and the andoxidant capacity of plasma; with many of these studies 
demonstrating that antioxidant vitamin supplementation attenuates these factors 
(Bachi et al., 1995, Morrison et al., 1999, Morrow et al., 1995, Oguogho et al., 
2000, Reilly et al., 1996). A few studies have also examined the effect of dietary 
supplementation with plant extracts such as soy, black tea, onion, olive oil on 
plasma and/or urinary 8-iso-PGF2,, or F2-isoprostane concentrations in healthy 
human subjects with only olive oil consumption showing a beneficial effect 
(Djuric et al., 2001, Hodgson et al., 1999a, O'Reilly et al., 2001, Visioli et al., 
2000). The results presented in this study suggest that AGE possesses antioxidant 
activity in vivo and may be useful in reducing the increased oxidative stress 
associated with smoking and atherosclerosis. 8-iso-PGF2,, is also a pro- 
atherogenic biologically active isoprostane that has been shown to enhance 
vasoconstriction, smooth muscle cell proliferation, and platelet activation, and 
hence any reduction in the circulation of this product of lipid peroxidation by 
AGE would also reduce its potentially pro-atherogenic properties (Fukunaga et 
al., 1993, Hoffman ct al., 1997, Kang et al., 1993, Kromer & Tippins, 1996, 
Lahaie et al., 1998, Minuz et al., 1998, Pratico et al., 1996). 
8-iso. PGF2a is formed in situ from free radical attack on arachidonic acid in 
membranes and lipoproteins. It is Presumably cleaved by phospholipases and 
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circulates in the plasma where it may exert its pro-atherogenic biological effects 
prior to excretion in the urine (Morrow et al., 1990a, 1990b, 1992, Pratico et al., 
1998). This study has shown that AGE supplementation decreases total plasma 
and free urinary 8-iso-PGF2,, concentrations which may initially suggest that AGE 
prevents the formation of this isoprostane. Another scenario may be that AGE 
affects phospholipase activity and hence the release of 8-iso-PGF2,, from 
membranes and lipoprotcins. The large decreases observed in total plasma 8-iso- 
PGF2c 
,, concentrations 
in non-smokers and smokers (29% & 35%, respectively) 
suggest that AGE supplementation is reducing the formation of these compounds. 
This remains to be confirmed and may be clarified by measuring free and total 8- 
iso-PGF2, in the plasma and examining the effect of AGE on phospholipase 
activity directly. 
In this study it has been demonstrated that AGE is an effective antioxidant plant 
extract with numerous mechanisms of action that reduce free radical-mediated 
modification of lipids and proteins in vitro and in vivo. One of the main 
limitations of this study is that no comparison can be made with other garlic 
extracts because the chemical composition of commercially available garlic 
preparations varies widely (Lawson, 1996). In this study a commercial aged 
garlic extract (AGE, Kyolic) was used which contains high concentrations of 
water-soluble compounds and is standardised to SAC, its' major organosulphur 
compound. In contrast, garlic powder extracts contain mainly oil-soluble 
compounds and are standardised to allicin. Garlic oil preparations are rich in 
other sulphur compounds such as the allyl sulphides, ajoenes, and viny1dithiins. 
Many studies also utilise raw garlic, the composition of which cannot be 
standardised because growth and storage conditions affect garlic bulb 
composition. In this study the phenolic content of AGE has been investigated and 
related to the antioxidant effects of this extract (Chapter 4). Few studies have 
investigated the antioxidant potential of non-sulphur constituents in garlic 
preparations and this needs to be explored further. Many of the reported 
beneficial effects of these garlic preparations are attributed to the major sulphur 
compounds in these preparations but fpw human dietary intervention studies have 
been performed using the presumed active constituents. More human intervention 
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studies are needed using standardised garlic preparations and their major sulphur 
and non-sulphur constituents. Until this time confusion will persist when trying to 
interpret results from studies using different garlic preparations. 
In summary, AGE possesses superoxide-scavenging ability, reduces 15- 
lipoxygenase-mcdiatcd lipid peroxidation of linoleic acid and isolated human 
LDL and Cu2"-mediated lipid peroxidation and protein oxidation of isolated 
human LDL. Numerous properties were also identified that may be responsible 
for these antioxidant effects. AGE has a substantial and varied phenolic content, 
which may in part be responsible for the antioxidant mechanisms observed, such 
as chelation of Cu2+ and preservation of the LDL antioxidant P-carotene. The 
efficacy of AGE in preventing oxidation of LDL may also be attributed to its 
ability to bind to or become incorporated within isolated human LDL. These 
antioxidant effects, properties and mechanisms were all observed using cell-free 
assays, in vitro LDL oxidation studies, and chromatographical analyses. The final 
aim of this study was to identify the antioxidant properties of AGE in vivo. The 
dietary supplementation study confirmed that smoking is a syndrome of increased 
oxidative stress as evidenced by a decreased antioxidant capacity of plasma to 
scavenge superoxide and increased plasma and urinary levels of 8-iso-PGF2,,, a 
novel marker for oxidative stress in vivo. Dietary supplementation with AGE 
alleviated oxidative stress in smokers by significantly increasing the antioxidant 
capacity of plasma to scavenge superoxide and significantly decreasing plasma 
and urinary 8-iso-PGF2,,. Plasma and urinary 8-iso-PGF2,, was also significantly 
decreased in non-smokers but to a lesser extent. The collective results presented 
in this study suggest that AGE exerts numerous antioxidant effects in vitro and in 
vivo and if taken as a dietary supplement may reduce the development and 
progression of atherosclerosis. 
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6.1. Future Work 
This study provides evidence to suggest that one of the mechanisms behind the 
efficacy of AGE in reducing the oxidation of LDL is that it may bind to or 
become incorporated within the LDL particle. This can be supported by finiher 
studies involving extraction and isolation of these compounds bound to LDL 
followed by chromatographical analysis to identify these compounds. The nature 
of the compounds in AGE that become associated with the LDL particle might 
also provide some insight into why AGE may act to preserve P-carotene levels. 
This study has shown that AGE is a rich and varied source of polyphenolic 
compounds. Specific identification of these compounds would be advantageous. 
Because whole AGE is a complex phytochemical, the diethyl ether extract of 
AGE would be more suitable for these analyses which could be performed using a 
gas chromatography-mass spectrometry and should enable identification of any 
phenolic compounds present. A comparative study with other commercial garlic 
preparations may also be useful. 
A small dietary supplementation study in smokers and non-smokers confirmed the 
in vivo antioxidant properties of AGE. This supplementation study ideally needs 
to be expanded to include more volunteers, which would provide more significant 
evidence for the role of AGE in reducing oxidative stress in vivo. A comparative 
dietary supplementation study with other commercial garlic preparations would 
also be interesting. Total plasma 8-iso-PGF2,, concentrations (free + esterified) 
are elevated in smokers. Analysis of these lipid peroxidation products esterified 
to LDL isolated from smokers and non-smokers would specifically identify 
whether LDL from smokers is subject to increased lipid peroxidation in vivo and 
would lend credence to the hypothesis that the link between and risk of 
atherosclerosis may be attributed to enhanced LDL oxidation. AGE 
supplementation could then be assessed by its ability to reduce the amount of 8- 
iso-PGF2,, esterified to LDL. This may be a more direct, specific, and sensitive 
method of measuring oxidised lipids in LDL and the efficacy of antioxidant 
supplementation on reducing the content of these oxidised lipids in LDL in vivo. 
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SUBJECT INFORMATION SHEET 
Aged Garlic Extract as an Antioxidant in Cardiovascular Disease. 
Background information: 
There are various risk factors associated with cardiovascular disease such as 
increased serum cholesterol and triglyceride concentrations, increased 
susceptibility of blood platelets to aggregate, decreased fibrinolytic (clot 
dissolution) activity and increased susceptibility of low density lipoprotein (LDL) 
to oxidation. One of the most cost-effective ways of controlling this disease is to 
supplement the diet with phytochernicals known to have anti-cardiovascular and 
antioxidant properties. One such phytochernical is Aged Garlic Extract (AGE). 
Recent in vitro studies have shown AGE to have antioxidant properties. This 
antioxidant property of AGE will be investigated ftu-ther in this clinical trial. 
About the study: 
Hypothesis: It is likely that once AGE is consumed it modifies the LDL particle 
making it less prone to oxidation and reduces the oxidative stress the LDL particle 
is subjected to, hence reducing the risk of cardiovascular disease. A novel family 
of markers of oxidative stress occurring within the body is the F2 isoprostanes. 
Increased levels of F2 isoprostanes have been reported in humans with conditions 
thought to be associated with oxidative stress such as smoking, diabetes, 
hypercholesterolemia, and atherosclerosis. These oxidation products circulate in 
the plasma and are excreted in urine. This project will investigate the levels of 
this marker in both urine and plasma samples before and after ingestion of AGE 
and will provide further information on the antioxidative mechanisms by which 
AGE may prevent or delay cardiovascular disease. 
Your part in the study: 
Both smokers and non-smokers are required for this small clinical trial. You will 
be required to give a blood sample (10- 1 5mls) and a urine sample at the beginning 
of the trial. You will then be required to take a specified daily dose of AGE 
(5mls) for a period of two weeks. A blood and urine sample will again be taken. 
You will then be required to stop taking AGE for two weeks and a final blood and 
urine sample will be taken. The levels of F2 isoprostanes in these blood and urine 
samples will then be measured. 
You will not have to alter your diet or life style and there is minimum pain 
involved in giving a venous blood sample. 
Contact information: 
Stephanie Ann Dillon (PhD researcher): Ex 2483 
Dr. Khalid Rahman (Supervisor): Ex 2087 
Dr. Gordon A Lowe (Supervisor): Ex 2142 
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QUESTIONNAIRE FOR DIETARY SUPPLEMENTATION STUDY 
VOLUNTEERS 
Name: 
Sex (male/female): 
Age (years): 
Weight (kilograms/pounds): 
Height (metes/inches): 
Average weekly alcohol consumption: 
Please provide as much information as possible on type of alcohol i. e. red/white 
wine, premium/normal strength beer, bottles/pints of beer, types of spirits/ 
liqueurs, alcopops. 
Average number of cigarettes smoked per day: 
Do you have any known medical conditions (yes/no): 
If yes to above are you taking any prescribed medication (yes/no): 
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Aged Garlic Extract as an Antioxidant in Cardiovascular Disease - Dietary 
Supplementation Study 
Individual Clinical and Biochemical Characteristics of Clinical Trial Subjects 
Non-Smoker 1 (Female): 
Age 28 
Weight (kilograms) 44.54 
Height (metres) 1.58 
Body Mass Index 18 
Alcohol(units/week) 9 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (g/]L) 69.68 59.09 75.15 
Plasma Cholesterol (mmol/L) 3.5 4.14 3.97 
Plasma Triglycerides (mmol/L) 0.61 0.48 0.64 
Plasma Creatinine (mg/dL) 0.65 0.74 0.8 
Creatinine Clearance (mUmin) 88.79 79.14 73.34 
Urinary Creatinine (mg/mL) 0.15 0.73 0.45 
Plasma 8-epi-PGF7,, (pg/mL) 687.67 474.65 553.93 
Urinary 8-epi-PGF2, (pg1mg creatinine) 297.36 215.28 601.05 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (gmol/L) 
15.12 15.12 14.2 
209 
Non-Smoker 2 (Female): 
Age 34 
Weight (kilograms) 61 
Height (metres) 1.69 
Body Mass Index 21 
Alcohol(unitstweek) 18 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (gfL) 62.31 67.96 73.21 
Plasma Cholesterol (mmol/L) 4.31 4.66 4.78 
Plasma Triglycerides (mmol/L) 0.43 0.46 0.57 
Plasma Creatinine (mg/dL) 1.15 1.33 1.2 
Creatinine Clearance (mUmin) 65.36 66.08 62.41 
Urinary Creatinine (mg/mL) 1.83 3.3 1.23 1 *23 
Plasma 8-epi-PGF2. (pg/mL) 173.52 135.45 115522.96 , 96 
Urinary 8-epi-PGFu (pg/mg creatinine) 168.81 102.89 136.11 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (jimol/L) 
23.81 23.85 26.97 
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Non-Smoker 3 (Male): 
Age 22 
Weight (kilograms) 89 
Height (metres) 1.89 
Body Mass Index 24 
Alcohol(units/week) 36 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 79.85 74.62 72.52 
Plasma Cholesterol (mmol/L) 4.69 4.7 3.98 
Plasma Triglycerides (mmol/L) 0.71 0.62 0.5 
Plasma Creatinine (mg/dL) 1.34 1.39 1.38 
Creatinine Clearance (mUmin) 108.76 105.12 105.71 
Urinary Creatininc (mgImL) 1.19 1.93 3.46 
Plasma 8-epi-PGFU (pg/mL) 356.91 187.93 207.42 
Urinary 8-epi-PGF2. (pglmg creatinine) 1613.38 785.48 1316.97- 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (jimol/L) 
14.53 18.70 18.60 
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Non-Smoker 4 (Female): 
Age 40 
Weight (kilograms) 89.09 
Height (metres) 1.61 
Body Mass Index 35 
Alcohol(units/week) 3.5 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 76.33 79.85 75.6 
Plasma Cholesterol (mmol/L) 5.98 5.82 6.2 
Plasma Triglycerides (mmol/L) 1.41 1.56 1.16 
Plasma Creatinine (mg/dL) 0.61 0.7 0.71 
Creatinine Clearance (mlJmin) 172.31 150.65 148.95 
Urinary Creatinine (mg/mL) 2.12 0.39 1.37 
Plasma 8-epi-PGFu (pg/mL) 530.99 292.99 661.31 
Urinary 8-epi-PGF2. (pg1mg creatinine) 708.47 567.72 i-21 5-6 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (gmol/L) 
15.87 19-58 20.60 
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Non-Smoker 5 (Male): 
Age 48 
Weight (kilograms) 72.54 
Height (metres) 1.68 
Body Mass Index 25.9 
Alcohol(units/week) 4 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 70.71 63.19 68.86 
Plasma Cholesterol (mmol/L) 5.45 5.35 5.69 
Plasma Triglycerides (mmol/L) 1.16 0.89 1.67 
Plasma Creatinine (mg/dL) 0.85 0.93 0.92 
Creatinine Clearance (m]LJmin) 109.5 100.21 100.66 
Urinary Creatinine (mg/mL) 1.13 0.61 1.86 
Plasma 8-epi-PGF2,, (pg/mL) 666.75 484.53 701.97 
Urinary 8-epi-PGF2. (pg/mg creatinine) 853.44 683.08 760 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (pmol/L) 
20.45 21.86 2185 
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Non-Smoker 6 (Male): 
Age 38 
Weight (kilograms) 82.7 
Height (metres) 1.77 
Body Mass Index 26.5 
Alcohol(units/week) 35 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (g/]L) 71.31 79.64 68.86 
Plasma Cholesterol (mmol/L) 3.02 3.22 2.97 
Plasma Triglycerides (mmol/L) 0.27 0.28 0.35 
Plasma Creatinine (mg/dL) 0.88 0.93 0.91 
Creatinine Clearance (mIJmin) 133.49 125.5 128.81 
Urinary Creatinine (mg/mL) 0.29 0.28 1.37 
Plasma 8-epi-PGF2. (pg/mL) 304.03 440.18 268.75 
Urinary 8-epi-PGF2. (pg/mg creatinine) 720.88 679.54 241.9 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (ýLmol/L) 
25.84 22.80 25.15 
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Non-Smoker 7 (Female): 
Age 56 
Weight (kilograms) 76.36 
Height (metres) 1.63 
Body Mass Index 29 
Alcohol(unitstweek) 12 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 76.33 79.85 75.6 
Plasma Cholesterol (mmol/L) 5.07 4.84 4.73 
Plasma Triglycerides (mmol/L) 2.7 1.86 1.77 
Plasma Creatinine (mg/dL) 0.88 0.76 0.94 
Creatinine Clearance (mlJmin) 86.28 99.38 80.77 
Urinary Creatinine (mg/mL) 0.29 0.53 0.67 
Plasma 8-epi-PGFu (pg/mL) 776.33 343.95 445.64 
Urinary 8-epi-PGF2,. (pg1mg creatinine) 1449.3 483.35 279.11 
Plasma Antiox-idant Capacity (Equivalent 
Ascorbate Units (gmol/L) 
15.92 17.63 16.58 
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Non-Smoker 8 (Female): 
Age 38 
Weight (kilograms) 63.63 
Height (metres) 1.5 
Body Mass Index 26.5 
Alcohol(units/week) 6 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (g1L) 69.6 65.55 72.94 
Plasma Cholesterol (mmol/L) 3.97 3.72 3.74 
Plasma Triglycerides (mmol/L) 0.74 0.68 0.4 
Plasma Creatinine (mg/dL) 0.93 0.93 1.03 
Creatinine Clearance (mUmin) 82.83 82.83 74.45 
Urinary Creatinine (mg1mL) 0.24 0.2 0.22 
Plasma 8-epi-PGFu (pg/mL) 441.64 382.34 446.21 
Urinary 8-epi-PGFu (pg/mg creatinine) 1266.41 957.91 1087.02- 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (gmol/L) 
18.23 17.68 15.46 
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Non-Smoker 9 (Male): 
Age 64 
Weight (kilograms) 56.4 
Height (metres) 1.68 
Body Mass Index 20 
Alcohol(units/week) 0 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (gfL) 75.03 60.14 69.2 
Plasma Cholesterol (mmol/L) 4.96 5.2 5.58 
Plasma Triglycerides (mmol/L) 1.6 1.7 2.1 
Plasma Creatinine (mg/dL) 1.26 1.16 1.14 
Creatinine Clearance (m]Llmin) 47.12 51.54 52.42 
Urinary Creatinine (mg1mL) 0.22 0.19 0.22 
Plasma 8--epi-PGFu (pg/mL) 278.88 119.07 361.34 
Urinary 8-epi-PGFu (pg/mg creatinine) 216.7 218.08 298.41 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (gmol/L) 
20.97 23.58 19.84 
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Non-Smoker 10 (Male): 
Age 48 
Weight (kilograms) 92.3 
Height (metres) 1.88 
Body Mass Index 26.1 
Alcohol(units/week) 17 
Cigarettes/day 0 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 84.04 71.56 68.16 
Plasma Cholesterol (mmol/L) 4.58 4.69 4.5 
Plasma Triglycerides (mmol/L) 0.47 0.72 0.53 
Plasma Creatinine (mg/dL) 1.18 1.16 1.19 
Creatinine Clearance (mUmin) 100.09 101.43 99.44 
Urinary Creatinine (mg/mL) 0.75 0.5 1.49 
Plasma 8-cpi-PGFu (pg/mL) 220.62 271.52 162.08 
Urinary 8-epi-PGF7,,, (pg/mg creatinine) 1187.21 646.03 950.36 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (gmol/L) 
12.78 15.12 13.78 
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Smoker 1 (Female): 
ge 25 
Weight (kilograms) 70 
Height (metres) 1.68 
Body Mass Index 25 
Alcohol(units/week) II 
Cigarettes/day 20 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 76 71.96 64.8 
Plasma Cholesterol (mmol/L) 3.34 4.13 4.14 
Plasma Triglycerides (mmol/L) 0.36 0.44 0.91 
Plasma Creatinine (mg/dL) 1 1.01 1.06 
Creatinine Clearance (mUmin) 95.41 94.1 90.1 
Urinary Creatinine (mg1mL) 1.42 2.12 2.37 
Plasma 8-epi-PGF2,,, (pg/mL) 583.2 337.9 531.58 
Urinary 8-epi-PGF2. (pg/mg creatinine) 1248.43 632.03 910.47 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (gmol/L) 
14.1 15.12 5.76 
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Smoker 2 (Female): 
Age 30 
Weight (kilograms) 53 
Height (metres) 1.58 
Body Mass Index 21 
Alcohol(units/week) 0 
Cigarettes/day 25 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 63.91 63.4 79.92 
Plasma Cholesterol (mmolVL) 5.95 6.13 6.08 
Plasma Triglycerides (mmol/L) 0.82 1.81 1.38 
Plasma Creatinine (mg/dL) 0.62 0.72 0.82 
Creatinine Clearance (mlJmin) 110.74 95.59 84.27 
Urinary Creatinine (mg/mL) 1.81 1.37 2.09 
Plasma 8-epi-PGF2,, (pgtmL) 889.58 701.97 542.64 
Urinary 8-epi-PGF2. (pg/mg creatinine) 2241.61 1243.38 1695.89 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (ýLmol/L) 
7.33 52.11 25.98 
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Smoker 3 (Male): 
Age 25 
Weight (kilograms) 70 
Height (metres) 1.73 
Body MassIndex 23 
Alcohol(units/week) 47 
Cigarettes/day 10 
Day 0 Day14 Day 28 
Plasma Protein (g/L) 68.49 71.96 66.09 
Plasma Cholesterol (mmol/L) 3.22 3.22 3.7 
Plasma Triglycerides (mmol/L) 0.44 0.54 0.87 
Plasma Cieatinine (mg/dL) 0.91 0.89 0.81 
Creatinine Clearance (mUmin) 122.92 125.62 137.38 
Urinary Creatinine (mg/mL) 1.23 0.87 0.57 
Plasma 8-epi-PGF2,,, (pg/mL) 716.58 355.75 746.72 
Urinary 8-epi-PGF2. (pg/mg creatinine) 1270.34 861.56 1379.59 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (Itmol/L) 
9.22 18.10 11.34 
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Smoker 4 (Female): 
Age 37 
Weight (kilograms) 63.63 
Height (metres) 1.68 
Body Mass Index 22.6 
Alcohol(units/week) 49 
Cigarettes/day 25 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 70 67.9 72.36 
Plasma Cholesterol (mmol/L) 4.65 5.13 5.11 
Plasma Triglycerides (mmol/L) 0.59 1.13 1.15 
Plasma Creatinine (mg/dL) 0.81 0.86 0.94 
Creatinine Clearance (mlJmin) 103.08 94.04 87.14 
Urinary Creatinine (mgtmL) 1.7 1.75 2.23 
Plasma 8-epi-PGF2. (pg/mL) 736.39 519.94 537.11 
Urinary 8-epi-PGFu (pg1mg creatinine) 1745.02 937.71 1303.18 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (Amol/L) 
7.71 9.19 5.71 
222 
Smoker 5 (Male): 
Age 48 
Weight (kilograms) 70 
Height (metres) 1.76 
Body Mass Index 23 
Alcohol(unitstweek) 10 
Cigarettes/day 10 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 78.46 76.66 79.14 
Plasma Cholesterol (mmoML) 5.59 5.57 5.06 
Plasma Triglycerides (mmol/L) 1.02 0.92 0.73 
Plasma Creatinine (mg/dL) 1.22 1.23 1.44 
Creatinine Clearance (mlJmin) 73.03 72.71 62.11 
Urinary Creatinine (mg1mL) 0.87 0.91 1.74 
Plasma 8-epi-PGFU (pg/mL) 956.91 868.16 819.41 
Urinary 8-epi-PGFu (pg/mg creatinine) 3537.43 2124.72 3128.84 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (pmo]VL) 
6.46 34.03 5.22 
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Smoker 6 (Male): 
Age 35 
Weight (kilograms) 97 
Height (metres) 1.88 
Body Mass Index 28 
Alcohol(units/week) 2 
Cigarettes/day 20 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 88.2 67.82 97.09 
Plasma Cholesterol (mmol/L) 4.46 3.82 4.65 
Plasma Triglycerides (mmol/L) 0.52 0.79 1.03 
Plasma Creatinine (mg/dL) 1.36 1.34 1.36 
Creatinine Clearance (m]L, /min) 111.36 112.6 111.03 
Urinary Creatinine (mg/mL) 3.45 2.23 2.52 
Plasma 8-epi-PGFu (pg/mL) 859.46 563.78 598.56 
Urinary 8-epi-PGF2,,, (pg/mg creatinine) 1519.56 958.64 1013.81 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (pmol/L) 
6.77 15.94 6.46 
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Smoker 7 (Female): 
Age 57 
Weight (kilograms) 54 
Height (metres) 1.53 
Body Mass Index 22 
Alcohol(unitstweek) 0 
Cigarettes/day 15 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 69.23 62.39 70.18 
Plasma Cholesterol (mmol/L) 4.79 3.98 4.4 
Plasma Triglycerides (mmol/L) 1.04 0.6 0.39 
Plasma Creatinine (mg/dL) 1.03 0.99 1.06 
Creatinine Clearance (mUmin) 51.62 53.36 49.8 
Urinary Creatinine (mg/mL) 0.85 0.73 0.39 
Plasma 8-epi-PGF2. (pg/mL) 301.25 252.56 521.48 
Urinary 8-epi-PGF2,, (pg/mg creatinine) 697.56 552.13 804.5 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (gmol/L) 
15.92 14.66 13.19 
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Smoker 8 (Female): 
Age 40 
Weight (kilograms) 55.5 
Height (metres) 1.6 
Body Mass Index 21.5 
Alcohol(units/week) 27 
Cigarettes/day 25 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 71.42 84.54 76.06 
Plasma Cholesterol (mmol/L) 5.47 5.37 5.89 
Plasma Triglycerides (mmol/L) 0.62 0.88 0.58 
Plasma Creatinine (mg/dL) 0.82 0.81 0.85 
Creatinine Clearance (mlJmin) 73.13 72.71 69.75 
Urinary Creatinine (mg1mL) 0.14 0.99 0.23 
Plasma 8-epi-PGF2. (pg/mL) 704.88 431.42 578.88 
Urinary 8-epi-PGFu (pg1mg creatinine) 1732.66 343.53 716.84 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (ýLmol/L) 
10.21 13.80 13.56 
226 
Smoker 9 (Male): 
60 
Weight (kilograms) 68.72 
Height (metres) 1.69 
Body Mass Index 24.2 
Alcohol(units/week) 30 
Cigarettes/day 15 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 70.39 72.7 74.55 
Plasma Cholesterol (mmol/L) 5.98 6.55 6.13 
Plasma Triglycerides (mmol/L) 0.74 0.62 0.79 
Plasma Creatinine (mg/dL) 1.05 1.07 1.01 
Creatinine Clearance (mlJmin) 75.75 74.04 78.56 
Urinary Creatinine (mg/mL) 0.95 1.25 1.28 
Plasma 8-epi-PGFu (pg/mL) 491.86 162.08 204.88 
Urinary 8-epi-PGF2. (pg/mg creatinine) 867.22 435.38 837.47 
Plasma Antiox-idant Capacity (Equivalent 
Ascorbate Units (ýLmol/L) 
14.44 23.20 10.47 
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Smoker 10 (Male): 
Age 53 
Weight (kilograms) 73.2 
Height (metres) 1.65 
Body Mass Index 26.8 
Alcohol(units/week) 0 
Cigarettes/day 20 
Day 0 Day 14 Day 28 
Plasma Protein (g/L) 78.41 77.12 85.31 
Plasma Cholesterol (mmol/L) 5.46 5.1 4.98 
Plasma Triglycerides (mmol/L) 1.12 1.39 1.23 
Plasma Creatinine (mg/dL) 0.85 0.95 0.93 
Creatinine Clearance (mlJmin) 103.38 92.04 93.66 
Urinary Creatinine (mg/mL) 0.12 0.38 0.1 
Plasma S-epi-PGFu, (pg/mL) 758.63 323.25 989.3 
Urinary 8-epi-PGF2,,,, (pg/mg creatinine) 870.93 161.97 1421.74 
Plasma Antioxidant Capacity (Equivalent 
Ascorbate Units (pmol/L) 
4.25 8.52 6.87 
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APPENDIX XIII 
Dietary Supplementation with Aged Garlic 
Extract Reduces Plasma and 
Urine Concentrations of 8-iso-Prostaglandin 
F2cc in Smoking 
And Non-Smoking Men and Women 
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APPENDIX XIV 
Preliminary Evidence to Suggest that 
Antioxidant Phenolics in Aged Garlic Extract 
Protect against In- Vitro Copper Oxidation of 
LDL 
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PRELIMINARY EVIDENCE TO SUGGEST THAT ANTIOXIDANT 
PHENOLICS IN AGED GARLIC EXTRACT PROTECT AGAINST DV VITRO 
COPPER OXIDATION OF LOW-DENSITY LIPOPROTEIN (LDL). 
Stepbanie Dillon, David Billington, Gordon Lowe and Khalid Rahman. 
School of Biomolecular Sciences, Liverpool John Moores University, Byrom 
Street, Liverpool L3 3AR 
Several studies suggest that aged garlic extract may protect against the 
development and progression of atherosclerotic disease. Aged garlic extract 
contains many phenolic and sulphurous components, and S-allylcysteine has been 
identified as a potential antioxidant. Initial work in this laboratory indicated that 
aged garlic extract acted in two ways to protect against LDL oxidation by copper. 
A novel enzyme assay based on the inhibition of xanthine oxidase activity by 
copper demonstrated the copper chelation properties of the whole aged garlic 
extract. However, a diethyl ether extract of the aged garlic extract did not exhibit 
any copper chelation properties but markedly reduced copper oxidation of LDL 
assessed by both TBA-RS (lipid peroxidation) and electrophoretic mobility 
(protein oxidation). This is in contrast to recent studies in which fresh garlic and 
other commercial garlic preparations have been shown to be pro-oxidants. 
Spectrophotometric and HPLC analysis indicated that the diethyl ether 
extract of the aged garlic extract contained several components with a 274nm 
peak. Further analysis by thin layer chromatography of the diethyl ether extract 
using a ethylacetate : methanol : water (10: 2: 1) solvent system, and using 
detection by both UV and ferric chloride indicated that at least 4 phenolic 
compounds are present. Using catechin as the standard the Folin & Ciocalteu 
phenol assay demonstrated that the total phenolic content of the whole aged garlic 
extract was 22.7mg/ml, and the diethyl ether extract contained 1.1 mg/ml. 
Further studies are underway to determine the nature of these phenolic 
compounds. 
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